001,114,243,BACKGROUND,BASED,COLORECTAL,CONCLUSION,COX,CXR,GOVERNMENT,HRS,INTERVIEW,LABEL,METHODS,OVARIAN,PRESS,PUBLISHED,RESULTS,SCREENING,TRIAL,UNIVERSITY
HOWEVER,NON,NSCLC,TODAY
EVERY,STILL
177,BACKGROUND,LABEL,MEDICAL,METHODS,SIXTEEN,THERE,THREE
99M,DUE,HYNIC,LATER,SPECT,TOC
DUE,HOWEVER,ZDA
549,956,DYSIDEA,ESI,NMR,THEIR,VIETNAMESE
177,239,BACKGROUND,CRP,HOWEVER,LABEL,METHODS,PENTRAXIN,RESULTS
AFTER,AWS,BENTALL,EXCHANGER
AFTER
ANOVA,BACKGROUND,CRP,ICU,LABEL,METHODS,POD,RESULTS,THERE,WBC
002,057,290,292,AMONG,BACKGROUND,BRISTOL,CHECKMATE,LABEL,METHODS,MYERS,NIVOLUMAB,NSCLC,OVERALL,RESULTS,TREATMENT
18F,690,BECAUSE,DISCOVERY,DSTEP,ELITE,HOWEVER,PET,PSF,SUV,TOF
HOWEVER
137,366,413,965,JANUARY,THREE
100,956,GST,HOWEVER,MNO,PCR,PEG,ROS
177,956,985,AES,ICP,NCI,NMR,PAMAM,TEM,THEREFORE,VIS
BACKGROUND,CONCLUSION,EGD,LABEL,METHODS,UNDERGOING,USING
280,AGREEMENT,BACKGROUND,END,LABEL,METHODS,PATHOLOGIC,RESULTS,TNM
ADHESIONS,BACKGROUND,EIGHT,LABEL,LAD,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THERE
MRI,SPIOS
CHEST
AFTER,ESOPHAGEAL,IVA,LNS,NEC,NSE,STAGE
093,318,411,527,726,811,BETWEEN,GROUP,JAPAN,JLCRG,MARCH,UFT
BETWEEN,GRADE,HOWEVER,MAY,NSCLC,OCTOBER,TKI
001,003,006,009,022,169,32X10,35X10,467,591,72X10,BACKGROUND,CH12Q24,GECCO,INSTITUTE,LABEL,METHODS,NETWORK,PRESS,PUBLISHED,RESULTS,SH2B3,UNIVERSITY
INC,PUBLISHED,SCREENING
ASSOCIATES,BAPTIST,FLORIDA,RADIOLOGY,SOUTH
ASSESSMENT,BANQIAO,EPA,ICP,MODEL,XUANWEI
C60,CYTOTOXIC,DOX,LEWIS
BASED
239,MAYAK,POTENTIAL,YEARS
001,149,169,185,378,399,807,BACKGROUND,CD3,CONCLUSION,COX,FOXP3,HEIDELBERG,HOWEVER,HRS,IMMUNOCRIT,LABEL,LABORATORY,METHODS,PRESS,PUBLISHED,REGARDING,RESULTS,UNIVERSITY
169,BACKGROUND,COMPARISON,CONCLUSION,CONTINUED,COX,EVALUATION,HOWEVER,LABEL,METHODS,METRICS,NSCLC,PRESS,PUBLISHED,RESULTS,SOLID,UNIVERSITY
122,BACKGROUND,CHESTER,ERDHEIM,GENENTECH,LABEL,LANGERHANS,METHODS,RESULTS,ROCHE,THERE
ELDERLY,HOWEVER
MALIGNANT,REGARDING,THERE
ALK,FURTHER,HOWEVER,SEVERAL,TKI
OPTIMIZED
001,169,CHANGES,CONTOUR,COPYRIGHT,DIR,INC,LABEL,MEASURING,METHODS,OBJECTIVE,PET,PURPOSE,RESULTS,RIGID,THERE
139,154,169,COPYRIGHT,CROWN,DISTANT,EASTERN,FDG,GROUP,IMAGING,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PET,PUBLISHED,PURPOSE,RESULTS
169,ADDITIONAL,AES,COPYRIGHT,EASTERN,FIFTY,GROUP,INC,LABEL,MATERIALS,METHODS,MTD,NSCLC,OBJECTIVE,PRECISION,PURPOSE,RESULTS,THERE,TREATMENT
011,028,032,033,102,108,109,118,138,169,170,172,201,260,303,ACT,BETWEEN,CONTINUED,COPYRIGHT,CSI,EBT,FVC,INC,IQR,LABEL,MARCH,METHODS,OBJECTIVE,PFT,PULMONARY,PURPOSE,RESULTS,THERE,THESE,TLC
BACKGROUND,CURRENT,LABEL,METHODS,PULMONARY,RESULTS,SOCIETY,THERE
100,115,117,169,183,232,BACKGROUND,COPYRIGHT,EDUCATION,FUNDING,GERMANY,INNOVATION,LABEL,LTD,METHODS,RESULTS,STATE,SWISS,THOSE,THREE
160,916,946,956,968,BILIRUBIN,CONCLUSION,DAILY,LABEL,METHODS,OBJECTIVE,PACO2,RESULTS,SETTING,SPRAGUE
19DEL,ACCORDING,CONCLUSION,L858R,LABEL,METHODS,MUTATIONS,OBJECTIVE,RESULTS,SOCIETY
216,270,282,284,350,566,604,ALK,AMONG,IHC,III,LABEL,METHODS,NSCLC,OBJECTIVE,RESULTS,VENTANA
JANUARY,LABEL,LOCAL,METHODS,OBJECTIVE,RESULTS,THERE,UNIVARIATE
177,ACADEMY,CHINESE,COLLEGE,CONCLUSION,DEC,FEDERATION,GYNECOLOGY,IB1,IB2,IIA,JAN,JUL,LABEL,MEDICAL,METHODS,NECUC,OBJECTIVE,OBSTETRICS,PATHOLOGIC,PFS,RECURRENT,RESULTS,TEN,UNION
236,911,BSS,EOL,INDIVIDUAL,INSURANCE,MEDICAL,MRI,PET,TAIWANESE,UNDERGOING
016,143,150,293,356,7TH,ACCORDING,APM,COMMITTEE,DFS,EFFECTIVE,GREATER,HOWEVER,JANUARY,JOINT,NSCLC
000,114,398,456,580,649,933,974,APRIL,CIS,COCHRAN,ECM,GALBR,HOWEVER,III,ORS,POTENTIAL,SIX,SMD,STUDIES
001,259,343,399,412,473,949,JANUARY,MEIER,NSCLC,PATIENT
036,BASED,COPYRIGHT,EMA,FGF,HOWEVER,III,NINTEDANIB,PDGFR,PHASE,PROUS,SCIENCE,THERE
169,FMS,MAM,USING
00001,002,AAS,CIS,ELECTRONIC,HRS,III,NSCLC,OTHER,TCC,TOXICITIES
GIVEN,PRIMARY
SEBACEOUS,THREE,TORRE
HISTOLOGIC,SURGERY
00084,013,169,215,485,BACKGROUND,CCP,COPYRIGHT,COX,LABEL,LTD,METHODS,MORTALITY,NOVEL,PCR,PRIMARY,RESULTS
169,COPYRIGHT,HISTOLOGIC,INC,PUBLISHED,SOCIETY
160,169,AFTER,COPYRIGHT,INC,PRIMARY,PUBLISHED,PULMONARY,SOCIETY
956,BACKGROUND,CONTEXT,FIBER,LABEL,METHODS,OBJECTIVE,SIMILAR,SIMILARLY,SOURCES,THERE
BACKGROUND,CONTEXT,LABEL,METHODS,NOVEL,OBJECTIVE,OBJECTIVES,SOURCES
THESE
945,947,ACCORDING,AMONG,CD3,CD4,CTL,ELISA,FCM,IFN,INJECTION,LDH,MTT,PHA,TANREQING,TNF
945,946,947,CHINESE,CONCLUSION,DDP,EFFORTS,ELISA,FUZHENG,IFN,INTERVENED,LABEL,LEWIS,METHODS,OBJECTIVE,RESULTS,TCM,TGF,TNF
945,946,AKT,CELASTROL,CHINESE,GSK,PCR,RAF,THEREFORE,WESTERN
ASIAN,CAP,CD143,CIS,FEM,ORS,SCHOLAR,SNP,THERE
169,GENOMIC,LABORATORY,PRESS,PUBLISHED
169,33342,AMONG,ANNEXIN,BACKGROUND,CONCLUSION,COPYRIGHT,GASTRIC,HOECHST,LABEL,METHODS,MTT,OBJECTIVE,PHASE,PROTEIN,PURPOSE,RESULTS,ROSAMULTIC,SGC
277,CONCLUSION,HOWEVER,LABEL,METHODS,OBJECTIVE,RESULTS,RXWBS,SPECT,THESE,TNM,WBS
169,COPYRIGHT,ERP,INC,SURGERY
AFTER,ANEURYSMAL,BACKGROUND,CONCLUSION,LABEL,METHODS
122,125,250,CONCLUSION,LABEL,METHODS,OBJECTIVE,ONCOLOGIC,PURPOSE,RAPID,RESULTS,SINCE,TRANSIENT
00001,009,889,CONTROLLED,FURTHER,HOWEVER,LABEL,LRF,LVI,METHODS,NSCLC,OBJECTIVE,PURPOSE,RESULTS,THERE,THESE,VPI
100,EXPRESSION,LABEL,METHODS,MUC,NSCLC,OBJECTIVE,PCR,PURPOSE,RESULTS
001,APRIL,DFS,GIVEN,LABEL,METHODS,NSCLC,OBJECTIVE,OCTOBER,PURPOSE,RESULTS
CURRENT,WHETHER
100,150,CESSATION,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
001,002,003,004,007,013,021,029,031,038,044,049,AAD,HENCE,LABEL,MEIER,METHODS,MPM,OBJECTIVE,OBJECTIVES,PCI,RESULTS,SPECIMENS,USING
100,122,138,525,945,BEP,LABEL,LONGEST,METHODS,OBJECTIVE,OBJECTIVES,PACLITAXEL,RESULTS,TEN,THESE
122,169,178,194,300,380,381,652,660,ADC,AUC,CA125,CEA,COPYRIGHT,CYFRA21,IRELAND,LTD,NSCLC,SCC,THREE
169,COPYRIGHT,LTD,PCI,SMALL
215,645,BACKGROUND,COLLEGE,COMMISSION,HOWEVER,INC,LABEL,METHODS,PUBLISHED,RESULTS,SOCIETY,THESE
100,133,AFTER,AIM,BETWEEN,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,OTHER,RESULTS,SEMSS,THERE,ULTIMATELY
113,AIM,INSTITUTE,JANUARY,LABEL,METHODS,OBJECTIVE,RESULTS,ROMANIA
CEA,CONCLUSION,LABEL,OBJECTIVE,SCREENING,TRIAL
ANOMALOUS,COLORECTAL,CONCLUSION,LABEL,OBJECTIVE,OVARIAN,SCREENING,TRIAL
101,177,1ST,FEWER,FIFTY,HENCE,OCTOBER,REASONS,SEPTEMBER,THESE
FDG,FINALLY,MRI,PPDLBCL,PRIMARY
18F,224,229,740,780,788,808,843,853,875,897,925,JANUARY,SCN,SUV,THERE
MRI
AFTER,FOLLOWING
GUIDELINES,HOWEVER,HT3,NK1,SOCIETY,THEREFORE,THESE
CCR,GRADE,MAY,NON,THERE,THEREFORE,UNIVERSITY
1ST,AFTER,CHEST,MHE,THREE

CUSHING,PULMONARY

THERE
120,2ND,AFTER,LEUCOVORIN
CLINICIANS,PCI,TKI
549,841,956,CCD,CON,MRC,WHILE
000,099,100,181,193,236,449,453,464,507,AMONG,CALIFORNIA,COHORTS,CRUDE,EXPOSURES,HODGKIN,IMPORTANCE,LABEL,METHODS,OBJECTIVE,PERMANENTE,RELEVANCE,RESULTS,SETTING,STUDIES
160,169,18F,COPYRIGHT,FIFTY,FLT,HOWEVER,INC,KNOWLEDGE,LABEL,MATERIALS,METHODS,OBJECTIVE,PET,PURPOSE,RESULTS,USING
100,160,169,CONCLUSION,COPYRIGHT,GRADE,HDR,INC,LABEL,MATERIALS,METHODS,NSCLC,OBJECTIVE,PRIMARY,PURPOSE,RESULTS,THERE
000,CD161,CIBERSORT,FOXM1,HOWEVER,KLRB1,MOLECULAR
160,169,680,956,AIR,COPYRIGHT,FVB,HISTOLOGY,INC,KUPFFER,MBS,NIR,OCCASIONAL,PVA,VIVOTAG
CONCLUSION,DOPPLER,LABEL,PAS,PRIMARY,PTE,UNLABELLED
135,169,COPYRIGHT,LABEL,METHODS,NUCLEAR,OBJECTIVE,OBJECTIVES,PATHOLOGY,RESULTS,SOCIETY
111,177,ACTUARIAL,CONCLUSION,DSS,GRADE,KNOWLEDGE,LABEL,LOCAL,METHODS,OBJECTIVE,RESULTS,SECONDARY,TREATMENT
ADVANCE,CONCLUSION,ITV,LABEL,METHODS,OBJECTIVE,RESULTS,STUDIES
15Q15,169,17Q24,OVERALL,SNP
00018,037,125,127,268,607,BACKGROUND,CEA,CYFRA,LABEL,LAMC2,METHODS,NON,NSCLC,PROGNOSTIC,RESULTS,SCC
003,004,005,120,169,AMONG,BACKGROUND,CONCLUSION,COX,DFI,INC,LABEL,MEIER,METHODS,PULMONARY,RESULTS,WHILE,WILEY
169,AUTHORS,BCL,BH3,COPYRIGHT,FOLLOWING,INC,MYC,PUBLISHED,TAXOL,THESE,USING
160,169,COPYRIGHT,EPIGENETIC,GSK2879552,INC
160,169,COPYRIGHT,INC,INHIBITION
150,169,BACKGROUND,CONCLUSION,COPYRIGHT,EVALUATION,HOWEVER,LABEL,LOW,LTD,METHODS,NSCLC,RESULTS,SOLID,TREATMENT,TUMOURS
BACKGROUND,CONCLUSION,LABEL,MALIGNANT,METASTATIC,METHODS
160,169,AKT,ALK,COPYRIGHT,ERK,H3122,INC,THROUGH
169,945,946,947,948,ANTICANCER,CD8,COPYRIGHT,HOWEVER,INSTITUTE,TH1,THESE,TREGS
169,916,AIM,ANTICANCER,BACKGROUND,COPYRIGHT,DDS,DISCUSSION,INSTITUTE,LABEL,LPETG,MATERIALS,METHODS,N59SRTA,OBJECTIVE,RESULTS,SEVERAL,THESE
134,169,COPYRIGHT,H69,INC,LACTATE,LDH,MICRORNAS,MIR,MTT,NSCLC,PCR,THESE
169,COPYRIGHT,IRELAND,LTD,MSC,POTENTIAL
AVASTIN,CETUXIMAB,EWING,PNETS,PRIMITIVE
BASED,BECAUSE
DCR,EIGHT,NSCLC,ORR,TTP

5AS,ARRANGE,ASK,TOBACCO
169,COPYRIGHT,HOWEVER,IRELAND,KSN,LTD,MES,MICROARRAY,PRIMARY,TNNT1,UTERINE
CEA,CURRENT,HOWEVER,TABLE
169,500,COPYRIGHT,EXPRESSION,KNOCKDOWN,PRR11,REMARKABLY,SIRNA
215,809,951,A2780,ATM,DOWNSTREAM,I257V,L517P,N447S,ND5,PF6,ROS,SUPEROXIDE,WHOLE
107,132,133,169,183,250,265,500,AFTER,BACKGROUND,BETWEEN,COPYRIGHT,DEC,EVALUATION,FUNDING,IMPRESS,LABEL,LTD,MARCH,MAY,METHODS,NSCLC,OPTIMUM,PACIFIC,RESULTS,SOLID
103,150,157,169,183,201,224,227,392,395,397,398,795,ADVERSE,ASIAN,BACKGROUND,BOEHRINGER,CLINICIANS,COPYRIGHT,FUNDING,INGELHEIM,IQR,LABEL,LTD,LUX,METHODS,RESULTS,THERE
005,012,105,139,CONCLUSION,HT3,LABEL,METHODS,OBJECTIVE,PERHAPS,RESULTS,SOCIETY,TREATMENT
042,CONCLUSION,EPIDERMAL,LABEL,METHODS,OBJECTIVE,RESULTS
160,320,954,CNR,CONCLUSION,EMPHYSEMA,FBP,GGO,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,RESULTS,SIMULATED,THERE,THESE
169,AMONG,BACKGROUND,CONCLUSION,INC,LABEL,LIMITED,MEIER,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,WILEY
156,191,APC,BACKGROUND,ESTIMATED,INCIDENCE,JOINPOINT,LABEL,MALIGNANT,METHODS,PERCENT,PLEURAL,POPULATION,RATES,RESULTS,UMBRIAN
DUE
PROVING
ABOUT,AKT,BIM,DESPITE,DUSP6,ETS,GTP,MEK,NSCLC,RAF,RAS,REDUCTION,RTK,SRC,THEREFORE,THESE
169,ALK,ATLAS,COPYRIGHT,LTD,SEQUENCING,THESE,TREATMENT
169,AKT,COPYRIGHT,FEDERATION,ILT,NSCLC,PUBLISHED,SOCIETIES
169,410,AKT,COPYRIGHT,FEDERATION,HOWEVER,INHIBITION,MIR,NSCLC,PUBLISHED,SOCIETIES
001,049,6TH,APRIL,CONCLUSION,DOPPLER,HOWEVER,IVA,LABEL,METHODS,NEITHER,OBJECTIVE,RESULTS,RIGHT,RVFAC,TAPSE,TDI
169,ALK,COPYRIGHT,FINALLY,INC,THESE
160,169,BACKGROUND,COPYRIGHT,HOWEVER,INC,LABEL,METHODS,PC9,PUBLISHED,RESULTS,SOCIETY
126,156,190,ENB,PRIMARY,THESE,UPPER
169,COPYRIGHT,INC,PUBLISHED,SOCIETY,VARIOUS
169,COPYRIGHT,INC,PUBLISHED,SOCIETY
169,COPYRIGHT,DESPITE,INC,MK2,THESE

169,946,ACUTE,AKT,AUTHORS,CAS9N,CCP,CME,DYNAMIN,EGF,H1299,RPE,THESE
169,193,543,703,AMSTERDAM,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,NSCLC,OBJECTIVE,PURPOSE,RESULTS,RPA,UNIVARIATE,WORLD
001,110,160,169,193,303,945,946,BACKGROUND,BIOMARKER,BMP,COPYRIGHT,EGF,HGF,IGF,IGFBP,INC,LABEL,LOW,METHODS,NSCLC,PUBLISHED,RESULTS,SDF,SOCIETY,THESE,TNF,WHITNEY
BACKGROUND,LABEL,METHODS,RESULTS,SMALL,THEREFORE
945,BACKGROUND,FMS,LABEL,METHODS,RESULTS
BMJ,BRITISH,GROUP,LIMITED,PUBLISHED,PUBLISHING,SOCIETY
PALLIATIVE
100NM,169,24H,5GY,945,AKT,CL1,COPYRIGHT,HIF,INC,KEY,LABEL,METHODS,MTT,OBJECTIVE,PTX,RESULTS,TUNEL,WESTERN
169,209,APRIL,AUSTRALIA,CONCLUSION,DIAGNOSIS,IMAGING,INC,LABEL,METHODS,MOLECULAR,NUCLEAR,PULMONARY,RESULTS,SIXTY,SOCIETY,SPECT,THERE,THREE,UNLABELLED
177,215,6XFFF,CONCLUSION,FFF,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,PLANS,RESULTS,STAGE,TREATMENT
439,668,AID,ASXL1,BACKGROUND,DARWINIAN,GRANT,HOWEVER,LABEL,METHODS,MUTATIONS,RESULTS,SCIENTIFIC,SOMATIC
ACADEMY,COPYRIGHT,CSD,ETHICAL,HOSPICE,JOURNAL,MEDICAL,PALLIATIVE
102,160,215,224,300,354,GENOMIC,GIVEN,HOWEVER,MENDELIAN,SIMILAR,SINCE
876,AGE,BASED,CRC,INSURANCE,SIR,SPM
001,157,297,444,628,740,AFTER,CAP,IDS,INCIDENCE,INSURANCE,IRR,MEIER,NHIRD,POISSON,PYS
176,177,185,FDG,IMAGE,PET,PHYSICIANS,ROBOT,STATE
000,160,169,945,BACKGROUND,COPYRIGHT,FIFTY,INC,LABEL,METHODS,MOLECULAR,PUBLISHED,RESULTS,SURGERY
ANAPLASTIC,BACKGROUND,CONCLUSION,IMAGING,LABEL,METHODS,VIDEO
AZD6244,BACKGROUND,CONCLUSION,DIFFERENT,LABEL,METHODS,NSCLC,ORR,PFS,RESULTS
101,AUC,BACKGROUND,FURTHER,HOWEVER,LABEL,METHODS,NSCLC,PCR,RESULTS,THERE
215,246,454,529,APPLIED,BACKGROUND,CONTEXT,ERBB2,INDIANA,LABEL,METHODS,OBJECTIVE,RESULTS,ROCHE,SCIENCE
150,169,956,ATLAS,CONCLUSION,LABEL,METHODS,NOD,NSCLC,OBJECTIVE,PATIENT,PDX,PURPOSE,RESULTS,SOCIETY,SURGICALLY,TKI
169,315,321,ADDITIONAL,AFTER,CONCLUSION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SOCIETY
139,169,AIM,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,CRC,INSTITUTE,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,SMALL,TNM
111,161,169,198,AIM,ANTICANCER,COMPARING,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,METHODS,OBJECTIVE,PRIMARY,RESULTS,SPECT,SRS,TOMOGRAPHY
169,AIM,ANTICANCER,CONCLUSION,COPYRIGHT,CPB,ILD,INSTITUTE,LABEL,MARCH,METHODS,NSCLC,OBJECTIVE,RESULTS
169,569,AFRICAN,AGE,AMERICANS,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,COX,INSTITUTE,INSURANCE,LABEL,MEIER,METHODS,RESULTS
169,215,AIM,ANTICANCER,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,METHODS,MEV,MPM,OBJECTIVE,RESULTS,THREE,UNTIL
000,001,169,661,675,747,AIM,AMONG,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,END,INSTITUTE,LABEL,METHODS,OBJECTIVE,RESULTS,SIR
001,169,177,AIM,ANTICANCER,BACKGROUND,BCE,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,MBDLC,METHODS,NTX,OBJECTIVE,RESULTS,THERE
169,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,EPIDERMAL,INSTITUTE,LABEL,MATERIALS,METHODS,MUTATIONS,NSCLC,RESULTS,SWEDISH,TKI,WESTERN
169,358,716,AIM,ANTICANCER,CONCLUSION,COPYRIGHT,IIFESTYLE,INSTITUTE,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,TAIWANESE,XRCC3
025,169,AIM,ANTICANCER,CONCLUSION,COPYRIGHT,COX,G719S,G719X,G874S,INSTITUTE,L858R,L861Q,LABEL,MARCH,METHODS,NON,NSCLC,OBJECTIVE,PFS,RESULTS,THREE,TKI,TREATMENT
169,963,ANTICANCER,BRCA1,COPYRIGHT,H2A,HISTONE,INSTITUTE,NCI,TAKEN
215,SEVERAL,THEREBY,THESE
HOWEVER,MICRORNAS,MMP15,NSCLC,RHO,ROCK1,THESE,TNF,TRAIL
169,ALK,HOWEVER,NSCLC
033,036,054,382,III,THROUGH
001,CONCLUSION,COX,LABEL,METHODS,NSCLC,OBJECTIVE,RESULTS,TNM,USP9X
169,231,233,COPYRIGHT,PUBLI,PUBLISHED,SAS
169,231,233,COPYRIGHT,PUBLI,PUBLISHED,SAS
169,231,233,ALK,COPYRIGHT,HOWEVER,HSP,INHIBITORS,INTERGROUP,NON,NSCLC,PFS,PROTEIN,PUBLI,PUBLISHED,SAS,SHOCK,SMALL,STRATEGIES,THESE
174,BAYER,LOW
129,160,169,COPYRIGHT,HCC,INC,TAKEN
169,3DPET,4DPET,665,716,733,750,CONCLUSION,COPYRIGHT,EVALUATION,FDG,INTER,IRELAND,ITV,LABEL,LTD,METHODS,OBJECTIVE,PET,PURPOSE,RESULTS
B16,KHT,THESE
169,946,954,BIOLOGY,FINALLY,FURTHER,INC,K11,K48,LPS,MOLECULAR,NFKB2,PAGET,PARTIAL,SCF,SOCIETY
035,169,312,353,355,ACCORDING,ALLELIC,AMONG,ASIAN,BPH,COPYRIGHT,DUE,GENOTYPING,HRM,INC,MINOR,PCA,PCR,PSA,SERBIAN
CONCLUSION,GLC,LABEL,METHODS,MTT,NSCLC,OBJECTIVE,PCR,RESULTS
169,ACADEMY,CRMP5,EATON,GABAB,GAD65,HUD,LABEL,LAMBERT,MA2,METHODS,NEUROLOGY,OBJECTIVE,OTHER,RESULTS,SERUM
BASED,CHINA,KOREA,OBC
001,022,036,169,277,304,503,547,590,593,599,624,640,682,988,BACKGROUND,COPYRIGHT,COX,INC,LABEL,METHODS,NLR,NSCLC,PLR,RESULTS,SIX
100,169,CONCLUSION,COPYRIGHT,GROUP,INC,LABEL,MATERIALS,METHODS,NSCLC,OBJECTIVE,PURPOSE,RADIATION,RESULTS,STRIKINGLY,THERAPY,V45,V55
131,138,156,169,229,256,372,ACCORDING,AMONG,BACKGROUND,CONCLUSION,CONTEXT,DTC,FACTORS,LABEL,MEIER,METHODS,OBJECTIVE,OVERALL,RESULTS,SOCIETY,WBS,YOUNGER
ERLOTINIB,MARCH,SMOKING
HOWEVER
001,005,106,947,EIGHT,FIFTEEN,GAD,GAD65,IMPORTANCE,LABEL,METHODS,OBJECTIVE,PNS,PREDICTORS,RELEVANCE,RESULTS,SETTING
125,169,183,956,APRIL,BACKGROUND,COPYRIGHT,DEPARTMENT,DUE,FUNDING,FURTHER,INSTITUTE,LABEL,LTD,METHODS,RADIATION,RESULTS,SECONDARY,SIMON,UNIVERSITY
169,474,4T1,AUTHORS,COPYRIGHT,IRELAND,LTD,PRLRS,PUBLISHED,USING
001,004,005,006,016,019,040,046,160,169,BACKGROUND,CHICAGO,COPYRIGHT,IBM,INC,LABEL,METHODS,MVD,NSCLC,PUBLISHED,RESULTS,SOCIETY,STATISTICS,THEIR,THESE
160,169,ASP,BAX,CADM1,COPYRIGHT,FOXA2,GLU,HDAC1,HDAC3,HOWEVER,HSP,INC,NR0B2,THESE
CAD,CTR,EWING,MC3T3,THESE
100,153,186,783,ATLAS,FINALLY,RCC,THESE
ASIAN,AVAIL,COMBINING,DISEASE,III,JO19907,NSCLC,RANDOMIZED,RESULTS
INSTITUTE,JOINPOINT,OVERALL,PANAMANIAN,REGRESSION,STATISTICS
AMONG,OVERALL
021,HOWEVER,NSCLC,PET,RFS,SIX
18F,FDG,NSCLC,PET,RFA
016,100,149,215,407,508,CONCLUSION,FIRSTLY,IPA,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,RESULTS,USING
100,169,99M,CONCLUSION,CURRENT,IMAGING,INC,KNOWLEDGE,LABEL,MAA,METHODS,MOLECULAR,NMI,NUCLEAR,RESULTS,SOCIETY,SPECT,THREE,UNLABELLED
001,169,239,BACKGROUND,DEPLETION,E2F,HOWEVER,LABEL,MEIER,METHODS,MICROARRAY,PHD,PRESS,PUBLISHED,RESULTS,STUDENT,THESE,UHRF1,UNIVERSITY
169,764,AKT,APC,BON,BRCA1,COPYRIGHT,EP300,EXCAVATOR,INC,KDR,NCI,NET,RB1,STK11,THESE,UMC11,YY1
65310,945,AFTER,HOWEVER,PULMONARY
HOWEVER,OTHER,PLANT,REDUCTIONS
160,169,COPYRIGHT,ERBB1,ERBB2,FGF,FGFR1,GROUCHO,HOWEVER,INC,PREVIOUSLY,TSA
169,BIOLOGY,DNMT1,FURTHER,INC,KIT,MOLECULAR,SOCIETY,THESE
003,004,731,909,ADIPOSITY,ALPHA,BLOOMBERG,COLORECTAL,GOVERNMENT,HOPKINS,INCIDENCE,JOHNS,NUTRITION,OVARIAN,OVERALL,PRESS,PREVENTION,PUBLISHED,SCREENING,SEX,THERE,TOCOPHEROL,TRIAL,UNIVERSITY
ACCORDING,COX,FLAVONOIDS,THEIR
MAJOR,MRI,PET
BASED,CHINA,DALYS,DISABILITY,DISEASE,GBD,THERE,YLD
000,038,055,060,118,120,130,140,152,154,214,230,235,236,260,280,284,330,360,404,410,429,458,460,600,605,770,926,970,CHINA,CONCLUSION,GBD,LABEL,METHODS,OBJECTIVE,PAF,RESULTS
000,100,150,169,196,206,269,303,521,529,749,787,830,892,968,CHINA,CONCLUSION,DISEASE,GBD,LABEL,METHODS,OBJECTIVE,PREVENTION,RESULTS,THEIR,YLD,YLL
177,197,332,592,997,BETWEEN,CONCLUSION,LABEL,MARCH,METHODS,OBJECTIVE,OCTOBER,RESULTS,UNIVARIATE
169,BACKGROUND,CONCLUSION,GRADE,INC,LABEL,MACCALLUM,METHODS,PATIENT,PETER,RESECTION,RESULTS,THERE,WILEY
7TM,FTP
ALGORITHM,ASIAN,BACKGROUND,ENGLAND,GROUP,LABEL,METHODS,NAMES,RESULTS,SOUTH
169,AUTHORS,BUTADIENE,CLARA,COPYRIGHT,INHALATION,IRELAND,LTD,METABOLIC,PUBLISHED,PULMONARY,RESULTS,SINCE,VOC,WHERE
169,459,461,816,AFTER,CONCLUSION,COX,DESPITE,HIV,HODGKIN,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SOCIETY
068,08092,102,169,257,600,64YEARS,800MG,AES,BACKGROUND,COPYRIGHT,EORTC,GRADE,LABEL,LTD,METHODS,NON,NSCLC,PAZOPANIB,PFS,RESULTS,SMALL,TKI
160,169,189,614,BACKGROUND,COPYRIGHT,INC,LABEL,METHODS,PET,PUBLISHED,RESULTS,SIX,SOCIETY,THERE
BECAUSE
943,VARIOUS
169,COPYRIGHT,FRA,LPS,PCR,PREVIOUSLY,SOCIETY,WESTERN
169,BIG,OTHER,PRESS,PUBLISHED,RIGID,SUBXIPHOID,SURGERY,THROUGH,UNIVERSITY
169,COPYRIGHT,CSC,IRELAND,LTD
100,169,177,400,AFTER,CONCLUSION,HENCE,IFP,IMAGING,INC,LABEL,METHODS,MOLECULAR,NUCLEAR,PET,PTF,RESULTS,SIX,SOCIETY,TBF,UNLABELLED,VOLUMES
137,169,557,791,ASSESSMENT,CBCTS,COPYRIGHT,COX,CRT,D43,HISTOLOGIC,INC,LABEL,MATERIALS,METHODS,NEITHER,NSCLC,OBJECTIVE,OVERALL,PERCENTAGE,PURPOSE,RESULTS
001,013,019,165,169,COPYRIGHT,COX,FACTORS,GLASGOW,INC,JANUARY,LABEL,MATERIALS,METHODS,NSCLC,OBJECTIVE,PROGNOSTIC,PURPOSE,RESULTS,RPA,SCORE,SEPTEMBER
AFTER,CHEST,UNDER
AFTER,BECAUSE,CHEST,FORTY
169,COPYRIGHT,INC,MOFFITT,NSCLC,SEVERAL,V600E
169,945,COPYRIGHT,HTO,NSCLC,SOCIETY
669,AKT,ELISA,GFP,HEPATOCYTE,HGF,LABEL,MET,METHODS,MTT,NSCLC,OBJECTIVE,PI3KP85,PURPOSE,RESULTS,THESE,THR,TKI,WESTERN,XENOGRAFT
001,100,160,169,183,18G,664,COMPARING,COMPARISON,CONCLUSION,GEORG,KEY,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SMOKERS,STUTTGART,THERE,USING
018,026,037,046,060,135,177,185,200,286,99M,AFTER,MAA,PET,PFS,SPECT
METASTASES,NSCLC,PANCREATIC,RCC
CENTRAL,CIS,MEDLINE,NSCLC,OPTIMAL,ORS,PFS,SEVEN,THERE
084,160,169,177,CONCLUSION,COPYRIGHT,DEPARTMENT,FIFTY,GERMANY,HALLE,INC,LABEL,METHODS,NK1,OBJECTIVE,PURPOSE,RADIATION,RANDOMIZED,RESULTS,SAALE,UNIVERSITY
001,006,122,169,ACT,BACKGROUND,CONCLUSION,COPYRIGHT,DOCTORS,FACTORS,IQR,LABEL,LTD,METHODS,NSCLC,RESULTS
169,ANALYZING,AUTHORS,BACKGROUND,CONCLUSION,COPYRIGHT,FIRST,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SRT,TCP
005,CONCLUSION,DEPARTMENT,EXPLORE,HENCE,JANUARY,LABEL,METHODS,OBJECTIVE,RADIOLOGY,RESULTS,SIXTY,TNB
169,AZD9291,COPYRIGHT,INC,T790M
100,168,200,350,584,ASSESSMENT,BACKGROUND,CD4,CHEST,CROSS,HIV,LABEL,METHODS,PREVALENCE,RESULTS,SMOKING,THREE
BACKGROUND,BRCA1,FINALLY,FURTHER,LABEL,METHODS,RESULTS,THESE
001,400,AFFYMETRIX,INSULIN,PPB,SAMPLES
TREATMENT
122,169,224,AMONG,LABEL,METHODS,OBJECTIVE,PRE,PRESS,PUBLISHED,RESULTS,T1BN0,UNIVERSITY
001,135,169,312,AMONG,CANDIDATE,CONCLUSION,LABEL,LOW,METHODS,OBJECTIVE,PURPOSE,R331W,RESULTS,SOCIETY,THESE,VALIDATION,WHOLE
000,100,161,169,315,925,BIOMEDICAL,BOARD,CDC,CHINA,CONCLUSION,COPYRIGHT,EDITORIAL,GANSU,LABEL,METHODS,MORTALITY,OBJECTIVE,PUBLISHED,RESULTS,TREND
001,002,177,281,735,CONCLUSION,GTV,KNOWLEDGE,LABEL,LNS,METHODS,NSCLC,OBJECTIVE,RESULTS
169,BACKGROUND,CONCLUSION,COPYRIGHT,COX,FINALLY,KRG,LABEL,METHODS,OBJECTIVE,PCR,PURPOSE,RESULTS,RU486,SIRT1,TAKEN,THIRD,WESTERN
169,BPD,NCSLC,NSCLC,PDT,RESULTS,SIMILAR,THESE
100,169,183,600,ASIAN,BACKGROUND,BOEHRINGER,COPYRIGHT,FUNDING,GLY719XAA,HOWEVER,INGELHEIM,LABEL,LEU858ARG,LEU861GLN,LTD,LUX,METHODS,RESULTS,SER768ILE,THERE,THESE,THR790MET
169,ANN,ARTIFICIAL,BACKGROUND,CEA,CYFRA,FINALLY,HOWEVER,ITALY,KNN,LABEL,LLM,LOGIC,MACHINE,METHODS,MPM,MTX,NEAREST,NEIGHBOUR,NETWORK,RESULTS,SWITCHING
160,293,757,CNS,COMPETING,CONCLUSION,COX,INC,LABEL,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UNIVARIATE
169,FGFR2,GOLGI
001,016,169,254,BACKGROUND,COPYRIGHT,FIFTY,III,INC,LABEL,METHODS,NSCLC,OPTIONS,PATHOLOGIC,PUBLISHED,RESULTS,SOCIETY,THERE
169,946,956,COPYRIGHT,IRELAND,LTD,MMP,THESE
033,BMJ,GROUP,HOWEVER,LIMITED,NSCLC,PUBLISHED,PUBLISHING
169,946,COPYRIGHT,EMT,IRELAND,LRRFIP1,LTD,SILENCING,WNT
169,COPYRIGHT,EBV,EPSTEIN,INC,PUBLISHED,SOCIETY
169,CD3,CD4,CD8,COPYRIGHT,INC,PUBLISHED,SOCIETY
169,COPYRIGHT,HOWEVER,INC,PUBLISHED,SOCIETY
169,COPYRIGHT,ENGLISH,INC,PUBLISHED,PULMONARY,SOCIETY
120,169,183,184,203,257,333,388,538,541,545,548,800,BACKGROUND,BETWEEN,COMPANY,COPYRIGHT,EASTERN,ELI,FEB,FUNDING,GROUP,INCLUDING,JAN,LABEL,LILLY,LTD,METHODS,NEITHER,OVERALL,RESULTS
000,065,100,160,188,514,530,845,AMONG,BACKGROUND,BMJ,BRONI,COR,DIAGNOSTIC,GROUP,ITALIAN,ITALY,LABEL,LIMITED,METHODS,MONFALCONE,MONFERRATO,NAZIONALE,OPERATING,PUBLISHED,PUBLISHING,RENAM,RESULTS,TRIESTE
100,ACCORDING,AFFYMETRIX,ANNOTATION,BACKGROUND,COL10A1,DAVID,DISCOVERY,EXPRESSION,FINALLY,GENOMES,GEO,INITIALLY,KYOTO,LABEL,METHODS,OMNIBUS,RESULTS,TMEM100
CAR,CRLF2,FINALLY,SHORT,TSLPR
TAKEN,UROKINASE
ALK,CRIZOTINIB,DOCKING,EVIDENCES,FDA,HENCE,HOWEVER,NSCLC,THESE
000003177,001,044,150,155,305,310,BACKGROUND,DIAGNOSTIC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RATIONALE,RESULTS,UTB
6TH,AFTER,BARRE,BASED,SEVERAL,UNDER
AFTER,BECAUSE,LATER,PECOMAS,THEREFORE
DFS,HOWEVER,NSCLC,SIX,SIXTEEN
002,016,033,102,117,177,ACEIS,HOWEVER,NSCLC,RASBS
3RD,BASED,HOWEVER,INTRONR,SERUM,SINCE
169,846,BACKGROUND,COPYRIGHT,INC,LABEL,MEDICAL,METHODS,PUBLISHED,RESULTS,SOCIETY,UNION,UNIVARIATE,UNIVERSITY
158,169,211,BACKGROUND,COPYRIGHT,INC,LABEL,METHODS,PUBLISHED,RESULTS,SOCIETY
021,115,BACKGROUND,BSA,CONCLUSION,GEFITINIB,LABEL,METHODS,NSCLC,PFS,RESULTS
AKT,EPIDERMAL,FOXO1,HOWEVER,NSCLC,TKI
126,169,BACKGROUND,CASES,CHRONIC,CLINICIAN,CLINICIANS,COPYRIGHT,DISEASE,INITIATIVE,IRELAND,LABEL,LIMITED,LTD,METHODS,NSCLC,OBJECTIVE,PULMONARY,PURPOSE,RESPONSES,RESULTS,SURGERY,WORLD
246,312,ACCORDING,BETWEEN,NOVALIS,OCTOBER,OCTREOTID,PET,TOTAL
BASED,CTV,INSTITUTE,ITV,PTV,USING
001,177,185,18FDG,3DCRT,4N1,AFTER,CUP,DSS,GTV,GTVCT,ICT,PET,PRIOR,VOLUMETRIC
10878,265,281,546,AMONG,BACKGROUND,CONCLUSION,LABEL,METHODS,NAB,NSCLC,ORR,PFS,PHASE,QOL,RESULTS,TWIST,USING
000,AOR,BACKGROUND,IMPLANTING,LABEL,METHODS,RESULTS,WHILE
116,945,946,947,956,COMPOUNDS,HCT,IC50S,MALAYSIAN,NMR,THEIR,VITEX,VITEXOLIDE
169,COPYRIGHT,EXPEC,FOLLOWING,SOCIETY,THERE
000,024,160,169,200,AUTHORS,CONVERSELY,HOWEVER,JAPAN,LTD,PTY,PUBLISHING,SCIENCE,SUMMARY,THEREFORE,WILEY
163,169,200,ADL,ADVERSE,AMONG,BACKGROUND,CTCAE,EASTERN,GROUP,INSTITUTE,LABEL,METHODS,RESULTS,SIXTY,SOCIETY,WITHOUT
215,ARIZONA
169,183,200,956,CELLS,MMP,MRC,QDS,QUANTUM
160,169,COPYRIGHT,INC,NON
160,169,COPYRIGHT,FAK,GEO,HOS,INC,KNOCKDOWN,MEANWHILE,SPON1,SPONDIN,SRC,TAKEN,TREATMENT
169,COLLEGE,FINALLY,PHYSICIANS,ROYAL,THERE,THEREFORE,VARIOUS
169,177,326,665,956,AVERAGE,CLARK,INC,INTRA,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,ROSWELL,THERE,THREE,WILEY
946,BECAUSE,CERTAIN,CLR01,LYS,THEREFORE
BACKGROUND,LABEL,METHODS,OBJECTIVE,RESULTS,SEVENTEEN
017,111,143,151,169,183,206,207,ADT,AVENTIS,BACKGROUND,COPYRIGHT,DOCETAXEL,EARLY,FUNDING,GLEASON,IQR,LABEL,LIGUE,LOCAL,LTD,METHODS,NEITHER,RESULTS
001,008,017,272,AMONG,BACKGROUND,BRISTOL,CHECKMATE,LABEL,METHODS,MYERS,NSCLC,RESULTS,TREATMENT
113,134,169,753,AGE,CONCLUSION,COPYRIGHT,DFS,ENDPOINTS,GTV,III,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PURPOSE,RBE,RESULTS
100,ABI,APPLIED,BIOSYSTEMS,BLAST,CONCLUSION,DAB,DENMARK,FFPBS,KIT,LABEL,METHODS,OBJECTIVE,PCR,POLYMERASE,PRISM,QIAMP,RESULTS,STATISTICA,USA
001,218,4B5,CONCLUSION,INTRATUMOR,LABEL,METHODS,OBJECTIVE,RESULTS,THERE,VENTANA
BASED,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS
169,954,COPYRIGHT,ICP,IRELAND,L858R,LTD,MEIER,RFS,SPRY2
169,ANTICANCER,COPYRIGHT,HOWEVER,INSTITUTE,THESE
169,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,CTA,ESO,ESOPHAGEAL,INSTITUTE,LABEL,MATERIALS,METHODS,RESULTS
003,169,ANTICANCER,COPYRIGHT,CRC,GROUP,INSTITUTE,LMS,OVERALL,SEVENTY,THERE
169,AIM,ANTICANCER,BACKGROUND,CEA,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,METHODS,OBJECTIVE,RESULTS,SURGERY,THERE
169,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,METHODS,RESULTS,THREE
169,946,ANTICANCER,BACKGROUND,BASED,CATENIN,CONCLUSION,COPYRIGHT,HMB,HMB45,INSTITUTE,LABEL,LAM,LHS,MATERIALS,METHODS,RESULTS,THERE
169,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,EZR,INSTITUTE,LABEL,LAM,MATERIALS,METHODS,MYH10,PCR,RAPAMYCIN,RESULTS
169,947,ADC,CARLO,CONCLUSION,COPYRIGHT,D02,D50,D95,INC,LABEL,METHODS,MONTE,OBJECTIVE,PURPOSE,RESULTS,TCP
100,122,160,169,945,946,BED10,COLORECTAL,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
CONCLUSION,LABEL,METHODS,NSCLC,OBJECTIVE,PFS,PURPOSE,RESULTS
169,AKT,BIOLOGY,ERK,FINALLY,GLUT1,HOWEVER,INC,LAD,MEK,MOLECULAR,ONCOGENIC,PPP,RAS,SOCIETY,TAKEN
169,34A,COPYRIGHT,HEPG2,MSA,SOCIETY,THESE
169,BELGICA,CHIRURGICA,COPYRIGHT,EARLY,INITIAL,VIDEO
177,219,242,250,252,494,995,BMJ,GROUP,LABEL,LIMITED,METHODS,OBJECTIVE,PUBLISHED,PUBLISHING,RESULTS
BECAUSE,BLOOD,THEREFORE
185,FDG,PATHOLOGIC,PET
BLOOD,LIBRARY,MEDLINE,NSCLC,PFS,SERUM
COPYRIGHT,III,PROUS,SCIENCE,VEGFR
169,177,285,BACKGROUND,LABEL,METHODS,MVMMS,NUTRITION,OBJECTIVE,PREVALENCE,RESULTS,SOCIETY
IMT,RENAL,WILMS
ALK,CONCLUSION,CRIZOTINIB,LABEL,METHODS,NSCLC,OBJEVTIVE,OOR,PFS,RESULTS,UNASSIGNED
169,ALK,INSTEAD,NOTABLY,NPM,NSCLC
169,BIOLOGY,CONSISTENT,FOS,INC,INDUCIBLE,JUN,MOLECULAR,PREVIOUSLY,SOCIETY,TAP73,THESE

47Q,COUNTER
ABORIGINAL,ABOUT,AMONG,APRIL,CONCLUSION,FRAMING,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OCTOBER,OUTCOME,RESULTS,SETTING,SHS,SIMILARLY,TALKING
001,138,169,175,276,CHINESE,CONCLUSION,III,LABEL,METHODS,NSCLC,OBJECTIVE,OVERALL,PFS,PURPOSE,RESULTS,SOCIETY
001,10877,10878,149,169,1YEAR,583,5DAYS,732,CONCLUSION,COPYRIGHT,COX,DIAGNOSIS,FACTORS,IRELAND,LABEL,LTD,MATERIALS,METHODS,NSCLC,OBJECTIVE,PET,PURPOSE,RECEIPT,RESULTS
ACCORDING,EMT,EPITHELIAL,H1299,HES,HEY,HYPOXIA,JAGGED1,NOBILETIN,NOTCH,TREATMENT
HO1,INCREASED,ISR,THESE
CRT,DMEAN,FFF,FLATTENING,MUS,NSCLC,OCTOBER,THERE
169,AFTER,AUTHORS,BRCA1,FIRST,LTD,MALIGNANT,PTY,PUBLISHING,SCIENCE,WILEY
001,003,011,014,021,029,126,147,164,166,197,200,285,321,374,376,429,486,499,548,577,583,588,648,733,741,791,792,82G,831,874,924,931,934,965,AUG,CAUCASIANS,CHINA,CONCLUSION,HOWEVER,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THEREFORE
001,015,046,168,223,ABSENCE,CONCLUSION,COX,CRT,EASTERN,GROUP,LABEL,METHODS,NSCLC,OBJECTIVE,PFS,PURPOSE,RELATIVELY,RESULTS,THERE
ETHIC,HOWEVER,MALIGNANT,MPM
163,173,178,289,660,BACKGROUND,CLEAR,ENGLAND,HOWEVER,ICERS,LABEL,METHODS,NSCLC,QALYS,RESULTS,SUBJECT
169,529,955,ACS,BACKGROUND,BMI,CONCLUSION,COPYRIGHT,III,INC,LABEL,METHODS,NSQIP,OBESE,OVERWEIGHT,PROPENSITY,RESULTS,WORLD,WORSE
169,BACKGROUND,COPYRIGHT,CRF,CRP,LABEL,LTD,METHODS,RESULTS
003,022,128,169,387,473,512,823,951,BACKGROUND,COPYRIGHT,DFS,INC,LABEL,METHODS,MORBIDITY,OPERATIVE,PROPENSITY,PUBLISHED,QOL,RESULTS,SOCIETY,UNMATCHED,USING
001,062,169,284,370,BACKGROUND,CARDIAC,COPYRIGHT,COX,INC,INDEX,LABEL,MEIER,METHODS,MORTALITY,PUBLISHED,RESULTS,REVISED,SOCIETY
169,72H,AUTHORS,BACKGROUND,COPYRIGHT,GB3,GCS,H1299,HOWEVER,INC,LABEL,METHODS,MPM,NSCLC,P31,PUBLISHED,RESULTS,THERAPY
169,COPYRIGHT,KINGDOM,PUBLISHED,SAS
169,366,BDA,BH4,COPYRIGHT,INC
150,160,BETWEEN,ELDERLY,EPIDERMAL,ERLOTINIB,L858R,LABEL,MARCH,METHODS,NSCLC,OBJECTIVE,PURPOSE,RESULTS
001,011,012,101,150,157,160,161,224,326,913,931,946,967,BRCA1,CHI,COX,LABEL,MEIER,METHODS,NSCLC,OBJECTIVE,OVERALL,PURPOSE,RESULTS,SIMILARLY
169,ACS,AMONG,CNA,COPYRIGHT,HOWEVER,III,INC,NSCLC,SCC
001,169,887,888,BACKGROUND,COPYRIGHT,FALSE,FNA,INC,LABEL,METHODS,PUBLISHED,RESULTS,SOCIETY,SPECIMENS,TCP,THERE
169,408,COPYRIGHT,IRELAND,LTD,NTRK1,PCR,THESE,TPR,USING
169,JNK,LARYNGEAL,SRY,THEREFORE,TU212
169,304,946,947,948,949,950,951,952,963,964,ABD,COPYRIGHT,HOWEVER,INHIBITION,MOL,NCI,PHYSIOL,SOCIETY,UTR
630,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PULMONARY,RESULTS,THESE
193,248,525,760,954,CONCLUSION,DELAY,IIP,LABEL,MATERIALS,METHODS,OBJECTIVE,OCTOBER,RESULTS,T1A,T1B
SCIENTIFIC,THESE
169,MOAP1,NSCLC,PRESS,PUBLISHED,UNIVERSITY
169,BELGIUM,CONCLUSION,COPYRIGHT,DTT,IRELAND,JAPAN,LABEL,LTD,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS,SEVERAL,THESE,UZB
160,169,954,COPYRIGHT,HOWEVER,INC,NON,NSCLC,THESE,TKI
AFTER,MCG,MRI,MULTIFOCAL,PET,THROUGH
AMONG,HENCE,HOWEVER,P63,PCR,TOTALLY
001,100,177,CONCERNING,CONCLUSION,KNOWLEDGE,LABEL,MEDICAL,METHODS,NSCLC,OBJECTIVE,PTV,RESULTS,STAGE,THERE,THESE,TOKYO,UNIVERSITY
169,916,ALTOGETHER,BIOLOGY,FINALLY,HIPPO,INC,MOLECULAR,PDZ,SOCIETY,TAZ
001,150,160,BACKGROUND,CONCLUSION,GMR,HOWEVER,LABEL,METHODS,RESULTS
169,21153,21162,289,945,946,BARKANA,BECAUSE,CARDIAC,COPYRIGHT,H1299,HAVIV,KARLISH,MARCOVICH,RABAH,SJD,SOCIETY,TAL,THESE,XENOPUS
HISTOLOGY,MAJOR,NON,NSCLC,NSQ,OVERALL,PARAMOUNT,PEMETREXED,QOL,QUALITY
169,945,946,947,ATL,COPYRIGHT,INC,PREVIOUSLY,THESE
CONCLUSION,FRANKEL,JANUARY,KARNOFSKY,LABEL,LOG,METHODS,RESULTS,SCORE,SIXTY,SPINE,UNLABELLED,VERTEBRAL
169,ADVANTAGES,ALK,COPYRIGHT,LTD,NSCLC,TKI
ACT,CONCLUSION,HEPATIC,HST,INSURANCE,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,RESULTS,SOT,THERE
001,104,153,169,189,293,HEMATOLOGY,LOG,OVERALL,SOCIETY,THERE
169,COPYRIGHT,CPT,INC,NSCLC,REGARDLESS
130,157,169,177,956,ATP,BIP,COPYRIGHT,DOCKING,H1299,INC,INS,INSP3
160,215,CKD,COCKCROFT,EPI,EQUATIONS,FORTY,GAULT,LABEL,METHODS,MSA,NSCLC,OBJECTIVE,PURPOSE,RESULTS,SCR,STUDIES
169,177,2N0M0,972,986,BACKGROUND,COPYRIGHT,COX,INC,LABEL,MEIER,METHODS,PUBLISHED,PULMONARY,RESULTS,SOCIETY
ACP,ASSESSMENT,CLINICIANS,EVALUATION,GRADE,GRADING,IMPORTANCE,JANUARY,LABEL,METHODS,OBJECTIVE,OCTOBER,PSYCHINFO,RELEVANCE,RESULTS,SERIOUS,SEVENTEEN
443,938,956,BACKGROUND,HOWEVER,IMT,IPT,LABEL,LABORATORY,LESIONS,METHODS,MORPHOLOGY,OBJECTIVE,REPORTS,RESULTS,THERE
053,100,177,324,877,945,APRIL,BACKGROUND,COX,HIF,HYPOXIA,LABEL,MAY,METHODS,OBJECTIVE,RESULTS
001,003,037,169,244,BACKGROUND,CGEMS,COLORECTAL,DRE,INC,LABEL,MARKERS,METHODS,OVARIAN,PCA,PGS,PSA,RESULTS,SCREENING,TRIAL,WILEY
231,GPIIB,MDA,THESE
169,AKT,BRIEFLY,COPYRIGHT,DSB,ECS,FINALLY,H1975,IRELAND,LTD,NSCLC,USING,VEGR2
017,037,100,169,183,190,ACCURAY,AWARD,BACKGROUND,BECAUSE,COPYRIGHT,ESTIMATED,FUNDING,GRADE,INC,IQR,LABEL,LTD,METHODS,NCI,NSCLC,RECURRENCE,RESULTS,ROSEL,SCIENCE,SIX,STARS,SUPPORT,THREE
DESPITE,FOLLOWING,GEM,HOWEVER,SMV,STAGE,THEREFORE,THREE
215
046,134,669,784,AMONG,BASED,COMMITTEE,THESE
GRADE,HANGE,HOWEVER,III,LUX,MAY,PFS,SEVEN,TKI
100,600,AICHI,ALDH2,JAPAN,MEDICAL,MULTI
101,298,341,639,AEGIS,ALLEGRO,AUC,BACKGROUND,CURRENT,LABEL,METHODS,RESULTS
169,945,ACCORDING,BNIP3,COPYRIGHT,DESPITE,HIF,INC,KNOCK,NSCLC,TAKEN,TREATMENT
15P,169,5MM,ANOVA,BASED,BEV,CONCLUSION,COPYRIGHT,CYBERKNIFE,FIFTEEN,FURTHER,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
007,169,ASA,BACKGROUND,CARDIAC,CONCLUSION,COPYRIGHT,INCIDENCE,LABEL,LTD,METHODS,MORBIDITY,OVERALL,RESULTS,THERE
170,177,213,956,BCL,MCF,PREVIOUSLY,THESE
169,CAR,CASCS,CLINICALLY,FAP,FIBROBLAST,HOWEVER,MALIGNANT,PRIOR,THESE
000,100,169,APRIL,BRCA1,COPYRIGHT,ERC,ERCC1,HOWEVER,III,LITERATURE,LTD,MALIGNANT,MESOTHELIN,MPM,MUTATIONS
002,150,169,399,ADDITIONAL,AMONG,BACKGROUND,BSC,CONCLUSION,COPYRIGHT,COX,LABEL,LTD,MCC,METHODS,PFS,RESULTS,RIGHT
169,945,AUTHORS,MET,METHIONINE,RXR,SAM

169,BIOLOGY,CONVERSELY,EVANS,INC,MOLECULAR,NADPH,NCX,PAR,REVERSE,ROS,SEA0400,SOCIETY,TARGETING
169,676,713,HOSPITALS,JAPAN,LABEL,METHODS,OBJECTIVE,PRESS,PUBLISHED,RESULTS,STAGE,UNIVERSITY
001,104,177,747,AUC,BACKGROUND,BPE,CEA,CONCLUSION,FIFTY,HOWEVER,LABEL,METHODS,MPE,PLEURAL,RESULTS,USING
CAD,EIGHT,HOWEVER,ROI,SMOTE,SVM
AFTER,BMJ,CIS,EMP,GROUP,LABEL,LIMITED,METHODS,MINNESOTA,OBJECTIVE,ORS,PUBLISHED,PUBLISHING,RESULTS
169,ERK,MEK,MET,ONCOGENIC,RAS,REMARKABLY
169,239,945,AMONG,COPYRIGHT,DIGITAL,EVALUATION,HEALTHY,IRELAND,LABEL,LTD,METHODS,MIP,NSCLC,OBJECTIVE,RESULTS,SCORE
169,945,ATP,BECAUSE,CONSISTENT,COPYRIGHT,H1299,HIF,HSP90,L80,SOCIETY,THEREFORE,THESE
160,DOCETAXEL,JANUARY,LABEL,METHODS,NOVEL,NSCLC,OBJECTIVE,PURPOSE,RESULTS
AGE,DISTANT,III,JANUARY,LABEL,MEIER,METHODS,OBJECTIVE,RESULTS
266,ADC,LABEL,METHODS,OBJECTIVE,RESULTS,TNM,UNIVARIATE
001,004,007,010,035,160,165,169,954,CHINESE,COPYRIGHT,HAN,INC,KARNOFSKY,MST,OVERALL,STAT3
145,1522B,AG0,MCT,RIBES,SCT,THESE,UNDER
946,AMONG,BEL,IC50S,PC3,SAR,SGC
HRQOL,JANEIRO,LABEL,METHODS,NON,NSCLC,OBJECTIVE,QUALITY,RESULTS,RIO,TREATMENT
169,945,AGS,ANTITUMOR,BATF3,CD103,CD8,COPYRIGHT,IFN,INC,SIMILARLY,THESE
169,BCC,BRCA1,COPYRIGHT,EARLY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PATHOLOGY,RESULTS,SIX,SOCIETY,THESE
169,ALI,CONCLUSION,COPYRIGHT,DISEASE,LABEL,METHODS,NSCLC,OBJECTIVE,OBJECTIVES,PATHOLOGY,RESULTS,SOCIETY
BACKGROUND,ISOPURE,LABEL,REPLACING,RESULTS
EGF,EPIDERMAL,L858R,PREVIOUSLY,T790M,THESE,TKI,Y1068,Y1086,Y1173
PERINEURAL
001,110,AIS,BETWEEN,HOWEVER,TAKEN,TTF
169,CAM,CHROMATIN,GEO,LABEL,LUCIFERASE,METASTASIS,METHODS,OBJECTIVE,PRESS,PUBLISHED,RESULTS,TRANSWELL,UNIVERSITY,WOUND
150,169,178,610,AUC,COPYRIGHT,FORTY,INC,LABEL,MATERIALS,METHODS,MONDAYS,OBJECTIVE,PURPOSE,RESULTS,TUESDAY
169,954,COPYRIGHT,NAC,PUBLISHED,ROS,SINCE,SO2
169,ALK,ANAPLASTIC,BACKGROUND,BASEL,CONCLUSION,FNA,HOWEVER,ICC,LABEL,METHODS,RESULTS
068,157,281,519,805,868,954,ABSTRACTS,BMJ,GROUP,LABEL,LIMITED,MEDLINE,METHODS,OBJECTIVE,PUBLISHED,PUBLISHING,REFERENCE,RESULTS,SURGERY,SYSTEMATIC
169,DAMPS,FOUNDATION,IMMUNOLOGY,JOURNAL,THESE
169,COPYRIGHT,INC,KEY,MEK
169,COPYRIGHT,INC,NIVOLUMAB,PUBLISHED
169,COPYRIGHT,HOWEVER,INC,MONOCLONAL
169,COPYRIGHT,CURRENT,INC,MALIGNANT
169,COPYRIGHT,DESPITE,INC,NSCLC
169,AIM,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,METHODS,OBJECTIVE,PLC,RESULTS,THEREFORE
001,133,169,675,933,ANTICANCER,BACKGROUND,CHI,CONCLUSION,COPYRIGHT,COX,EXCEL,INSTITUTE,LABEL,METHODS,MICROSOFT,PRIMARY,PRISM,RADIATION,RESULTS,USING
169,ALK,ANTICANCER,ATM,COPYRIGHT,INSTITUTE,KIRSTEN,NSCLC,STK11,TESTING
169,176,500,956,AMONG,ANTICANCER,COPYRIGHT,FDG,FORTY,INSTITUTE,PET,THESE
012,027,169,AIM,ANTICANCER,BACKGROUND,CONCLUSION,CONVERSELY,COPYRIGHT,INSTITUTE,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS
169,AAA,AIM,ANTICANCER,CONCLUSION,COPYRIGHT,FORTY,GUIDELINES,INSTITUTE,LABEL,METHODS,OBJECTIVE,PBC,RESULTS,THEIR,THESE
169,AIM,AKT,ANOIKIS,ANTICANCER,BACKGROUND,BCL,CONCLUSION,COPYRIGHT,ERK,INSTITUTE,LABEL,MATERIALS,METHODS,MTT,OBJECTIVE,RESULTS
169,AIM,ANTICANCER,BACKGROUND,BLOOD,CONCLUSION,COPYRIGHT,CTC,INSTITUTE,LABEL,METHODS,OBJECTIVE,RESULTS,RFA,SCREENCELL
169,AMONG,ANRIL,ANTICANCER,COPYRIGHT,INSTITUTE,PLD
169,AIM,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,FPR,INSTITUTE,LABEL,MATERIALS,METHODS,OBJECTIVE,PCR,RESULTS
169,963,ANTICANCER,BRCA1,CHINESE,COMET,COPYRIGHT,DMC,H2A,INSTITUTE,NCI,TAKEN,WESTERN
169,177,956,AIM,ANTICANCER,CONCLUSION,COPYRIGHT,FORTY,III,INSTITUTE,LABEL,METHODS,NSCLC,OBJECTIVE,PTX,RESULTS,TUBB3
169,177,916,AIM,ANTICANCER,AUC,BACKGROUND,BL6,C57,CONCLUSION,COPYRIGHT,EGF,FINALLY,INSTITUTE,LABEL,LEWIS,LLC,MATERIALS,METHODS,OBJECTIVE,RESULTS,SIMAX,USING
169,AIM,ANTICANCER,BACKGROUND,CFP,CONCLUSION,COPYRIGHT,GFP,INSTITUTE,LABEL,MATERIALS,METASTASES,METHODS,OBJECTIVE,OLYMPUS,PANCREATIC,RESULTS,RFP,THREE,XPA
169,ANTICANCER,COPYRIGHT,FIRST,HOWEVER,III,INSTITUTE,NSCLC,PFS,SEVERAL,THEREFORE,TKI
169,ANTICANCER,COPYRIGHT,INSTITUTE,MALIGNANT,MPM
AFTER,CNS,CRANIOTOMY,III,RESTAGING
121,169,BACKGROUND,HOWEVER,KIT,LABEL,METHODS,MULTITECH,PNA,RESULTS,SOCIETY
ACH,ACTIVATION,AFTER,AKT,HOWEVER,M3R,NSCLC,TAKEN
177,BACKGROUND,CONCLUSION,INC,LABEL,METHODS,NTG,PUBLISHED,RESULTS,SEM
001,008,169,HODGKIN,INC,NHL,USING,WILEY
CHEST,HOWEVER
6TH,AFTER,MARCH,THESE
2ND,RIGHT
IRINOTECAN,LIVER,PCG,UPPER
100MG,AUC
B12,CONCLUSION,GRADE,HOWEVER,LABEL,METHODS,OBJECTIVE,RESULTS,THERE,THEREFORE
ALK,MOLECULAR,NSCLC,T790M,TKI
169,231,233,4TH,COPYRIGHT,LEA,PUBLISHED,SAS,SOCIETY,THERAPY,UNDER
ALK,NSCLC
215,365,809,ABCA1,ACOT4,AFRICAN,AMERICANS,BLOOD,DISCOVERY,ESP,EXOME,HEART,IMPORTANCE,INSTITUTE,JANUARY,LABEL,METHODS,NHLBI,OBJECTIVE,PDE4DIP,PROJECT,RELEVANCE,RESULTS,SEQUENCING,SETTING,THESE,ZFHX3
169,COPYRIGHT,FGFRS,LTD,NSCLC
169,321,BIOLOGY,INC,MDA,MOLECULAR,SOCIETY,UTR
169,COPYRIGHT,MACROPHAGE,MIF,SOCIETY

HISTONE
ILD
ALK
250,ACTIVATING,AFTER,ALK,CAUCASIAN,GEFITINIB,HOWEVER,NSCLC
169,177,BECAUSE,CONCLUSION,EVALUATION,HOUNSFIELD,IMAGING,INC,INTER,LABEL,METHODS,MOLECULAR,NUCLEAR,PEDIATRIC,PET,RESULTS,SDS,SEGBASE,SEGWBONEAD,SEGWBONEPE,SOCIETY,UNLABELLED,VOI
BRAIN,HOWEVER,THERAPIES
169,COPYRIGHT,HEART,INC,PUBLISHED,SOCIETY
ERLOTINIB,HOWEVER,NSCLC,PFS
160,169,APN,AUTHORS,B16,GIVEN,H1299,LTD,NOD,PTY,PUBLISHING,SCIENCE,THESE,WILEY
001,10878,AWARENESS,BACKGROUND,BELIEFS,HOWEVER,LABEL,METHODS,RESULTS,SMOKERS,SMOKING,THESE
CHEST,DPB,HOB
004,005,006,026,194,CONCLUSION,LABEL,METHODS,NVBNA,OBJECTIVE,RCT,RESULTS,VBN
177,215,ACUTE,AMONG,CONCLUSION,IPF,LABEL,MEANWHILE,METHODS,OBJECTIVE,PCR,RESULTS,TTV
ATM,BCL,CSC,JUN,LABEL,METHODS,MTT,NSCLC,OBJECTIVE,PRO,PROTEIN,PURPOSE,RESULTS,RIP,SER,THR,TRADD
ANAMORELIN,AREAS,BACKGROUND,COVERED,LABEL,METHODS,NSCLC,OPINION,TARGETING
CAD,FCM,GGO
169,ASTRO,BECAUSE,COMMITTEE,CURRENT,GUIDELINE,III,IMPORTANT,LABEL,METHODS,NSCLC,OBJECTIVE,PANEL,PRACTICAL,PURPOSE,RADIATION,RESULTS,SOCIETY,THERE
169,CONSISTENT,DESPITE,FP3,RDB,TAKEN,VARIOUS
169,504,789,AML,BENZENE,CHINA,CHINESE,HLD,HODGKIN,POISSON,RRS
169,COPYRIGHT,FINALLY,LTD,SILIBININ,SILYBUM,STAT3
169,BAHRAIN,COPYRIGHT,COUNCIL,DESPITE,HODGKIN,LTD,QATAR,SAUDI
101,AFTER,APRIL,BACKGROUND,BETWEEN,CLINICIANS,CONCLUSION,FDG,HODGKIN,LABEL,METHODS,ONTARIO,PET,RESULTS,SOMETIMES
160,169,218,945,ECTOPIC,HOWEVER,SLIT2,SRC,THESE,UTR
001,160,169,172,412,535,AUTHORS,CURRENTLY,HOWEVER,LTD,MALIGNANT,PTY,PUBLISHING,SCIENCE,THREE,WELFARE,WILEY
100,160,169,946,956,ACC,AMP,ASPIRIN,AUTHORS,COA,LIMITED,MRC,PNT1A,PRE,PRESS,SALICYLATE
ASSOCIATED
BASED,PET,SEVERAL
101,169,AMONG,BACKGROUND,BAL,CONCLUSION,INC,LABEL,METHODS,PROCEDURE,RESULTS,THERE,WILEY
137,169,PREDICTIVE,USING
104,208,BDE,BLOOMBERG,CASES,COLORECTAL,GOVERNMENT,HOPKINS,INCREASING,JOHNS,OVARIAN,PBDES,PRESS,PUBLISHED,SCREENING,TRIAL,UNIVERSITY
AZD9291,C797S,PCR,T790M,TKI
178,568,BACKGROUND,BMI,CONCLUSION,COX,ENGLAND,FUNDING,HOWEVER,INSTITUTE,LABEL,LIMITATION,METHODS,OBJECTIVE,OVERWEIGHT,PRIMARY,RESULTS,SERVICE,SETTING,UNIVERSITY,WHETHER
001,006,1544C,169,20Q11,215,348,699,915,998,COPYRIGHT,FKBPL,HOWEVER,INC,PRO137LEU,PRO515LEU,PUBLISHED,SOCIETY,VAL284MET
169,AKT,COPYRIGHT,ERK,HENCE,IRELAND,LTD,MEK,NSCLC,RAS
169,175,916,945,946,AFTER,COPYRIGHT,FACTORS,INC,INT,JAC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,V20,VENTINT,VENTJAC
169,ADC,AST,COPYRIGHT,FURTHER,INC,NSCLC,ROS,SCC,SIMILAR
048,130,169,174,548,AUTHORS,COPYRIGHT,COX,DSS,III,INC,LABEL,MATERIALS,METHODS,NOMOGRAMS,NSCLC,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,TNM,VARIABLES,WORLD
100,169,177,947,BASED,COPYRIGHT,CYBERKNIFE,HOUNSFIELD,INC,KOREA,LABEL,LOKIT,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THOSE,THREE
169,COPYRIGHT,DUE,HOWEVER,LTD,NSCLC
0GY,169,4GY,5GY,7GY,8GY,BACKGROUND,CONCLUSION,COPYRIGHT,D95,FUNCTIONAL,IRELAND,LABEL,LTD,MATERIALS,METHODS,MLD,NSCLC,OBJECTIVE,PET,PLANS,PTV,PURPOSE,RESULTS,SUV,THERE,V10,V20,V30,V40,V50,V60,VLUNG
COPYRIGHT,OCT,SLACK
001,019,265,329,342,409,413,452,803,917,999,ANOVA,BECAUSE,CHI,METHODS,MIS,RESULTS,THERE
112,160,166,169,250,374,946,99M,CONCLUSION,HOWEVER,IMAGING,INC,JANUARY,LABEL,MAA,MARCH,MBQ,METHODS,MOLECULAR,NUCLEAR,RESULTS,SOCIETY,SPECT,THESE,UNLABELLED,VOLUMES
169,BACKGROUND,LABEL,MEDICAL,METHODS,MINNESOTA,NORTH,OSA,RESULTS,SHORE,SOCIETY,THERE,THREE,UNIVERSITY

169,BACKGROUND,END,ESOPHAGEAL,GISTS,HODGKIN,HOWEVER,LABEL,METHODS,OVARIAN,RESULTS,SIR,SOCIETY,SPR,THERE,THESE
EVALUATION,HOWEVER
DOSIMETRIC,ECS,PTV,V20,VERSION
CIS,FURTHER,INSURANCE,MDS,NHI,ORS,OVERALL,TAIWANESE
ADDITIONAL,BASED,CTS,DOSIMETRIC,FDG,FLT,MAXIMUM,METABOLIC,MVS,NSCLC,ORS,OVERLAP,PET,PVS,SUVMEAN,TCP,TOTALLY
MBC,RECURRENCE
AMERICA,AUSTRALIA,BACKGROUND,GROUP,LABEL,METHODS,MONOGRAPHS,NORTH,RESULTS,SMR,SOURCES,WORKING
ADJUSTING,BACKGROUND,BLACK,EXAMINE,HOWEVER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,RATIONALE,RESULTS,SCREENING,SMOKING,TRIAL
025,149,272,313,362,589,643,878,946,BACKGROUND,C509T,CHINESE,G875A,GENOTYPING,HOWEVER,LABEL,METHODS,RESULTS,SNP,TGF,TGFB1
BACKGROUND,DDP,DNMT1,DNMTS,LABEL,METHODS,MICRORNAS,MTT,NSCLC,PCR,RESULTS,SPC,UTR,WHILE
169,947,BIOLOGY,CATENIN,EXPRESSION,HAI,HGF,HOWEVER,INC,MET,MOLECULAR,NSCLC,SOCIETY,SPINT,TAKEN,THEREFORE
169,183,375,AFTER,BACKGROUND,BETWEEN,CD79B,CLL,COPYRIGHT,FUNDING,GENENTECH,GRADE,HODGKIN,LABEL,LTD,MARCH,METHODS,NHL,NOV,RESULTS,SERIOUS,SEVEN
WHETHER
160,239,500,APRIL,BETWEEN,CONCLUSION,EASTERN,FEBRILE,GROUP,LABEL,METHODS,NSCLC,OBJECTIVE,PEMETREXED,PFS,PURPOSE,RESULTS,SEPTEMBER,SIXTEEN,THERE
093,169,496,638,735,CLPTM1L,HOWEVER,ISRAELI,SMOKING
150,185,ADP,GPC,LY293,METHOXY,MITOTIC,NMR,POLYMERIC,TREATMENT,TUBULIN
000,160,169,176,183,513,BACKGROUND,BASED,BETWEEN,DUE,EUR,FEDERAL,GEORG,INSURANCE,LABEL,METHODS,NUMBERS,OUTPATIENT,PHYSICIANS,POPULATION,PREVALENT,REGISTRIES,RESULTS,STATISTICS,STATUTORY,STUTTGART,THESE,WINHO
160,169,183,FDG,GEORG,PET,STUTTGART
130,150,500,625,750,900,BACKGROUND,HBR,KEY,LABEL,METHODS,NON,NSCLC,RESULTS,T790M,TREATMENT
127,222,240,253,AMONG,AZD9291,BACKGROUND,LABEL,METHODS,RESULTS,T790M
169,BACKGROUND,COX,FINLAND,FINNISH,HEART,HISTORICAL,INC,LABEL,MEIER,METHODS,OBJECTIVE,POSTSTROKE,PURPOSE,RESULTS,STATISTICS,YOUNG
169,231,233,CONCLUSION,COPYRIGHT,LABEL,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SAS,THERE
160,AFTER,APRIL,BACKGROUND,BETWEEN,CNS,CONCLUSION,JANUARY,LABEL,METHODS,NSCLC,RESULTS,SURVIVALS
001,009,025,169,492,AKT,BACKGROUND,INC,LABEL,MALDI,METHODS,MUTATIONS,OBJECTIVE,OBJECTIVES,RAF,RAS,RESULTS,SOMATIC,TOF,WILEY
956,DU145,NTUB1,SOLANUM
169,199,229,BACKGROUND,CCAT2,INC,LABEL,LNM,METHODS,MYC,OBJECTIVE,OBJECTIVES,PCR,RESULTS,TNM,WILEY
231,956,CHCL3,EIGHT,KAEMPFERIA,MDA,MYANMAR,PSN,TIG
100,169,AMONG,BAL,CMV,HCT,HEMATOLOGY,HHV,HRV,IPS,MORTALITY,NEWER,SOCIETY
169,AIM,ANY,BACKGROUND,BRITISH,CONCLUSION,CONTINUITY,ENGLAND,GENERAL,JOURNAL,LABEL,METHODS,OBJECTIVE,PATIENT,RESULTS,SECONDARY,SETTING,TRS
169,227,AFRICAN,AMERICANS,CONCLUSION,LABEL,METHODS,NSCLC,OBJECTIVE,PURPOSE,RESULTS,SMARCA4,SOCIETY
169,BCL,COPYRIGHT,FBXW7,HENCE,MCL,SCF,SOCIETY,TORKINIBS
169,947,ATM,ATR,BIOLOGY,ERK,HOWEVER,INC,MOLECULAR,NCI,SOCIETY,TAKEN
169,COPYRIGHT,INC,RCC,RENAL
058,079,101,169,286,781,ADJUSTING,COLORECTAL,CONCLUSION,COPYRIGHT,GLEASON,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,OVARIAN,PSA,RESULTS,RISKS,SCREENING,TRIAL
036,169,384,387,CHINESE,COPYRIGHT,NFKB1,THERE
169,BID,COPYRIGHT,DR5,HOWEVER,IRELAND,LTD,SRB,TAKEN
001,169,688,794,AMONG,BACKGROUND,END,INSURANCE,LABEL,METHODS,PATIENT,RATES,RESULTS,SOCIETY,VARIATION
003,160,169,967,BACKGROUND,BECAUSE,BRIEFER,COPYRIGHT,INC,KRUSKAL,LABEL,MEIER,METHODS,PUBLISHED,RESECTIONS,RESULTS,SOCIETY,STAGE
197,300,956,BECAUSE,GMP,MIC50,MTHGPRT,THESE
945,946,AMONG,ANXA2,MET5A,THEREAFTER,THESE
946,954,AB1,EVALUATION,KIT,MCS,MPE,TREATMENT
079,100,105,304,467,691,920,AMONG,BACKGROUND,COPENHAGEN,GENERAL,LABEL,METHODS,NEVER,OBJECTIVE,OBJECTIVES,POPULATION,RATIONALE,RESULTS
169,AIM,COPYRIGHT,LTD,RESULTS
001,160,169,459,631,714,AMONG,BACKGROUND,CCI,COPYRIGHT,COX,CRS,FACTORS,INC,INDEX,LABEL,METHODS,NSCLC,PROPENSITY,PUBLISHED,RESULTS,SOCIETY,THERE
169,AFTER,COPYRIGHT,INC,PUBLISHED,SOCIETY
004,160,169,BACKGROUND,COPYRIGHT,INC,LABEL,LIPOB,METHODS,POSTERIOR,PUBLISHED,RESULTS,SOCIETY,TEA,THERE
169,AMONG,COPYRIGHT,EGFRS,EPIDERMAL,IMMUNOBLOT,NSCLC,PUBLISHED
169,946,BECAUSE,C5A,COPYRIGHT,DEPLETION,INC,TGF,TH1,TH2,USING
169,177,398,5DN,945,946,FASEB
BACKGROUND,BDUMP,BMJ,GROUP,LABEL,LIMITED,METHODS,PUBLISHED,PUBLISHING,RESULTS,THESE,TREATMENT
008,169,177,ACRIN,BLAND,CONCLUSION,FDG,III,IMAGING,INC,LABEL,MERCK,METHODS,MOLECULAR,NSCLC,NUCLEAR,PET,RCS,RESULTS,SOCIETY,SOLID,SUV,SUVPEAK,UNLABELLED
116,500,CONCLUSION,JANUARY,LABEL,METHODS,OBJECTIVE,OCTOBER,RESULTS,TES,THERE
001,019,105,140,669,BACKGROUND,LABEL,METHODS,OBJECTIVE,OVERALL,RESULTS
ASIAN,BACKGROUND,FIRST,III,JANUARY,LABEL,METHODS,NSCLC,OBJECTIVE,ORR,PFS,RESULTS,TTP
GTN,PLACENTAL,PRIMARY,PSTTS
FIRST,HOWEVER,TKI
AVP,ECTOPIC,OTHER,SIADH
ALK,CRIZOTINIB,INCREASED,NON
BACKGROUND,LABEL,METHODS,MRI,STAGING,ULTRASOUND
AFTER,BACKGROUND,BRONCHIAL,DOCETAXEL,FIBEROPTIC,LABEL,MATERIALS,METHODS,NSCLC,PULMONARY,RESULTS,SPIROMETRY
512,64257,BACKGROUND,LABEL,METHODS,OBJECTIVE,RESULTS,SIR,SUBSEQUENT
BACKGROUND,CUMULATIVE,FDG,LABEL,MEIER,METHODS,NSCLC,PET,RADDX,RECORDS,RESULTS,SIXTY

130,BACKGROUND,CIGARETTE,CONCLUSION,HNC,LABEL,METHODS,PRIMARY,RESULTS,SECONDARY,SIXTY
169,APMIS,GIANT,LTD,PUBLISHED,WILEY
ANOTHER,AREAS,ASIAN,BACKGROUND,BASED,COVERED,DEL19,L858R,LABEL,METHODS,NSCLC,OPINION,ROUTINE
169,954,E2F,FINALLY,MARK2,MARKS,MAX,MYC
283,656,AHS,AMONG,BMJ,GROUP,LABEL,LIMITED,METHODS,NEWLY,NORTH,OBJECTIVE,POISSON,PUBLISHED,PUBLISHING,RESULTS,RRS
DCLDS,LANGERHANS
001,022,182,954,BACKGROUND,CHROMATIN,LABEL,MEIER,METHODS,OBJECTIVE,OBJECTIVES,PEARSON,RATIONALE,RESULTS
113,144,181,286,312,BOSNIAK,CAPTURE,CONCLUSION,ELECTRONIC,IIF,III,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,OCTOBER,PATHOLOGIC,RESULTS,THERE,WEB
CENTERS,POPULATION,THESE
100,169,295,590,BACKGROUND,BETWEEN,CIS,COLORECTAL,CONCLUSION,DBP,FURTHER,LABEL,METHODS,NUTRITION,OBJECTIVE,ORS,OVARIAN,RESULTS,SOCIETY,VITAMIN
169,BRITAIN,COPYRIGHT,EMT,FINALLY,GREAT,IRELAND,LTD,NSCLC,PUBLISHED,SOCIETY,WILEY
108,126,167,169,299,762,AMONG,HEAVY,HOWEVER,POISSON,SPC
004,160,250,CONCLUSION,DCR,FORTY,GEFITINIB,HOWEVER,LABEL,MAY,METHODS,NSCLC,OBJECTIVE,OCTOBER,OPTIMIZED,PCR,PFS,PNA,PURPOSE,REGARDING,RESULTS,SEVENTY,SMALL,TKI
101,169,CONCLUSION,ENROLLMENT,LABEL,METHODS,NOGUCHI,OBJECTIVE,PRESS,PUBLISHED,RESULTS,THERE,UNIVERSITY
169,BASED,CL1,COPYRIGHT,FIRSTLY,HOWEVER,IRELAND,JNK,JUN,LTD,MAP,MMP,PIPOXOLAN,PUBLISHED,THEREFORE,THESE
001,160,278,421,CHI,CRC,ESPECIALLY,HOWEVER,MEIER,STAGE
AKT,CTL,EMT,METASTATIC,NANOG,PREVIOUSLY,TCL1A,THEREFORE,THESE
129,169,AMONG,CONCLUSION,GRADE,LABEL,METHODS,NIVOLUMAB,NSCLC,OBJECTIVE,PROGRAMMED,PURPOSE,RANDOMIZED,RESULTS,SOCIETY,THREE
001,169,649,CIS,CONCLUSION,HRS,L858R,LABEL,METHODS,NEVER,OBJECTIVE,PFS,PURPOSE,RESULTS,SOCIETY,THESE,WOMEN
169,182,538,772,CANCERS,CONCLUSION,LABEL,METHODS,NUTRITION,OBJECTIVE,PREVENTION,PURPOSE,RESULTS,SOCIETY
169,AIM,ANNEXIN,COPYRIGHT,FURTHER,INC,JNK,KEY,LABEL,METHODS,MNQ,OBJECTIVE,OXIDATIVE,RESULTS,ROS,WESTERN
169,945,947,COPYRIGHT,FURTHER,IRELAND,LTD,NCI,RESULTS,THESE,TNF
0MM,169,177,181,945,954,CHRONIC,COX,FURTHER,I3C,LPS,NNK,PRESS,PUBLISHED,SIL,THEREFORE,THESE,UNIVERSITY
160,INC,PUBLISHED,TYPICAL
FURTHER,THESE
946,RIG,TGF
160,CISPLATIN,CONCLUSION,HOWEVER,JNK,LABEL,METHODS,OBJECTIVE,PCR,PURPOSE,RESULTS,ROS,SIMILAR,TREATMENT
CLINICIANS,FORCE,PREVENTIVE,SCREENING,TRIAL
001,136,169,AIM,CONCLUSION,COPYRIGHT,CURRENT,ENF,FORTY,IRELAND,LABEL,LTD,METHODS,NSCLC,OBJECTIVE,PET,REPORTS,RESULTS,THERE,THESE
MLC
169,AUTHORS,FANCONI,ICL,LTD,PTY,PUBLISHING,SCIENCE,THESE,WILEY
169,ACCORDING,BACKGROUND,BECAUSE,COPYRIGHT,EIGHT,INC,JANUARY,LABEL,METHODS,RESULTS
169,946,ADDITIONAL,BACKGROUND,CONSORTIUM,CRC,HRQOL,LABEL,MCS,MEDICAL,METHODS,PCS,RESULTS,SOCIETY,TREATMENT
001,182,313,495,AMONG,BACKGROUND,KEYNOTE,LABEL,MERCK,METHODS,RESULTS
169,BACKGROUND,HOWEVER,LABEL,METASTATIC,METHODS,NSCLC,OLDER,ONTARIO,PATIENT,RESULTS,SOCIETY,THOSE
000,001,022,160,169,177,658,995,BACKGROUND,COPYRIGHT,DELAY,DELAYED,HOWEVER,INC,LABEL,METHODS,NSCLC,PROPENSITY,PUBLISHED,RESULTS,SOCIETY,STRATEGIES,THOSE,TREATMENT
AKT,APOPTOSIS,BACKGROUND,BAX,BID,CASPASE,HOWEVER,LABEL,METHODS,MTT,NSCLC,RESULTS,RYONG,THESE,WESTERN
169,956,COPYRIGHT,INC,PCR
169,956,CARROLL,COLIGAN,COMMITTEE,COPYRIGHT,ENSEMBL,FAIM3,FAS,FCR,HOWEVER,IGM,INC,MCANDREWS,MICHAEL,MOUSE
BACKGROUND,BASED,DESPITE,HODGKIN,HOWEVER,LABEL,METHODS,REDUCTION,RESULTS,STUDIES
160,169,BACKGROUND,COPYRIGHT,DEFINITIVE,INC,LABEL,LOBECTOMY,METHODS,NSCLC,PUBLISHED,RESULTS,SALVAGE,SOCIETY,THERE
112,388,419,858,942,AMBER,AMONG,BACKGROUND,EPIDERMAL,HOWEVER,L858R,LABEL,NSCLC,RESULTS,ROSETTA,STRUCTURAL,THESE
947,948
000,213,249,375,415,501,541,672,833,BACKGROUND,CENTRAL,DESPITE,LABEL,METHODS,REGARDING,RESULTS,SEYLL,YEARS
150,205,ALA205LEU,AMP,CATHEPSINS,LEU205ALA,MOLECULAR
AFTER,ASKIN
BACKGROUND,HGF,LABEL,MET,RESULTS,SCC,SEVERAL,THESE
DIETARY
185,554,604,677,681,710,715,739,744,748,760,766,781,784,837,839,897,923,AUC,CONCLUSION,FUDAN,LABEL,METHODS,NSCLC,OBJECTIVE,RESULTS
169,231,233,AFTER,COPYRIGHT,PEDIATRIC,PUBLISHED,SAS
100,DIAGNOSTIC,FDG,HOUNSFIELD,NPV,PET,PPV,SPN,SUV
169,BACKGROUND,HISTORY,HNC,LABEL,METHODS,RESULTS,SPLCS
016,024,109,169,1A1,416,ALDH1A1,BESIDES,COPYRIGHT,FURTHER,III,INC,LEUCINE,NSCLC,PCR,TNM
CONCLUSION,DCR,FACTORS,III,LABEL,METHODS,NSCLC,OBJECTIVE,RESULTS,TOTALLY,YCR
223,BACKGROUND,EPB41L3,INCUBATION,LABEL,MVS,NSCLC,RESULTS
120,160,BACKGROUND,CCL16,EMT,FEW,LABEL,RESULTS,SEVENTY
001,179,AFTER,FILIPINOS,HAWAIIANS,LABEL,METHODS,NMR,OBJECTIVE,OBJECTIVES,RESULTS,WHITE
A2780,BACKGROUND,BFU,FIRSTLY,HEPG2,LABEL,LEWIS,LLC,METHODS,MTT,MVD,NOTABLY,RESULTS,THESE
ABCC1,BACKGROUND,H69,H69AR,HOWEVER,KCNJ2,KIR21,KNOCKDOWN,LABEL,MDR,MEK,METHODS,PKC,RAS,RESULTS
000,100,152,312,330,CDC,CENTRAL,CESSATION,LABEL,METHODS,POPULATION,RICAN,STATISTICS,UNLABELLED
169,183,197,BIOLOGY,INC,LYS,MOLECULAR,PPE,SOCIETY,STRUCTURAL
169,452,ACADEMY,CLASS,CONCLUSION,FATAL,IMPAIRMENT,LABEL,METHODS,NEUROLOGY,NEUROPATHY,OBJECTIVE,POEMS,PREDICTED,RESULTS,ROCHESTER,SCALE,SCORE,SIX,SIXTY
169,EPIDERMAL,EVALUATION,HOWEVER,L858R,LABEL,METHODS,OBJECTIVE,PRESS,PUBLISHED,RESULTS,SEVENTY,SOLID,THERE,UNIVERSITY
005,161,169,926,BACKGROUND,COX,LABEL,MEIER,METHODS,RESULTS,SHS,SOCIETY,SPOUSAL,THERE
967
160,169,214,945,ABNORMALLY,AUTHORS,EPO,FDA,FINALLY,HIF,JOURNAL,PHT,PLACENTAL,SCD,SOCIETY,THESE,UTR
CHEST,PTE
ALECTINIB,ALK,COPYRIGHT,DUE,FDA,HOWEVER,III,JAPAN,NSCLC,PROUS,SCIENCE
001,003,169,AMONG,ANECDOTAL,BACKGROUND,ERLOTINIB,EVALUATION,FACTORS,LABEL,METHODS,RESULTS,SOCIETY,SOLID,TTC
169,BRITAIN,COPYRIGHT,GREAT,GREMLIN,IRELAND,JOURNAL,LAVOZ,LTD,PATHOLOGY,PUBLISHED,SOCIETY,WILEY
15A,CHICAGO,GLO,MICRORNAS,NSCLC,PCR,USA,UTR,WESTERN
072,15Q25,169,AMONG,BACKGROUND,COCHRAN,CONCLUSION,COX,GIVEN,LABEL,METHODS,PRESS,PUBLISHED,RESULTS,THESE,UNIVERSITY
169,COPYRIGHT,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PATHOLOGY,PULMONARY,RESULTS,SOCIETY,UNTIL,WHILE
169,COPYRIGHT,EWING,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PATHOLOGY,RESULTS,SOCIETY,THREE
08113,22113,EORTC,HOWEVER,NSCLC,OUTLINE,TREATMENT
AMONG,BACKGROUND,COMMITTEE,COX,GOVERNMENT,III,JOINT,LABEL,MEIER,METHODS,NSCLC,OLDER,PUBLISHED,RESULTS,USA
BMJ,BRITAIN,COX,CVD,FURTHER,GREAT,GROUP,IHD,LABEL,LIMITED,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,PUBLISHING,RESULTS,SMR
001,038,181,222,AFTER,COX,LABEL,LOBECTOMY,METHODS,NSCLC,OBJECTIVE,OBJECTIVES,PROPENSITY,RESULTS,THESE,UNIVERSITY
18F,FDG,INSTEAD,LABEL,NSCLC,OBJECTIVE,PET,THESE
449,480,8G7G3,CURRENTLY,HOWEVER,SPT24,TTF
BMJ,BRITISH,BTS,GROUP,GUIDELINE,LIMITED,PUBLISHED,PUBLISHING,SOCIETY
169,AZD6244,AZD9291,EARLY,EGFRM,H1975,MEK,NCI,PC9,RESISTANCE,T790M
150,169,CONCLUSION,HSP,HSP90,LABEL,METHODS,OBJECTIVE,PARTIAL,PURPOSE,RESULTS,SOCIETY,T790M
001,007,130,169,224,446,840,BACKGROUND,COLLEGE,COPYRIGHT,HOWEVER,INC,LABEL,METHODS,MST,OPERATIVE,PROPENSITY,PUBLISHED,RESULTS,SHORT,THERE,VIDEO
013,032,036,042,045,124,197,AGILENT,BACKGROUND,LABEL,METHODS,MIR,NSCLC,RESULTS,TOTAL
946,FOXQ1,INCREASED,LAMA4,THESE,THROUGH
169,4AI,593,ATP,COPYRIGHT,DENV1,DENV2,DENV3,INC,PKR
MALIGNANT
100,169,183,315,AFTER,BACKGROUND,BESIDES,COMPLIANCE,COPYRIGHT,FTE,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PATIENT,PURPOSE,RESULTS,SELECTION
160,AIM,CONCLUSION,HOWEVER,LABEL,MATERIALS,METHODS,MLD,OBJECTIVE,RESULTS
169,173,AUTHORS,CCL20,CLINICALLY,COPYRIGHT,IRELAND,LTD,NNK,PUBLISHED,THESE,TOBACCO
019,110,150,169,967,AUTHORS,COPYRIGHT,FEW,GROUP,HODGKIN,INC,LABEL,MATERIALS,METHODS,NHL,OBJECTIVE,PEARSON,PUBLISHED,PURPOSE,RADIATION,RESULTS,SEVERAL,THERAPY,THESE,V10,V15,V20
004,038,169,AER,CARDIAC,COPYRIGHT,CRT,DISEASE,HODGKIN,INC,LABEL,LAR,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
169,AUTHORS,COMMISSION,COPYRIGHT,ENL,EXTRANODAL,GROUP,HODGKIN,ILROG,INC,NHL,ORGAN,PUBLISHED,RADIATION,UNITS
169,ADDITIONAL,ASTN1,CSMD2,EXOME,EXPRESSION,MUTATED,PRESS,PUBLISHED,RB1,SCLCS,SMALL,SPTA1,THEREFORE,UNIVERSITY
007,027,035,169,AIM,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,MATERIALS,METHODS,NON,NSCLC,OBJECTIVE,RESULTS,SKAP2,SRC,THEREFORE
135,169,AIM,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,EPIRUBICIN,INSTITUTE,LABEL,METHODS,OBJECTIVE,RESULTS,SIXTY
169,AIM,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,INSTITUTE,LA1,LABEL,MATERIALS,METHODS,OBJECTIVE,PDCD4,PEI,RESULTS,SDA,THEREFORE
169,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,INSTITUTE,L858R,LABEL,LUNG3,LUNG6,LUX,MATERIALS,METHODS,MTT,NSCLC,RESULTS,TKI,WESTERN
100,143,155,169,210,372,AIM,ANTICANCER,BAL,CLUSTER,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,MATERIALS,METHODS,NSCLC,OBJECTIVE,RESULTS
169,CELLS,COPYRIGHT,FALLS,IGUASSU,OVERALL,PAN,SOCIETY,THESE
001,140,169,CONSORTIUM,GRADE,LABEL,MEDICAL,METHODS,OBJECTIVE,PRESS,PUBLISHED,RESULTS,SAPPORO,THERE,UNIVERSITY
169,915,972,APRIL,AUTHORS,BACKGROUND,CONCLUSION,COPYRIGHT,FACTORS,IQR,IRELAND,JANUARY,LABEL,LTD,METHODS,NHS,OVERALL,PUBLISHED,RESULTS
836,864,AMONG,ATLAS,AUC,BACKGROUND,CPG,EPIGENETIC,HOWEVER,LABEL,METHODS,RELIEFF,RESULTS,SEQ,SEQUENTIAL,TSS1500,VARIOUS
ATS,BASED,DIAGNOSTIC,MAC,NTM,SPN,WINDERMERE
163,BACKGROUND,DENDRIX,FURTHER,LABEL,LARGE,MAXIMUM,METHODS,MULTI,NBM,P53,PROBLEM,RAS,RESULTS,RME,RTK,SUB
169,946,BASED,COPYRIGHT,ECM,ENDOGENOUS,FN1,INC,LAMC1,TGF,TGFB1,THESE
169,AUTHORS,CAM,COPYRIGHT,GADD153,GEF,GEFITINIB,GRP78,INC,KNOCKDOWN,MEF,NSCLC,PUBLISHED,THESE
169,946,947,CD8,ELICITING,GENERATED,IFN,RADIATION,TGF
AMERICANS,GREATER,HIV,INSTITUTES,NIH
169,CONCLUSION,DIXON,FDG,FINALLY,GMM,IMAGING,INC,LABEL,METHODS,MOLECULAR,NUCLEAR,PET,RESULTS,SOCIETY,UNLABELLED
116,148,169,226,384,712,AMONG,BACKGROUND,BAL,CONCLUSION,COPYRIGHT,INDIA,LABEL,METHODS,PUBLISHED,RESULTS
COLORECTAL,ERSPC,GROUP,OVARIAN,PIVOT,PSA,RANDOMIZED,SCREENING,TRIAL
HODGKIN,THERE
176,177,945,954,BACKGROUND,BCL,CONCLUSION,HIF,IRI,LABEL,LEWIS,METHODS,PHOSPHO,RECIPIENTS,RESULTS,SOLTRAN,TLR,XENON
150,169,254,519,595,746,CHINA,CHINESE,COX,EASTERN,GROUP,LABEL,METHODS,NON,OBJECTIVE,PHASE,PRESS,PUBLISHED,RESULTS,STAGE,TARCEVA,TREATMENT,TRUST,UNIVERSITY
169,200,230,ALK,LADCS,RET,SNF,SWI,THESE,WHOLE
108,169,AKT,AUTHORS,BECAUSE,EXPRESSION,LTD,PTY,PUBLISHING,SCIENCE,WILEY
371,ACA,ANGIOGENIC,CAM,CD105,EXPRESSION,EXTENSIVE,LOW,MEL,MVD,NSCLC,SCC
169,ANALOGOUS,ANGPTL7,ATLAS,CD11B,CONCLUSION,EXPRESSION,HEPATIC,LABEL,LEWIS,LIVER,MYELOID,UNLABELLED
231,954,H1339,HSP90,INHIBITION,MDA,NKG2D,NVP,SP1,THEREFORE,THESE
ACCORDING,AFTER,CONCLUSION,ERM,GV248,LABEL,LENTI,LENTIVIRAL,LENTIVIRUS,METHODS,MOI,OBJECTIVE,PCR,RAT,RESULTS,WESTERN
104,145,169,279,DEPENDING,FOXM1,FUNCTIONAL,HOWEVER,LABORATORY,MITRA,PRESS,PUBLISHED,SOCIETY,USING

169,COPYRIGHT,INC,KEAP1,WHOLE
CLONTRACER,HOWEVER,RESISTANCE,THESE
PARP1,USING
REDUCED
169,AMONG,CHILDHOOD,CONCLUSION,DIFFUSION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SOCIETY,SURVIVORS,THESE
DIAGNOSIS
001,005,169,367,711,ACUTE,BACKGROUND,END,HOWEVER,IRR,LABEL,MATCHED,METHODS,MORTALITY,NSCLC,OVERALL,POISSON,RESULTS,SOCIETY
157,158,169,245,248,249,273,AUTHORS,BAP,COPYRIGHT,CPG,FOLLOWING,FURTHER,HUF,HUPKI,NER,PUBLISHED,SOMATIC,THEREFORE,WHILE,XPA
169,ARG,BIOLOGY,EMT,HOWEVER,INC,MOLECULAR,PRMT1,PROTEIN,SOCIETY,TAKEN,THEREFORE
AIR,FEW,ILD,THERE
169,COPYRIGHT,LTD,NSCLC
140,THERE
002,ART,BACKGROUND,CONVERSELY,HIV,HODGKIN,IRR,JOINT,KAMPALA,LABEL,METHODS,NATIONS,POISSON,PROGRAM,RESULTS,SAHARAN,THESE
169,COPYRIGHT,EMT,INC,NSCLC,TRIPARTITE
169,30D,CCNE2,COPYRIGHT,IRELAND,LTD,MICRORNAS,NSCLC
160,169,CONSISTENT,COPYRIGHT,EFFECTORS,INC,NSCLC,RAC,TRAIL
169,ALK,AMONG,COPYRIGHT,FGFR1,LTD,MET,NSCLC,RET
160,169,COPYRIGHT,HOWEVER,III,LOCALLY,METASTATIC,PUBLISHED,SAS
169,AFTER,COPYRIGHT,INC,LOBECTOMY,PUBLISHED,SOCIETY
169,AFTER,COPYRIGHT,GENERALLY,HOWEVER,INC,PUBLISHED,SOCIETY
169,COPYRIGHT,INC,PRIMARY,PUBLISHED,SOCIETY
169,COPYRIGHT,INC,PUBLISHED,SOCIETY
169,COPYRIGHT,INC,PUBLISHED,SOCIETY
169,COPYRIGHT,GIVEN,INC,PUBLISHED,SOCIETY
001,021,100,169,268,826,COPYRIGHT,INC,LABEL,MALIGNANT,METHODS,OBJECTIVE,PUBLISHED,RESULTS,SPN,SURGERY
169,ADVERSE,COPYRIGHT,DFS,DISTANT,INC,KARNOFSKY,LABEL,LRC,MATERIALS,MEIER,METHODS,NSCLC,OBJECTIVE,PURPOSE,RESULTS,THREE,TOXICITIES,TREATMENT
169,COPYRIGHT,III,MEDLINE,PUBLISHED,SAS
107,169,COPYRIGHT,INC,LABEL,LOW,METHODS,NUCLEAR,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS,SURGERY
169,AKT,COPYRIGHT,ERK,HUVEC,INC,NSCLC,PD0325901,SINCE
500,916,945,956,968,BACKGROUND,BAX,BCL,CLEAVED,CONCLUSION,DEX,LABEL,METHODS,OXIDATIVE,RESULTS,ROS,THEIR
COLON,EXPERIMENT,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
026,169,BRCA2,LATIN,PRESS,PUBLISHED,SNP,UNIVERSITY
HOWEVER,JANUARY,OCTOBER
125,169,228,283,327,373,624,658,677,725,729,799,874,COX,FURTHER,JAPAN,LABEL,METHODS,OBJECTIVE,PRESS,PUBLISHED,RESULTS,STAGE,UNIVERSITY
001,500,945,946,BACKGROUND,BED,DMEAN,HEART,LABEL,LADCA,METHODS,RESULTS,V10,V14,V90,V95
187,BACKGROUND,CLINICIANS,DETECTION,ITALIAN,LABEL,METHODS,OBJECTIVE,RESULTS,TRIAL
026,100,116,139,169,374,704,ASSESSMENT,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,RSI,SIXTY,THESE
169,230,233,584,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE
001,004,064,108,130,238,569,AFTER,CONVERSION,FEW,INTUBATED,OVERALL,SEPTEMBER,TEA
001,002,006,034,113,771,954,IIP,NTM
109,129,361,554,745,AMONG,DESPITE,HCV,INCREASING,WHETHER
99M,CURRENT,FDG,HOWEVER,MDP,NAF,PET
000,071,099,100,102,112,124,130,152,168,169,174,617,945,AFTER,BLOOMBERG,HOPKINS,HOWEVER,JOHNS,PLATEAU,PRESS,PUBLISHED,UNIVERSITY
169,946,AUTOPHAGY,COPYRIGHT,FOXO1,GAL,HDAC1,IMR,NRF,SIRT1,SIRT6,THEREFORE
1930S,1950S,PAP,SINCE
100,AMONG,CONCLUSION,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,PCR,PNA,PTC,PURPOSE,RESULTS,SEVENTY,THESE,V600E
485,7TH,CONCLUSION,EIGHT,GENERAL,LABEL,METHODS,MRI,OBJECTIVE,OPERATIVE,RECORDS,RESULTS,RULES,THREE
BECAUSE,RCC,UNDER
101,934,BMS,DES,HOWEVER,INCREASING,MARCH
CHEST,COLLEGE,PHYSICIANS,SINCE
047,AMONG,APRIL,ASPIRIN,EIGHT,MARCH,THREE
005,ACCORDING,AMONG,BACKGROUND,IHD,JANUARY,JAPAN,LABEL,LOBECTOMY,MATERIALS,MEN,METHODS,RESULTS,UNIVARIATE,UNIVERSITY,VIDEO
135,DRUGELUTED,IHD,SHORT,THERE,THESE,VSA
FIFTEEN,HOWEVER,THESE
458,BETWEEN,FORTY,SHORT,THERE
001,005,023,024,177,467,APRIL,CONCLUSION,FIFTY,LABEL,MARCH,RESULTS,THERE,UNLABELLED
399,411,418,ASIAN,BIOLOGY,CHINESE,THEIR,XRCC1
231,946,956,HOWEVER,HSA,MANNICH,MAP,MDA,THREE
BAL,CHEST
FOLLOWING,MINIMAL,THEREFORE,TKI


ABDOMINAL,PHYSICIANS,SEVEN,THEREFORE
137,160,169,250,53BP1,947,956,BRAGG,COPYRIGHT,FANCONI,GROWING,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RAD51,RBE,RESULTS
000,160,169,836,COPYRIGHT,EAR,INC,LABEL,LRT,MATERIALS,METHODS,MVA,OBJECTIVE,PURPOSE,RESULTS,SECONDARY,SIR
125,169,ADC,AIM,ALK,ATS,BASEL,ERS,IASLC,L858R,LABEL,METHODS,OBJECTIVE,RESULTS,SOCIETY,THESE
GPCRS,S1P,WHILE
124,317,513,CONGESTIVE,HOWEVER,INPATIENT,THERE
308,473,AKT,ALDH1,CD133,NSCLC,SER,SGPP1,TARGETING,THR
169,629,ACIDS,NUCLEIC,PRESS,PUBLISHED,UNIVERSITY,USING
101,103,105,109,12H,158,AUC,BACKGROUND,COMPARISON,CONCLUSION,LABEL,MATERIALS,METHODS,RESULTS
169,BACKGROUND,FNA,LABEL,MEDICAL,METHODS,PANCREATIC,RESULTS,SOCIETY,THERE
169,CD207,DESPITE,HEMATOLOGY,LANGERHANS,LCH,REGARDLESS,SOCIETY
143,169,BACKGROUND,COPYRIGHT,CPG,INC,LABEL,METHODS,PUBLISHED,RESULTS,SOCIETY
001,002,003,169,AFTER,BACKGROUND,C30,COPYRIGHT,EPD,HRQOL,INC,LABEL,MAXIMAL,METHODS,PUBLISHED,PULMONARY,QUALITY,RESULTS,SOCIETY,TREATMENT,WORLD
121,147,169,177,198,BACKGROUND,COPYRIGHT,INC,LABEL,METHODS,PUBLISHED,RESULTS,SOCIETY,THERE
169,BACKGROUND,COPYRIGHT,FEW,INC,LABEL,METHODS,PUBLISHED,RESULTS,SOCIETY
169,COPYRIGHT,DARWINIAN,OWING,PUBLISHED
169,231,946,COPYRIGHT,EMT,FAK,IRELAND,LTD,MDA,PACLITAXEL,STRIKINGLY,TAKEN,U87VIII
116,956,ANOTHER,H1299,HCT,ROS,SAN4601,SAN5201,SAN7401
169,COPYRIGHT,HLA,HOWEVER,INC,LFA,NKG2A
169,COPYRIGHT,CURRENT,LTD
100,169,291,ACCORDING,BACKGROUND,COPYRIGHT,GGO,INC,LABEL,METHODS,PUBLISHED,RECURRENCE,RESULTS,SOCIETY
109,169,BACKGROUND,COPYRIGHT,COX,INC,LABEL,METHODS,METHYLATED,NSCLC,PUBLISHED,RESULTS,SOCIETY,SURGERY
169,177,BACKGROUND,CONCLUSION,COPYRIGHT,DEFORMABLE,DIR,ELASTICITY,IRELAND,LABEL,LTD,MATERIALS,METHODS,MPN,OBJECTIVE,PURPOSE,RESULTS,VOLUMES
169,ACADEMY,ADDITIONAL,BACKGROUND,BASEL,GROUP,IAC,LABEL,METHODS,OBJECTIVE,PARIS,RATIONALE,REFERENCE,SOURCES
169,COPYRIGHT,INC,MALIGNANT,MPM,SEVERAL,THESE
169,33324,946,ANNEXIN,BAD,BAX,BCL,COPYRIGHT,H1299,HOECHST,IRELAND,LTD,MTT,NCI,WESTERN
169,AMONG,COPYRIGHT,EGF,IRELAND,LTD,RG3,THESE,THROUGH
169,CELLULITIS,COLLEGE,PHYSICIANS,ROYAL
100,945,946,AMRUBICIN,FEBRILE,GRADE,NSCLC,ORR
001,100,120,169,480,600,ADDITIONAL,ASPIRATES,BASEL,CHINA,JAPAN,LABEL,LBC,METHODS,OBJECTIVE,OL8,OLYMPUS,RESULTS,SEPTEMBER,TOKYO
215,ABDOMINAL,CLOSE,FIFTEEN,THERE,TREATMENT
160,947,DOTATOC,HOWEVER,PHE,TAKEN,THEIR,TYR
954,EPIGENETIC,MEDIP,THESE,USING
945,INHIBITION
169,987,COX,F2RL3,HARRELL,HRS,MASSARRAY,SMOKING,THESE
169,207,ATP,COX,GLN,NSCLC,TARGETING,THESE
169,16HBE,HOWEVER,INC,LOC728228,PCR,WILEY
169,COPYRIGHT,INC,NSCLC
160,169,1ST,231,233,ALK,AP26113,COPYRIGHT,HOWEVER,III,NSCLC,PROFILE,PUBLISHED,SAS
169,490,BCL,CCND1,COPYRIGHT,FEDERATION,GYNECOLOGY,IRELAND,LTD,MIR,OBSTETRICS,P53,SMARCD1,THESE
293,711,861,CONCLUSION,FIFTY,LABEL,METHODS,NSCLC,OBJECTIVE,RESULTS,THERE
001,005,008,017,026,CONCLUSION,LABEL,METHODS,NSCLC,OBJECTIVE,RESULTS,TNM,WESTERN
008,084,100,157,178,185,298,356,453,474,501,692,927,967,CONCLUSION,EUR,FDG,LABEL,METHODS,NPV,OBJECTIVE,PET,PPV,RESULTS,ROC,SPECT
177,CONCLUSION,LABEL,METHODS,MWA,OBJECTIVE,RESULTS,SEVEN,ULTRASOUND
945,947,BARRETT,DUOX1,DUOX2,KNOWLEDGE,NADPH,NOX,ROS
169,176,257,BACKGROUND,CBCTS,CONCLUSION,COPYRIGHT,IRELAND,LABEL,LTD,MATERIALS,METHODS,NCC,OBJECTIVE,PURPOSE,RESULTS,USING,VPE
169,COPYRIGHT,COX,DESPITE,INC,NSCLC,SILENCING,USP22
169,4DCTS,BECAUSE,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PFT,PULMONARY,PURPOSE,REGRESSION,RESULTS,V20,VALIDATION
131,162,169,214,323,500PG,504,COPYRIGHT,DIAGNOSTIC,DTC,INC,KEY,LABEL,MEIER,METASTASIS,METHODS,MIDKINE,OBJECTIVE,PRE,PROGNOSTIC,RESULTS,ROC
100,375,CNB,JANUARY,MOLECULAR,ROUGHLY
169,178,AIM,BMI,LABEL,MATERIALS,MEDICAL,METHODS,OBJECTIVE,RESULTS
169,946,ABL,ARG,HEART,INC,THESE
169,ALLOGENEIC,CONSISTENT,DLI,GVL,HEMATOLOGY,MEMBERS,SOCIETY,TREGS
019,169,CONCLUSION,DTC,FDG,FORTY,IMAGING,INC,LABEL,METHODS,MOLECULAR,NUCLEAR,PDTCS,PET,RESULTS,SOCIETY,THERE,THESE,THYROID,UNLABELLED,V600E
169,COPYRIGHT,INC,STUDIES,THESE
100,169,200,518A2,956,COPYRIGHT,DECREASED,FURTHER,HACAT,HOWEVER,IRELAND,LTD,MRC,NCI,ROS,TEMPONE,TXR
100,169,250,53BP1,956,CAPSAICIN,COPYRIGHT,DU145
169,360,386,400,ALK,ALKEX20,AMONG,COPYRIGHT,DCTN1,DETECTION,EML4EX6,IRELAND,LTD,NSCLC,OVERALL,PCR,PUBLISHED,SYSTEMATIC
001,005,169,353,BACKGROUND,COPYRIGHT,EXCLUDING,HEALTHCARE,INC,INPATIENT,LABEL,METHODS,NATIONWIDE,NIS,PROJECT,QUALITY,RESULTS,USING
65291,AFTER,HODGKIN,UNDER
100,945,AFTER,OVERALL,RCC
CBDCA,PFS,PTX
DTX,PTX,THEREFORE
CK7,HOWEVER,SUBSEQUENT,THEREFORE
STAGE
HOWEVER,PACLITAXEL,PFS
DESCRIBED,NOTABLY,RUNX3
THERE
RESPONSES,RESULTS
176,177,CONCLUSION,CT0,D95,DIR,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,PTV,RESULTS,THREE
169,945,946,AAN,AKT,BRITAIN,COPYRIGHT,GREAT,HOWEVER,IRELAND,LTD,PAI,PUBLISHED,SER15,SIMILARLY,SMA,SMAD3,SOCIETY,STZ,TGF,TUBULAR,UUO,WILEY
COMPETING,GRAPHICAL,MRE,THEREFORE,UTR,VIA,WHILE
169,AKT,CLEAVED,EXPRESSION,HOWEVER,LEC,LM2,VEGFR
169,ANEUPLOIDY,CELLS,CP110,MECHANISMS
169,CDC20,INC,SIXTY,WEBGESTALT,WILEY
169,CONCLUSION,CXCR4,DEN,HCC,LABEL,LIVER,MMP,MMP10,PREVIOUSLY,UNLABELLED
AKT,ALK,RAF
HOWEVER,NSCLC
001,008,032,113,GCN,INCREASED,LABEL,MATERIALS,METHODS,MYC,NSCLC,OBJECTIVE,OBJECTIVES,RESULTS,ROC,SCC,UNIVERSITY
AMONG,EIF3L
169,231,BAPTA,BIOLOGY,ENO,GOLGI,INC,LPS,MDA,MOLECULAR,ORAI1,SOCIETY,STIM1,THESE
152,170,200,247,274,280,291,300,320,690,956,AFTER,CATLE,EMT,ERK,HIF1A,HMOX1,HPL,INC,INCREASED,INORGANIC,PUBLISHED,SLC38A3,VIM
169,COPYRIGHT,INC,PECOMAS,TFE,THERAPY
CURRENTLY,ELISA,HOWEVER,SMOKING,TOF
ACR,COLLEGE,INDUCTION,LITERATURE,PANEL,RADIOLOGY,THERE
169,CONCLUSION,HIPAA,III,LABEL,MATERIALS,METHODS,OBJECTIVE,PATIENT,PURPOSE,RESULTS
945,BECAUSE,CMPTS,TEN,TTF
12A,169,945,946,AMONG,INC,MRC,TNF,WILEY
BACKGROUND,IIA,IIB,ITALY,LABEL,METHODS,POPULATION,PRESS,PUBLISHED,RESULTS,THESE,UNIVERSITY
169,APMIS,DESPITE,EMA,INTRA,LTD,MRI,PUBLISHED,WILEY
169,183,300,329,332,661,AFTER,BACKGROUND,COPYRIGHT,FEB,FUNDING,KARNOFSKY,LABEL,LTD,MERCK,METHODS,RESULTS,VORINOSTAT
169,348,ACIDS,CBP,FURTHER,H3K27,HOWEVER,NUCLEIC,PRESS,PUBLISHED,SIRT1,UNIVERSITY
169,FINALLY,G3BP1,SGS,UNDER,UTR
AREAS,BACKGROUND,COVERED,FURTHER,HOWEVER,LABEL,METHODS,NSCLC,OPINION,PROTEOMIC
115,169,COPYRIGHT,IONTORRENT,MALIGNANT,PUBLISHED,THERE
100,188,ACTIVIN,TNM
169,BIBX1382BS,CONCLUSION,COPYRIGHT,EGF,FUNCTIONAL,H1299,H3122,HOWEVER,IRELAND,LABEL,LTD,MATERIALS,METHODS,NSCLC,OBJECTIVE,PURPOSE,RESULTS,SINCE,STRIKINGLY
005,007,023,027,033,046,10878,110,169,331,808,ACCORDING,AFTER,BACKGROUND,CONCLUSION,COPYRIGHT,FURTHER,GROUP,IRELAND,LABEL,LTD,MALIGNANCY,MASAOKA,METHODS,RECURRENCE,RELAPSE,RESULTS,WORLD
169,CONTINUOUS,HOWEVER,LOW,PRESS,PUBLISHED,SMOKING,THESE,UNIVERSITY
001,130,140,165,166,169,313,529,852,977,AMERICANS,ASIAN,BACKGROUND,BECAUSE,CHINESE,CSM,DESPITE,END,HAWAIIANS,KOREANS,LABEL,METHODS,PACIFIC,PAKISTANI,PRESS,PROGRAM,PUBLISHED,RESULTS,SOUTH,THESE,UNIVERSITY,VIETNAMESE
005,029,047,102,169,222,508,578,896,BACKGROUND,CONCLUSION,CONVERSELY,COPYRIGHT,HCC,INC,JANUARY,KOREA,LABEL,MEDICAL,MEIER,METHODS,PIVKA,RECURRENCE,RESECTION,RESULTS,SAMSUNG
169,231,233,BACKGROUND,CAUCASIANS,CHINA,COPYRIGHT,HOWEVER,KNOWLEDGE,LABEL,MEDLINE,METHODS,OVERALL,PUBLISHED,RESULTS,SAS,STRATIFIED,THERE,THR241MET,TOTAL,XRCC3
BIOLOGICAL,COMMITTEE,CONCLUSION,EFFECTS,END,INCREASES,LABEL,MATERIALS,METHODS,OBJECTIVE,RADIATION,RESULTS,SCREENING,VII
100,120,177,CONCLUSION,FBP,FIFTY,IMAGE,LABEL,METHODS,OBJECTIVE,RADIATION,RESULTS
041,141,177,242,CHEST,CONCLUSION,HEALTHCARE,INDIVIDUAL,ITERATIVE,LABEL,MATERIALS,MAXIMUM,METHODS,MICRODOSE,MIP,OBJECTIVE,RESULTS,SIEMENS,STELLAR,THESE
339,APM,COX,DATABASES,JANUARY,NETWORK,PROGRAM,USING
174,CDK,IBRANCE,III,INSTITUTE,PHASE,USA
148,169,224,299,811,AMONG,BACKGROUND,COPYRIGHT,COX,END,III,INC,LABEL,METHODS,MPM,OVERALL,RESULTS
169,COPYRIGHT,FURTHER,INC
100,168,169,BACKGROUND,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,RESULTS,RFS
169,COPYRIGHT,IIA,LPS,PLA2G2A,PRE
001,149,169,183,285,BACKGROUND,BJS,CONCLUSION,GROUP,LABEL,LTD,METHODS,PUBLISHED,RESULTS,SOCIETY,TEN,WILEY
004,872,BACKGROUND,FREQUENTLY,LABEL,LAM,METHODS,MORTALITY,NINTH,POPULATION,RESULTS,REVISIONS,THERE,THESE,TSC
009,169,ADC,BACKGROUND,GUIDELINES,HOWEVER,LABEL,METHODS,NUCLEAR,RESECTIONS,RESULTS,SOCIETY
169,956,BIOLOGY,INC,MOLECULAR,NMR,SOCIETY
100,APC,CRC,FBXW7,SMAD4,SOMATIC,SYNE1
158,221,COHEN,INTERNS,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
162,169,179,885,999,AUC,AUTHORS,INC,NON,NSCLC,PIS,PSS,PUBLISHED,ROC,SMS,THESE,WILEY
001,003,169,496,635,AMONG,BACKGROUND,III,JANUARY,KARNOFSKY,LABEL,MEIER,METHODS,PROGNOSTIC,RESULTS,SOCIETY,STAGE,TNM
EIGHT,SCP1833,SCP4175,THESE
001,005,011,AIM,CONCLUSION,CRC,LABEL,METHODS,OBJECTIVE,PET,RESULTS,SERUM,SIX
169,454,BLEISWIJK,COPYRIGHT,ION,LABEL,MACHINE,METHODS,NGS,OBJECTIVE,OBJECTIVES,PATHOLOGY,RESULTS,ROCHE,ROTOR,SEQUENCER,SOCIETY,TORRENT,VENLO
169,531,AFRICAN,AMERICANS,COPYRIGHT,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PATHOLOGY,RESULTS,SOCIETY,THESE
169,COPYRIGHT,HACAT,HEPG2,LTD,ROOTS,WHILE,WILEY
112,BACKGROUND,BMJ,CARCINOID,DISEASE,GROUP,IBT,ICEBERG,LABEL,LIMITED,METHODS,MINIMUM,PUBLISHED,PUBLISHING,RESULTS
169,CK5,COPYRIGHT,IHC,INC,NSCLC,SCC,SEVERAL,TTF
100,128,169,ALK,BECAUSE,CK7,COLLOID,COPYRIGHT,INC,SEVEN,THREE,TTF
CALCIUM,CD318,CDCP1,CUB,FUNCTIONAL,ORAI1,STIM1,STOCS,THESE,TRASK
ANP,B16,THESE
945,947,ALTOGETHER,HOWEVER,MYC,SCF,USP,USP36
100,ALK,BACKGROUND,CONCLUSION,HRS,LABEL,METHODS,NSCLC,PFS,RESULTS
945,AMD3100,BACKGROUND,CXCR4,ENDOGENOUS,FINALLY,FUNCTIONAL,FURTHER,H1299,HIF,LABEL,METHODS,PCR,PRINCIPAL,RESULTS,SDF
012,033,119,BACKGROUND,CASES,E1L3N,LABEL,METHODS,MPM,PD1,RESULTS,THERE
IMMEDIATE

500,946,EIGHT,H1299,ITGB3BP,SHC,SRPK1,USING
ACADEMY,AWARD,BRINKER,DIMITRIOS,DOCTORATES,FOUNDATION,HARVARD,HONOR,INSTITUTE,KAROLINSKA,MEDAL,PRESIDENT,PREVENTION,PROFESSOR,UNIVERSITY
160,169,COPYRIGHT,H3K4ME1,HISTONE,HOWEVER,INC,OGT
CONCLUSION,LABEL,METHODS,OBJECTIVE,OCT,OHP,PCR,PURPOSE,RESULTS,WESTERN
HOWEVER,LOW,NSCLC,VIDEO
100,693,ADC,ALU,CPG,STAGE
125,160,169,COPYRIGHT,EXPRESSION,INC,MIR,MMP,NSCLC,PCR
001,012,017,169,218,COPYRIGHT,INC,MEIER,NSCLC,OLFM4,OVERALL
000,100,169,90S,AMONG
106,169,ABOUT,AIM,BRAIN,CNS,INSTITUTE,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,UNLABELLED
169,1MM,1SD,2MM,4MM,8MM,931,945,9MM,CONCLUSION,COPYRIGHT,GTV,III,INSTITUTE,IRELAND,LABEL,LTD,MATERIALS,METHODS,NSCLC,OBJECTIVE,PTV,PURPOSE,RESULTS,SIXTEEN
169,183,264,276,298,304,364,374,BIOLOGY,DDIT3,HOWEVER,INC,JUN,K14,KAT2A,MOLECULAR,SOCIETY,THESE,TNFRSF10A,TNFRSF10B,TRAIL
169,179,215,AMONG,CONCLUSION,COPYRIGHT,LABEL,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SAS,SPHINCTER,UPFRONT
169,AHR,COPYRIGHT,ILC2S,INC,STAT5,TH2
020,024,030,067,072,100,113,121,128,141,169,177,215,698,890,CONCLUSION,COPYRIGHT,ESTIMATED,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PERCENTAGE,PURPOSE,RESULTS,THESE,USING
000,001,002,006,102,169,1ST,2ND,3RD,440,4TH,5TH,956,ACUTE,BACKGROUND,CHINA,CONCLUSION,COPYRIGHT,III,INSTITUTE,IRELAND,JANUARY,LABEL,LTD,MATERIALS,METHODS,RESULTS,SEPTEMBER
169,BAX,BENZO,CL3,COPYRIGHT,EMSAS,ERK,EXPRESSION,H1299,H1355,H23,MYC,NSCLC,PD98059,PHOSPHO,SER15,SER20,TAKEN,WESTERN
100,BACKGROUND,LABEL,METHODS,QOL,RESULTS,THERE
169,AUTHORS,FK506,FKBPL,HOWEVER,IL8,LABEL,MOUSE,OBJECTIVE,RESULTS
169,392,946,BIOLOGY,ERK,INC,MH2,MOLECULAR,R175H,SER,SILENCING,SMAD2,SMAD3,SMAD4,SOCIETY,TGF
154,169,AIM,COLLEGE,CONCLUSION,COPYRIGHT,ENGLAND,FIFTY,LABEL,LTD,MATERIALS,MAY,METHODS,MRI,NETWORK,OBJECTIVE,PUBLISHED,RESPONSES,RESULTS,ROYAL,THERE
169,716751G,AFTER,ALK,AML,COPYRIGHT,INC,PCR,REVERSE
039,042,112,177,500,712,BACKGROUND,ELISA,LABEL,METHODS,NSCLC,RESULTS,THERE
169,16S,177,231,458,488,BCL,COPYRIGHT,FOURIER,IRELAND,LTD,MDA,MPCAB,NMR,THESE
169,CD8,COPYRIGHT,SCIENCE
163,169,964,FOS,GIANT,INC,MEIER,MICROARRAY,MMP,PROTEIN,PUBLISHED,RANKL,SOCIETY,WILEY
INTEGRATED,MOLECULAR
100,241,556,718,762,ADC,BACKGROUND,CUMULATIVE,FURTHER,HODGKIN,JANUARY,LABEL,METHODS,NNRTI,PIS,POISSON,RESULTS
006,015,027,169,215,247,251,657,AFTER,BACKGROUND,BONFERRONI,COLORECTAL,LABEL,METHODS,NUTRITION,OBJECTIVE,OBJECTIVES,OVARIAN,PEARSON,RESULTS,SCREENING,SERUM,SOCIETY,TRIAL,USUAL
169,440,AMONG,ANXIETY,DEPRESSION,LABEL,METHODS,OBJECTIVE,PRESS,PUBLISHED,RESULTS,SCALE,UNIVERSITY
045,AMONG,BACKGROUND,CONCLUSION,COX,EFFORTS,LABEL,METHODS,ORS,RESULTS,SEP
HOWEVER,IMAGING
NSCLC
000,100,186,264,410,413,433,543,544,688,700,709,993,BACKGROUND,BECAUSE,CXR,DANTE,DETECTION,HOWEVER,LABEL,METHODS,NOVEL,OBJECTIVE,OBJECTIVES,RATIONALE,RESULTS,SCREENING,SECONDARY,TECHNOLOGY,THEIR,TRIAL
AFTER,ERBB1,MNS
100,101,210,315,CAC,CHD,CONCLUSION,COX,HIPAA,IMAGE,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SCREENING,TRIAL
500,RESECTION,SURGERY,VINCI
AUTOPSY,CD117,GASTRIC,HISTOLOGY,HOWEVER,III,RADIATION
ACTN4,BINDING,CONSISTENT,DESPITE,HCC,HOWEVER,PLC,PRF,PROTEIN,THESE
BMJ,CALIFORNIA,CIS,COX,GROUP,HRS,INDEX,LABEL,LIMITED,METHODS,MORTALITY,OBJECTIVE,OBJECTIVES,PUBLISHED,PUBLISHING,RESULTS,SMR,WORKERS
169,ALK,AMONG,COPYRIGHT,INC,P2Y,PKC
342,BACKGROUND,BMJ,DISEASE,GROUP,LABEL,LIMITED,METHODS,ORS,PUBLISHED,PUBLISHING,RESULTS,THERE
169,BASED,COPYRIGHT,CXR,DTS,INTER,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THERE
ANCHORAGE,H2009,SIMILAR
001,002,10878,147,257,272,453,490,576,BACKGROUND,IQR,LABEL,METHODS,MPM,NEUTROPHIL,NLR,PET,RESULTS,SERUM,SEVENTY,TGV,TTP
006,012,BACKGROUND,BSC,C30,COMPLIANCE,EORTC,HRQOL,LABEL,METHODS,MPM,PATIENT,QLQ,RESULTS,SEVENTY
169,COPYRIGHT,EXOGENOUS,H1299,IRELAND,LTD,THESE,USING,UTR
001,160,169,3DCRT,COMBINING,COPYRIGHT,HODGKIN,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE,TREATMENT,V20GY
169,ADVERSE,AMONG,APRIL,COPYRIGHT,FURTHER,GRADE,INC,LABEL,MARCH,MATERIALS,METHODS,OBJECTIVE,PATIENT,PURPOSE,RBE,RESULTS,V20,V95
027,074,169,AFTER,CHEST,COPYRIGHT,HOWEVER,INC,INITIAL,LABEL,MATERIALS,METHODS,OBJECTIVE,PULMONARY,PURPOSE,RESULTS,THERE,WILMS
169,AGA,BACKGROUND,COLORECTAL,COPYRIGHT,CRC,EXPRESSION,INC,INSTITUTE,LABEL,LYMPH,METASTASES,METHODS,OBJECTIVE,PUBLISHED,RESULTS,STRATEGIES,VEGFC
169,664,751,773,803,804,830,860,973,ASIAN,MORTALITY,PCDFS,SMR,YUCHENG,YUSHO
230,584,CYTOSCAPE,DATASET,ENRICHMENT,EXPRESSION,INADL,LABEL,LIMMA,MAP,MATERIALS,METHODS,NSCLC,OBJECTIVE,OMNIBUS,PLCB3,PLCE1,PPI,PROTEIN,RESULTS
169,ADP,BAX,BCL,COPYRIGHT,GBA,HOWEVER,LEWIS,LTD,MCL,MYELOID,NSCLC,OVERALL,TUNEL,WESTERN,WILEY
169,726,956,B16,COLON,COMPLEX,COPYRIGHT,DFT,IRELAND,LTD,MDA
169,945,946,CONCLUSION,COPYRIGHT,CSC,DCC,DLQ,FITTING,GBM,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SLQ,SMALLER
000,169,200,569,ART,CONCLUSION,COPYRIGHT,CRT,INC,LABEL,LYS,MAASTRO,MATERIALS,METHODS,MODEL,NSCLC,OBJECTIVE,PET,PRIMARY,PURPOSE,QALYS,RESULTS
169,COPYRIGHT,HSP27,HSP70,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE,WESTERN
169,359,CONCLUSION,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SASKATOON,SEVENTY
001,169,BECAUSE,COPYRIGHT,CRI,EASTERN,INC,LABEL,METHODS,NSCLC,OBJECTIVE,PRE,PRIMARY,PURPOSE,RESULTS,SCALE,SECONDARY,SPR,TREATMENT,VAS
001,125,161,169,202,COMPETING,COPYRIGHT,CUMULATIVE,CURRENT,INC,LABEL,MATERIALS,MEIER,METHODS,NETWORK,NSCLC,OBJECTIVE,PURPOSE,RESULTS
169,215,COPYRIGHT,EIGHT,OVERALL,THEREFORE
123,F354L,FVPTC,JEGHERS,KDR,MET,N375S,PAPILLARY,PEUTZ,PPARG,PTC,Q472H,RET,STK11
BACKGROUND,CONTEXT,HOWEVER,LABEL,METHODS,PTS,SIX
001,225,323,ACTIVIN,BACKGROUND,CNC,CONTEXT,GIVEN,JANUARY,LABEL,MARCH,METHODS,MYOSTATIN,OBJECTIVE,OUTCOME,RESULTS,SETTING,THESE
169,AIM,ALK,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,HOWEVER,INSTITUTE,LABEL,MATERIALS,METHODS,NSCLC,OBJECTIVE,RESULTS,SDI
169,AIM,ANTICANCER,CONCLUSION,COPYRIGHT,DFS,DISTANT,INSTITUTE,LABEL,LOCAL,METHODS,NSCLC,OBJECTIVE,OUTCOME,RADIATION,RESULTS
169,AIM,ANTICANCER,CONCLUSION,COPYRIGHT,INSTITUTE,JANUARY,LABEL,METHODS,NSCLC,OBJECTIVE,RESULTS
169,177,AIM,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,LOBAR,METHODS,OBJECTIVE,RESULTS
104,169,254,293,422,678,ACTN4VA,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,HOWEVER,INSTITUTE,LABEL,MATERIALS,METHODS,RESULTS
169,ANTICANCER,BACKGROUND,COPYRIGHT,DISCUSSION,EWING,INSTITUTE,LABEL,METHODS,NMC,NUT
036,037,074,147,169,745,AIM,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,HOWEVER,INSTITUTE,LABEL,METHODS,OBJECTIVE,RESULTS,UNIVERSITY
001,169,AIM,ANTICANCER,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,MATERIALS,METHODS,NSCLC,OBJECTIVE,RESULTS
169,945,AIM,AKT,ANTICANCER,CK2,CONCLUSION,COPYRIGHT,FACSCAN,H1299,HOWEVER,INSTITUTE,LABEL,MATERIALS,METHODS,NSCLC,OBJECTIVE,PACLITAXEL,PARP1,RESULTS,TREATMENT
169,17A,947,ANTICANCER,BACKGROUND,CD3,CD4,CONCLUSION,COPYRIGHT,HOWEVER,IFN,IL17A,IL6,INSTITUTE,LABEL,METHODS,REGULATORY,RESULTS,ROR,TREGS
169,ANTICANCER,CHINESE,COPYRIGHT,INSTITUTE,NSCLC,SHH,SMO,SONIC,YANGZHENG
169,214,452,574,AIM,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,HNACC,HNSCC,INSTITUTE,LABEL,MATERIALS,METHODS,MIR,OBJECTIVE,RESULTS
169,4T1,APRIL,PRESS,PUBLISHED,SILENCING,STUDIES,TLR,UNIVERSITY
AMONG,BASED,SIMULATING,SYNTHETIC,UNTIL
BULKY,CROSS,CUMULATIVE,DETECTION,INERTNESS,INNOVATIVE,POC
000,150,800,900,CORRECTED,COSTS,GAMMA,HODGKIN,LABEL,METHODS,OBJECTIVE,PER,RESULTS,ZEALAND
169,405,624,COPYRIGHT,INC,INDIVIDUAL
BACKGROUND,DFI,LABEL,METHODS,POTENTIAL,RESECTION,RESULTS,THREE
169,183,421,ASCOT,BACKGROUND,COPYRIGHT,FUNDING,INSTITUTES,JUPITER,LABEL,LTD,MALMO,METHODS,PROVE,RESULTS,SIMILARLY
169,COPYRIGHT,H1299,HOWEVER,IRELAND,LTD,MYC,RAS
002,003,127,168,169,179,215,315,341,849,925,AFRICAN,COPYRIGHT,INC,MERGING,PUBLISHED,SOCIETY,STUDIES,TGSII
169,916,968,BAX,BCL,COPYRIGHT,H1299,HOWEVER,INC,NAC,ROS,THESE
169,945,ACCORDING,COPYRIGHT,IGFBP,INC,RESULTS,SERUM,VARIATIONS
BACKGROUND,BMJ,GROUP,INSPECTION,LABEL,LIMITED,METHODS,POE,PUBLISHED,PUBLISHING,RESULTS,SPN,THERE,TRIAL,USING
169,COPYRIGHT,FFF,FLATTENING,IRELAND,LTD
169,215,635,BACKGROUND,COPYRIGHT,FDR,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PURPOSE,RADIOMICS,RESULTS,UNIVARIATE
169,COPYRIGHT,DELETED,DIFFERENT,DLEC1,HNSCC,HOWEVER,PCR

ALK,BACKGROUND,EXPRESSION,IMT,LABEL,METHODS,THERE
AFTER,ARA,CCK,CONCLUSION,DDP,EFFECTS,LABEL,LRP,METHODS,NPC,OBJECTIVE,PCR,RESULTS,WESTERN
169,946,EMT,EPITHELIAL,OTHER,TGF
169,946,CSC,FUNCTIONAL,IKBKB,IKK,NOTABLY,THESE,WNT
169,EGF,FINALLY,MOUSE,RES,STAT3,STUDIES,TAKEN
169,233,HOWEVER,PCR,THESE
169,945,946,BIOLOGY,IPF,LEUKOCYTE,ONO,SMA,SOCIETY,TGF,TREATMENT
CHEST,LABORATORY,PTHRP
THREE
1ST,2ND,HEMORRHAGE,STENT
CLEAR
CUSHING,HORMONE,SINCE
177,ADHERENCE,AFTER,ASSOCIATED,AUC,AUCSS,CONCLUSION,ERLOTINIB,ESPECIALLY,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIXTY

AFTER,HOWEVER,PARTIAL
HOWEVER
50S,AFTER,HOWEVER,III,JANUARY,MAY,PET,RFA
EIGHT,JOHNSON,SJS,STEVENS
GRADE
500,BACKGROUND,CISPLATIN,CONCLUSION,GRADE,HOWEVER,LABEL,METHODS,NSCLC,RESULTS,THERE,THEREFORE
000,CHIBA,CURRENTLY,DAV,HEAVY,HIMAC,HOWEVER,HSP90,INSTITUTE,PROJECT
BRAGG,CHARGED,HENCE,PBT,TSUKUBA,UNIVERSITY
CONCURRENT,DISEASE,GRADE,GYE,NSCLC,PBT,V20
BMJ,COP,GOP,GROUP,LABEL,LIMITED,METHODS,OBJECTIVE,PUBLISHED,PUBLISHING,RESULTS,SIXTY,WHILE
ACTIVATION,BACKGROUND,EXPRESSION,HOWEVER,KNOCKDOWN,LABEL,METHODS,NOTCH,RESULTS,THEREFORE
100,854,ACTIONABLE,AGENA,AUSTRALIA,BACKGROUND,BIOSCIENCE,LABEL,MASSARRAY,METHODS,MPS,OVERALL,PANEL,RESULTS,WHEREAS
328,543,ARG458X,BACKGROUND,BAX,FUNCTIONAL,LABEL,LYS469GLU,METHODS,NEITHER,NSCLC,PPM1D,RESULTS,THEIR,THESE
001,008,252,291,CLEVELAND,DETAILS,DISTANT,HOWEVER,HPV,III,IMPORTANCE,IMPORTANT,IVB,JANUARY,LABEL,METHODS,OBJECTIVE,OPSCC,RELEVANCE,RESULTS,SECONDARY,SETTING
001,002,115,947,ASA,BACKGROUND,CHEST,COLLEGE,EDUCATION,EVALUATION,FIFTEEN,LABEL,METHODS,PHYSICIANS,QUALITY,RELATIVELY,RESULTS,SECONDARY,SOCIETY,THERE,THESE
104,CONCLUSION,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
450,BIVARIATE,LABEL,METHODS,MODEL,OBJECTIVE,OBJECTIVES,RECURSIVE,RESULTS,TAIWANESE
PJP
001,143,170,210,221,246,414,AFTER,AMONG,AUC,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS
118,120,162,169,200,300,956,CAD,COPYRIGHT,FALSE,FBP,IRELAND,LABEL,LTD,METHODS,NOISE,OBJECTIVE,OBJECTIVES,RESULTS,SEVEN,SIMILARLY
945,946,PDGFR,POSTMORTEM,PULMONARY,TREATMENT
ABELSON,ALK,ASP,EML,H2228,MTS,NSCLC,RECURRENT,THESE,TRP
167,169,291,BACKGROUND,COPYRIGHT,GCT,GIANT,JOINT,JOURNAL,LABEL,METHODS,RESULTS,SURGERY,THERE
169,APC,APPROACHES,APRIL,AVERAGE,BACKGROUND,CAUTION,END,FIRST,INSTITUTE,LABEL,METHODS,RESULTS,SOCIETY
169,BACKGROUND,BECAUSE,BLADDER,HIV,LABEL,METHODS,ORS,RESULTS,SOCIETY
263,311,500,ABT,AZD8055,BCL,BH3,BIM,HOWEVER,MCL,RB1,SCLCS,THEREFORE,TORC1,WHEREAS
001,169,APHASIA,BACKGROUND,COX,HEART,INC,INSTITUTES,LABEL,METHODS,OBJECTIVE,PNEUMONIA,PURPOSE,RECURRENCE,RECURRENT,RESULTS,SCALE,TIA
DESPITE,NSCLC,THEREFORE
001,305,CD133,COX,LABEL,MEIER,METHODS,NSCLC,OBJECTIVE,RESULTS,TNM
169,ALK,CD133,COPYRIGHT,EMT,ERK,H1299,HOWEVER,INC,NSCLC,TAKEN
100,CONCLUSION,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,OUTCOME,RESULTS
169,COPYRIGHT,EOC,INC,LABEL,METHODS,OBJECTIVE,PCR,PFS,PRSS3,RESULTS,THERE,THESE
160,COX,LABEL,MEIER,METHODS,NSCLC,OBJECTIVE,PURPOSE,RESULTS,STAT3
160,169,183,GEORG,HENCE,STUTTGART
160,169,183,ALK,GEORG,GERMANY,STUTTGART
160,169,183,DIAGNOSIS,GEORG,STUTTGART,WORLDWIDE
003,037,106,124,168,475,963,AMONG,BACKGROUND,CHEST,DIAGNOSTIC,ENGLISH,LABEL,METHODS,PROGRAMMES,RESULTS
645,749,AMONG,BACKGROUND,CRUDE,DIAGNOSIS,HODGKIN,LABEL,METHODS,RESULTS,SIMILARLY
222,BACKGROUND,LABEL,METHODS,RESULTS,SEA,THERE
BACKGROUND,ENGLAND,FURTHER,LABEL,METHODS,RESULTS,SERVICE,STAGE
001,AWARENESS,BACKGROUND,CAM,CLEAR,ENGLAND,ENGLISH,GPS,LABEL,LIFESTYLE,MEASURE,METHODS,OCTOBER,RESULTS,STATISTICS
355,486,BACKGROUND,ENGLAND,LABEL,MEN,METHODS,OVERALL,RESULTS,THERE,UNPROMPTED
ALK,ATP,CNS,FIG,HOWEVER,MET,ONCOGENIC,TAKEN,XALKORI
BECAUSE,FRAGILE,NSCLC,RELATED,SCC
160,169,COPYRIGHT,INC
160,169,ATL,AUTHORS,BRITISH,GRADE,JOURNAL,LTD,ORR,SEVERAL,WILEY
169,AKT,CAF,LEWIS
128,143,160,BASED,CHINESE,COX,DFS,ERCC1,HOWEVER,LABEL,MEIER,METHODS,NSCLC,OBJECTIVE,PURPOSE,RESULTS

DESPITE,HOWEVER,INITIALLY
HOWEVER,SMALL
100,138,169,30504,945,CONCLUSION,CROSS,GRADE,GROUP,LABEL,METHODS,OBJECTIVE,PFS,PURPOSE,RESULTS,SOCIETY,TEN,THREE
002,160,169,231,233,AMONG,COPYRIGHT,PUBLISHED,SAS
045,127,169,219,411,ACCORDING,BACKGROUND,BASED,CEA,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,NOTABLY,PDC,RESULTS
BACKGROUND,CISPLATIN,CONCURRENT,DISTANT,III,LABEL,MEDICAL,METHODS,NSCLC,OBJECTIVE,PFS,RESULTS,SIMILAR,SIX
FDA,NON,NSCLC,OCTOBER,VEGFR
003,024,032,125,130,293,HOWEVER,NSCLC,PCR
007,013,026,ACA,BMJ,CASP3,CD44S,DESPITE,EXPRESSION,FURTHER,GROUP,LABEL,LCC,LIMITED,METHODS,NSCLC,OBJECTIVE,OPN,PUBLISHED,PUBLISHING,RESULTS,RHAMM,THREE,UNION,WHILE
009,107,AUTHORS,BACKGROUND,CANCERLIT,COLLECTION,IPD,LABEL,MEDLINE,METHODS,NSCLC,OBJECTIVE,OBJECTIVES,QUALITY,RESULTS,SELECTION,SURGERY,THERE
107,108,169,249,ADULT,ADVERSE,ALISERTIB,AMONG,BACKGROUND,COMPANY,COPYRIGHT,CZECH,ENROLMENT,EVALUATION,FEB,FUNDING,INC,LABEL,LIMITED,LTD,MAY,METHODS,MILLENNIUM,RESULTS,SERIOUS,SOLID,THESE,USA
121,169,BCI,CRC,H3K4ME2,INC,SMYD3,THESE,WILEY
169,575,COPYRIGHT,FEDERATION,NSCLC,PUBLISHED,SOCIETIES,UTR
169,COPYRIGHT,COX,FDG,INC,JANUARY,LABEL,MEIER,METHODS,OBJECTIVE,OBJECTIVES,PET,PUBLISHED,RESULTS,SEVENTY,SIXTY,SURGERY,UNIVARIATE
169,A24,ANOTHER,AUTHORS,BASED,CD4,CTL,FURTHER,HLA,HNSCC,LPS,LTD,PTY,PUBLISHING,SCIENCE,SPS,TAA,WILEY
001,002,003,028,120,169,239,CONCLUSION,COPYRIGHT,ILA,IRELAND,LABEL,LTD,MATERIALS,METHODS,NSCLC,OBJECTIVE,RESULTS,THESE,TKI
169,1ST,743,BACKGROUND,COPYRIGHT,LABEL,LINKAGE,LTD,METHODS,OCTOBER,PRESCRIBED,RESULTS,SWEDISH,THESE
169,COPYRIGHT,INC,NSCLC,PUBLISHED,SOCIETY,THESE
001,017,159,160,169,177,967,BACKGROUND,BONFERRONI,COPYRIGHT,COX,INC,LABEL,MEIER,METHODS,PUBLISHED,RESULTS,SOCIETY,STUDENT
DEPLETION,HOWEVER,MIR,NAIF1,NSCLC,NUCLEAR
169,ABCG2,BIOMARKERS,CD271,COPYRIGHT,IRELAND,JARID1B,LTD,MMP,RESISTANT,V600E
169,CD103,CD8,COPYRIGHT,CTL,HOWEVER,INC,NSCLC,TCR,THESE,TIL,TIM
169,945,946,948,COPYRIGHT,EMT,FINALLY,H1650,NOTABLY,NSCLC,PKC,SNAIL,SOCIETY,TWIST,WHEREAS
169,GROUP,HOWEVER,III,JAPAN,PHASE,PRESS,PUBLISHED,STAGE,TNM,UFT,UNIVERSITY
001,005,009,034,114,115,296,525,ACCORDING,DFS,OVERALL,SEX,THEREFORE,TNM
005,027,046,121,356,ALCOHOLISM,BACKGROUND,DESPITE,EMERGENCY,GERMANY,LABEL,METHODS,RESULTS
IATROGENIC
169,BH3,COPYRIGHT,DYNAMIC,INC,PROFILING,THERE,WHILE
001,004,009,010,016,020,569,ADC,HOWEVER,LIMITED
ALK,FUSIONSEQ,HOWEVER,IMT,NTRK1,RET,TFG,THERE
001,169,BLOOD,CONCLUSION,FDG,HOWEVER,IMAGING,INC,LABEL,METHODS,MOLECULAR,NUCLEAR,PASTEUR,PET,RESULTS,SMALL,SOCIETY,SUV,UNLABELLED,WARBURG
169,ACT,CONCLUSION,FDG,IMAGING,INC,INSURANCE,LABEL,METHODS,MOLECULAR,NUCLEAR,PEARSON,PERFORMING,PET,RESULTS,SOCIETY,UNLABELLED
100,169,ALK,BACKGROUND,CONCLUSION,IHC,LABEL,MATERIALS,METHODS,NGS,PRESS,RESULTS,SCREENING,THREE
169,COPYRIGHT,FINALLY,HDACS,HISTONE,HOWEVER,IGF,IRELAND,LTD,MTT,NSCLC,OTHER,THESE,TREATMENT,USING
169,AUTHORS,COPYRIGHT,HSP70,HSP90,IRELAND,LTD,NVP,PUBLISHED,TREATMENT
169,2OCL3,4RU,956,ADP,AG311,ATP,COPYRIGHT,HMGB1,NH3,RU360,SOCIETY,THERAPY,THEREFORE
226,BACKGROUND,HOWEVER,LABEL,METHODS,NSCLC,PCR,RESULTS,WESTERN
046,114,132,138,362,652,906,AUSTRALIA,BACKGROUND,CONCLUSION,CONTEXT,LABEL,LITERATURE,METHODS,OBJECTIVE,PTHRP,QUEENSLAND,RESULTS,SETTING,SOLID,THERE
154,159,3OST2,APC,BACKGROUND,FAM19A4,LABEL,METHODS,PCR,PHACTR3,RASSF1A,RESULTS,THREE
107,120,169,227,238,746,AMONG,ANXIETY,BACKGROUND,GUIDELINES,HODGKIN,HOWEVER,LABEL,METHODS,PRESS,PUBLISHED,RESULTS,SPM,SURVIVORS,UNIVERSITY,VITAL
169,945,COPYRIGHT,INC,OSCAR,SFTPD,SURFACTANT,TNF
AGE,ANZDATA,AUSTRALIA,CIS,COX,HOWEVER,INDIGENOUS,JANUARY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OUTCOME,RESULTS,RRT,SETTING,TRANSPLANT,UNADJUSTED,ZEALAND
001,191,954,ABORIGINAL,AFTER,CONCLUSION,CROSS,LABEL,MEASURE,METHODS,NSW,OBJECTIVE,OUTCOME,OVERALL,RESULTS,RRR,SETTING,SOUTH,WALES
169,95D,BIOMEDICAL,BOARD,CCK,CDC,CHINA,CONCLUSION,COPYRIGHT,EDITORIAL,GFP,LABEL,LC3,METHODS,NSCLC,OBJECTIVE,PUBLISHED,RESULTS,SAECS,SMO,WESTERN
004,005,17558,19385,BACKGROUND,CAUCASIANS,CIS,HOWEVER,LABEL,METHODS,OCTOBER,ORS,RESULTS,TELOMERASE
AMERICANS,THEREFORE
120,129,CCA,END,HOWEVER,INCREASED,INSTITUTE,LOWER,RESULTS,SIR
001,263,542,953,AFFILIATED,AMONG,FIRST,GUANGZHOU,HOWEVER,MEDICAL,NSCLC,PCR,UNIVERSITY
181,470,562,ADR,ANNONACEAE,BASED,CAFFEIC,NCI,OVERALL,UA251
084,177,714,918,AFTER,CONTINUED,CUMULATIVE,EARLIER,HOWEVER
15Q12,169,215,BACKGROUND,DETECTION,GABAERGIC,LABEL,METHODS,PATHWAY,PRESS,PUBLISHED,RESULTS,RS73371737,UNIVERSITY
169,259,945,ACTIVATION,BIOLOGY,ERK,H1299,H89,INC,INHIBITING,MEK,MG132,MOLECULAR,PKA,RAF,REDUCED,SER,SIRT6,SIRTUIN,SOCIETY,THEREFORE,TREATMENT,WESTERN
100,125,130,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,UNDER
120,180
000,001,100,154,163,222,260,353,CHEST,CVATL,EARLY,LABEL,METHODS,OBJECTIVE,OCTOBER,RESULTS
001,BACKGROUND,FEV,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
113,119,135,138,146,147,177,1ST,3RD,CONCLUSION,FIRST,JANUARY,LABEL,MAY,METHODS,OBJECTIVE,OPERATIONS,RESULTS,VAS,VIDEO
140,150,CONCLUSION,LABEL,LIMITED,METHODS,OBJECTIVE,OBJECTIVES,OPERATION,RESULTS
1990S,300,CHINA
170,183,BACKGROUND,JANUARY,LABEL,MATERIALS,METHODS,RESULTS,VIDEO
169,ACADEMY,CIGARETTE,DICER
001,015,169,432,AAG,ALLYLAMINO,AUTHORS,FOUNDATION,HOWEVER,JOURNAL,LAC,LAST1,LATS1,LTD,MOLECULAR,TAKEN,WILEY,YAP
169,COPYRIGHT,CXCR2,CXCR4,INC,MIF,MSC
123,169,170,COPYRIGHT,MDR,PARKINSON,PGP
100,115,134,169,210,BACKGROUND,CARCINOMAS,CBX,FNA,LABEL,METHODS,RESULTS,SOCIETY,THERE
BMJ,GROUP,IDC,LIMITED,METASTATIC,OESTROGEN,PUBLISHED,PUBLISHING
169,BACKGROUND,COPYRIGHT,CT0,CTS,DVH,EQUIVALENT,EUD,HOWEVER,IRELAND,ITV,LABEL,LTD,METHODS,MFO,OBJECTIVE,PLANS,PTV,PURPOSE,RESULTS,ROBUSTNESS
001,169,AFFAIRS,AMONG,ASIAN,BACKGROUND,CANCORS,CHINESE,CONSORTIUM,ENGLISH,FURTHER,HISPANICS,LABEL,METHODS,NON,RESULTS,SOCIETY,SPANISH
CPG,IGE,THERAPIES
169,AUTHORS,HOWEVER,LTD,PTY,PUBLISHING,SCIENCE,WILEY
169,BACKGROUND,COPYRIGHT,IHC,INC,LABEL,MALIGNANT,METHODS,MEXICAN,MPM,OBJECTIVE,PUBLISHED,RESULTS
HOWEVER,WHILE
231,DESPITE,FINALLY,MDA,PROBING,USING
000,160,169,427,600,BACKGROUND,CHINA,COPYRIGHT,INC,KNOWLEDGE,LABEL,LIBRARY,METHODS,PUBLISHED,RESULTS,SOCIETY
169,COPYRIGHT,EPITHELIUM,ILC2S,LTD,TH2
117,169,183,BACKGROUND,BETWEEN,BRISTOL,COPYRIGHT,FUNDING,GERMANY,IQR,ITALY,LABEL,LTD,METHODS,MYERS,NIVOLUMAB,NOV,RESULTS,THERE,THESE,USA
169,EPIGENOMIC,INCREASED,KCA,KCNN4,NSCLC
002,008,135,169,COPYRIGHT,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RANDOMIZED,RESULTS,STERNAL,SURGERY
108,13433,AFTER,BACKGROUND,EXPRESSION,JAK,LABEL,METHODS,OBJECTIVE,OMNIBUS,RESULTS,TGF,WNT
BACKGROUND,DISCUSSION,LABEL,METHODS,OBJECTIVE
101,143,ACADEMY,BACKGROUND,DEPARTMENT,FIFTEEN,GULHANE,LABEL,MEDICAL,METHODS,OBJECTIVE,OCTOBER,RADIATION,RESULTS,THERE,TREATMENT
AFTER,IMPORTANT,NSCLC
SIADH,SMALL
BACKGROUND,BRONCHIAL,DIAGNOSES,LABEL,METHODS,OBJECTIVE,RESULTS
705,988,BACKGROUND,EARLY,LABEL,LOW,METHODS,OBJECTIVE,RESULTS
IRINOTECAN
1N9,2N6,4N6,5N3,ADC,BASED,FATTY,ROC,SCC
168,549,945,FINALLY,MPT,PCL,PTX,TAXOL
160,169,231,233,244,ALPES,BACKGROUND,CONCLUSION,COPYRIGHT,DESPITE,GPS,INSTITUTE,LABEL,MAY,MCS,METHODS,OBJECTIVE,PCS,PRESENT,PUBLISHED,RESULTS,SAS
AFTER,CISPLATIN,CONCLUSION,LABEL,METHODS,NON,NSCLC,OBJECTIVE,ORR,PARTIAL,PURPOSE,RESULTS,THREE
107,145,190,215,275,348,535,AMR,BASED,EPNEC,LABEL,METHODS,OBJECTIVE,ORR,PATIENT,PFS,PRIMARY,PRIOR,PURPOSE,RESULTS
169,COPYRIGHT,EPIDERMAL,ERK,INC,MAPKS
103,127,155,169,183,304,312,315,318,500,633,800,BACKGROUND,BETWEEN,COMPANY,COPYRIGHT,EASTERN,ELI,ENROLMENT,FEB,FUNDING,GROUP,LABEL,LILLY,LTD,METHODS,NOV,NSCLC,RESULTS,SERIOUS,THERE
160,169,BACKGROUND,COPYRIGHT,CTC,H1299,INC,LABEL,METHODS,PUBLISHED,RESULTS,SOCIETY
169,COPYRIGHT,INC,TOOLS
169,947,CD3,CD4,CD8,COPYRIGHT,HFE,IFN,LTD,MHC,PUBLISHED,THESE,TNF
CHEST,HOWEVER,IDIOPATHIC,IPF,SMALL
HOWEVER,IIB,METASTASES,PATIENT,PROGNOSIS,SPLENIC,STAGE,SURGERY,T3BN0M0
138,AFTER,CONSISTENT,FINALLY,H2081,NCI,RESULTS
000,125,169,CONCLUSION,GIP,GLP,HOWEVER,IMAGING,INC,LABEL,METHODS,MOLECULAR,NUCLEAR,RESULTS,SOCIETY,TYR,UNLABELLED,USING
001,169,177,179,267,311,ANATOMY,CONCLUSION,FDG,FNA,IMAGING,INC,LABEL,METHODS,MOLECULAR,NUCLEAR,PET,RESULTS,SOCIETY,SUV,THERE,UNLABELLED
009,014,015,084,099,177,916,BACKGROUND,LABEL,METHODS,NON,NSCLC,PCR,RESULTS
162,AKT,ERK,MEK
004,009,014,169,177,946,A549EPOB40,BACKGROUND,CD1,DIFFERENT,FOXN1,ICRNU,INHIBITION,LABEL,MEIER,METHODS,MSA,PRESS,PUBLISHED,RESISTANCE,RESULTS,SIDAK,SW480,TREATMENT,UNIVERSITY
169,215,GEWIS,INC,THROUGH,WILEY
018,023,103,185,18F,945,946,ANOTHER,CURRENTLY,FDG,FES,KETTERING,LOUIS,MBQ,PET,SEATTLE,SLOAN,SUV,UNIVERSITY,USING,WASHINGTON
101,DFS,EMT,HCC,HOWEVER,RAC,RHO,ROCK2,STMN1,THESE
169,ATP,BCL,COPYRIGHT,E1B,MIEAP,SINCE,SOCIETY,THESE,WHILE
169,COPYRIGHT,NETWORK,PROPONENTS,SURGERY
169,COPYRIGHT,NETWORK
AFTER,BACKGROUND,CONCLUSION,DEPARTMENT,DUE,LABEL,MEDICAL,METHODS,NEITHER,RADIATION,RESULTS,UNIVERSITY
001,005,008,100,101,180,BACKGROUND,CRC,FURTHER,JANUARY,LABEL,METHODS,MOLECULAR,RESULTS
001,169,189,214,ACRIN,BACKGROUND,CONCLUSION,COX,FDG,III,LABEL,LRC,METHODS,MTV,NSCLC,PET,PRESS,PUBLISHED,RESULTS,TGA,UNIVERSITY
169,512,COPYRIGHT,DOCK3,GEF,H1299,KNOCKDOWN,LTD,MICRORNAS,NSCLC
169,177,956,CHINA,COPYRIGHT,GUANGZHOU,LTD
169,628,CCK,COPYRIGHT,HOWEVER,HOXA5,INC,MICRORNAS,NSCLC,WESTERN
10877,139MONTHS,169,1FR,311MONTHS,3FR,3MONTHS,4FR,8FR,ADVERSE,ARC,COPYRIGHT,CTCAE,III,LABEL,LTD,METHODS,MODULATED,OBJECTIVE,OVERALL,PURPOSE,RESULTS,STS,THERAPY,TREATMENTS,VOLUMETRIC
780,BACKGROUND,LABEL,LNCAP,METHODS,OATP1B3,RESULTS,THERE
001,002,007,008,320,593,ASX,CONCLUSION,INCIDENTAL,LABEL,METHODS,MORTALITY,NSCLC,OBJECTIVE,OVERALL,RESULTS
ENDOSCOPIC,PANCREATIC,VARIOUS
CONCLUSION,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PATIENT,PRIMARY,PURPOSE,RESULTS,SOCIETY,SURGERY
31042,ADULT,AMERICA,CHEST,MPM,NORTH
LN2,SEPARATOR,SMALLER,THESE,VAPOR
121,169,ARMADILLO,ARVCF,INC,NSCLC,WILEY
BACKGROUND,CCNB3,CIC,FOXO4,GENERALLY,LABEL,METHODS,NEWER,RESISTANCE,THEIR
000,169,AGA,BACKGROUND,COLORECTAL,COPYRIGHT,CRC,GERMANY,INC,INSTITUTE,LABEL,METHODS,OBJECTIVE,OVARIAN,PUBLISHED,RESULTS,SCREENING,SIMILAR,TRIAL
105,157,169,199,434,BACKGROUND,CEA,CONCLUSION,COPYRIGHT,CRC,LABEL,LTD,METHODS,RESULTS,RFA,THERE
001,140,169,643,683,BACKGROUND,COPYRIGHT,LABEL,LTD,METHODS,NSCLC,RESULTS,SIX,THERE
169,790,COPYRIGHT,CPG,INC,NSCLC,PC9,T790M,TKI
169,177,945,946,947,956,ATP,COPYRIGHT,INCREASING,LTD,WHEREAS
169,ATP,COPYRIGHT,III,IRELAND,LTD,PGP,THESE
169,BIOLOGY,GEFITINIB,H1650,HOWEVER,INC,LAD,MOLECULAR,ROS,SEVERAL,SOCIETY,TARCEVA,THESE,WESTERN
169,ACCORDING,AIS,BACKGROUND,BASED,CONCLUSION,COPYRIGHT,HOWEVER,IRELAND,LABEL,LTD,MATERIALS,METHODS,MIA,RESULTS
169,177,COPYRIGHT,DEFORMABLE,INC,LABEL,LCS,LUMPECTOMY,MATERIALS,METHODS,OBJECTIVE,POPULATION,PTV,PURPOSE,RESULTS,SIMILARLY,SIXTEEN
120,169,COPYRIGHT,COX,FDG,INC,LABEL,MATERIALS,MAXIMUM,METHODS,OBJECTIVE,PET,PURPOSE,RESULTS,SUV
245,AKT,EGF,ERK,ETS,H1299,INHIBITORS,MAD,MYC,SNP,THESE,USING
169,AMERICANS,DUE,LESIONS,NORTH,SINCE,THESE
169,COPYRIGHT,INC
131,DTC,FDG,PET,WBS
169,500,AUTHORS,FOLLOWING,NAVIGATOR,PUBLISHED
100,160,169,BACKGROUND,COPYRIGHT,HOWEVER,INC,LABEL,MALIGNANT,METHODS,PUBLISHED,RESULTS,SOCIETY
118,169,185,249,294,330,479,724,BACKGROUND,BETWEEN,BOARD,COMPLEX,COPYRIGHT,HOWEVER,INC,LABEL,METHODS,MTB,OVERALL,PATIENT,PUBLISHED,RESULTS,SOCIETY
004,021,037,045,046,177,ADVERSE,CONCLUSION,DISEASE,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE
004,100,31G,9904341,PCR,PRESENTLY
036,AFP,ASIAN,AUC,CA153,CCAT2,CPG,ESOPHAGEAL,KYSE410,NSE
001,210,CCRCC,MALDI,NSCLC,TOF
008,009,021,024,030,128,COX,KLK13,MEIER,NSCLC,PCR,TOTAL
169,722,AFTER,AMONG,BACKGROUND,LABEL,METHODS,RESULTS,SOCIETY,STILL
169,ADVANCING,BECAUSE,BLOOD,CARDIOLOGY,COLLEGE,COPYRIGHT,FOUNDATION,GROUP,HEART,HIV,HLB,INC,INSTITUTE,NHLBI,PUBLISHED,WORKING
DECADES,THESE
169,188,BACKGROUND,CAREGIVERS,LABEL,METHODS,NEEDS,NETWORK,PATIENT,PREDICTION,RESULTS,SOCIETY,SUPPORTIVE,THEREFORE
169,ALCHEMIST,ALK,ENRICHMENT,HOWEVER,INSTITUTE,SEQUENCING,SOCIETY,TRIAL
169,BIOMARKER,EFFORTS,III,MAP,PHASE,S1400,SOCIETY,THERAPY
169,AEF,AMONG,COPYRIGHT,IRELAND,LABEL,LTD,MATERIALS,METHODS,MTWCS,OBJECTIVE,PURPOSE,RESULTS,THERE,THREE,UIP,WHILE
169,AMERICA,INFECTIOUS,PRESS,PUBLISHED,SOCIETY,TAKEN,UNIVERSITY
160,169,290,BACKGROUND,BASED,COPYRIGHT,FLV,INC,JANUARY,LABEL,METHODS,RESULTS
CAF,HOWEVER
NSCLC,TKI
006,011,013,021,025,026,125,199,ASA,BACKGROUND,BMI,CA125,CA199,CEA,CYFRA21,FORTY,LABEL,METHODS,NSE,PATIENT,PVB,RESULTS,SCC,SERUM,SOCIETY,VAS
013,956,BACKGROUND,LABEL,METHODS,PC9,RESULTS,THEREFORE,TUNEL,WST
AFTER,BACKGROUND,EPIGENETIC,EXPRESSION,H1299,LABEL,LUCIFERASE,METHODS,MMP,MSP,PCR,RESULTS,WESTERN
ALK,ECHINODERM,MEANWHILE,MPC,NSCLC
250,ADVERSE,ALK,BACKGROUND,CONCLUSION,CRIZOTINIB,CTC,DISTANT,EVALUATION,LABEL,METHODS,OBJECTIVE,PFS,RESULTS,SOLID,TUMOURS
115,ALK,ANAPLASTIC,BACKGROUND,IHC,LABEL,METHODS,NON,NSCLC,PCR,RESULTS,SCORPIONS,WHILE
172,ALK,AMONG,BACKGROUND,BESIDES,IHC,LABEL,METHODS,NSCLC,RESULTS
ALK,EPIDERMAL,NON,NSCLC,THEIR,TKI
ALK,CURRENTLY,NSCLC,THERE
BROWN,FDG,PET,SEVEN,THERE
100,FDG,HOWEVER,PET,SUV,WHOLE
500,COX,DDD,HOWEVER,INSURANCE,LOE
160,215,224,339,BMI,METABOCHIP,OBESITY,PATHWAY
160,215,224,459,BMI,PATHWAY
00019,00044,012,017,107,181,BACKGROUND,BMJ,CD4,CD8,DEE,GROUP,HOWEVER,LABEL,LIMITED,METHODS,PUBLISHED,PUBLISHING,RESULTS
500,DHA,EPA,HIV,OTHER,RAISING
100,2279744,309,309GG,309TT,EXPRESSION,NON,PRESENTLY,T309G

169,AKT,ASIAN,CAUCASIAN,FGFR1,PRESS,PUBLISHED,RET,TARGETING,THESE,UNIVERSITY,WHILE
169,COPYRIGHT,CTV,EARLY,GROUP,HODGKIN,HOWEVER,ILROG,INC,LABEL,METHODS,OBJECTIVE,PURPOSE,RADIATION,RESULTS,SEVEN,TEN
106,120,168,169,215,916,AUC,COPYRIGHT,INC,INDIVIDUAL,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,REGRESSION,RESULTS,ROI,USING
169,BECAUSE,RESULTS,SAPOSIN,THESE,USING,VIABILITY
169,184,185,412,617,BACKGROUND,COPYRIGHT,FUNDING,HOWEVER,HRS,LABEL,LTD,METHODS,RESULTS,SWEDISH,UNIVERSITY,VASALOPPET
000,146,160,169,172,400,BACKGROUND,COPYRIGHT,CRP,EASTERN,GROUP,INC,LABEL,METHODS,MPM,PERSISTENT,PLT,PUBLISHED,RESULTS,SOCIETY,VAT
100,150,169,400,600,BACKGROUND,CONCLUSION,LABEL,METHODS,MTD,PRESS,RESULTS,SAR245408,THERE
160,AUSTRALIA,BECAUSE,CONCLUSION,EMERGENCY,LABEL,METASTATIC,METHODS,NSCLC,OBJECTIVE,OBJECTIVES,OUTCOME,RESULTS
061,638,AMONG,BACKGROUND,COMBINING,DETECTION,EARLY,HOWEVER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PITTSBURGH,PLUSS,PROGRAM,RATIONALE,RESULTS,SCREENING,TRIAL
169,183,CHURG,FIRST,GEORG,IMPORTANT,STRAUSS,STUTTGART,SUBSEQUENT,WEGENER
BAX,BCL
ATTRACTIVE,EARLY
140,BACKGROUND,KINESIN,KLC,LABEL,METHODS,MIR,NSCLC,RESULTS
002,007,10877,ARF,BACKGROUND,LABEL,MALIGNANT,MEIER,METHODS,MPM,P14,P53,PFS,RESULTS,SCORE,UNTIL
BACKGROUND,EMT,EPITHELIAL,FAS,HEPG2,LABEL,METHODS,RESULTS
169,196,213,374,929,ANTICANCER,CENTERS,CONCLUSION,CONTROL,COPYRIGHT,DISEASE,INSTITUTE,LABEL,MATERIALS,METHODS,NUTRITION,OBJECTIVE,PREVENTION,RESULTS
001,169,375,AIM,ANTICANCER,CONCLUSION,COPYRIGHT,COX,FORTY,INSTITUTE,LABEL,METHODS,MPE,NSCLC,OBJECTIVE,PFS,RESULTS,SERUM
002,007,169,361,970,AIM,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,COX,HOWEVER,INSTITUTE,JANUARY,LABEL,METHODS,OBJECTIVE,RESULTS,SEN,SEVENTEEN,SUN,YAT
008,145,169,835,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,METHODS,NSCLC,RESULTS
169,AIM,ANTICANCER,CNS,CONCLUSION,COPYRIGHT,CSF,INSTITUTE,LABEL,METHODS,NSCLC,OBJECTIVE,PPS,RESULTS,T790M,TKI
100,123,169,956,ANTICANCER,CONCLUSION,COPYRIGHT,COUMARINS,INSTITUTE,LABEL,MMP,MRC,PCFDA,RESULTS,ROS,THESE,UNLABELLED
169,954,ANTICANCER,B19,COPYRIGHT,CURCUMA,EPHB2,HDAC4,INSTITUTE,SEPP1,STAT3
102,169,929,AMONG,BACKGROUND,BROADER,CONCLUSION,COX,END,HOWEVER,LABEL,METHODS,OVERALL,PRESS,PRIOR,PUBLISHED,RESULTS,UNIVERSITY
AFTERWARDS,GAS,NEITHER,SNIFFER,SOLID
169,FURTHER
150,169,567,CONCLUSION,LABEL,METHODS,NSCLC,OBJECTIVE,ORR,PATIENT,PFS,PURPOSE,RESULTS,SOCIETY,THERE
014,169,483,633,798,850,886,988,CONCLUSION,COX,LABEL,METHODS,NSCLC,OBJECTIVE,PURPOSE,RESULTS,SOCIETY
169,ALK,CONCLUSION,CRIZOTINIB,LABEL,METHODS,OBJECTIVE,PFS,PURPOSE,RESULTS,SOCIETY
169,AKT,ALK,COMPLETION,CONCLUSION,ERBB2,KIT,LABEL,METHODS,NSCLC,OBJECTIVE,PURPOSE,RESULTS,SIX,SOCIETY
169,CONVERSELY,COPYRIGHT,H1299,HN6,SOCIETY,TAKEN,THESE,WHEREAS
029,169,566,669,749,ABCB1,ATP,B17,CYP2A13,FASEB,FOXA2,III,INHALED,MDR,R257C,TAP,THEIR,UDP,UGT2B17
231,264,954,EXTENSIVE,FINALLY,MDA,MOUSE,QUE,RANKL,RAW,THEREFORE
169,ACCORDING,CHROMATIN,CONSISTENT,COPYRIGHT,H1299,HOWEVER,INC,PCC,PRR11,TAKEN
169,BIOLOGY,CONSISTENT,FOS,INC,MOLECULAR,NCI,REDUCED,SIMILAR,SOCIETY
100,169,ACCOUNTING,AIM,BACKGROUND,CONCLUSION,COPYRIGHT,COX,END,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,RESULTS,STATINS
169,567,BACKGROUND,BMI,CONCLUSION,COPYRIGHT,INC,LABEL,LOS,METHODS,NSQIP,OBESITY,OVERALL,POISSON,PROGRAM,QUALITY,RESULTS,WORLD
169,231,233,COPYRIGHT,PUBLISHED,SAS
130,197,945,CONCLUSION,FOS,FRA,LABEL,MB231,MDA,METHODS,OBJECTIVE,PURPOSE,RESULTS,SINCE,THESE,USING
DOCTORS,LIMITED,PULMONARY
954,BACKGROUND,CONCLUSION,CONTOURING,CTV,DESPITE,DR1,DR2,DRS,FDG,GTV,KAPPA,LABEL,MATERIALS,METHODS,NSCLC,OVERALL,PET,RESULTS,THEREFORE,TVS
EPITHELIAL,HLCCS,HOWEVER,LCC,LH2,UTILIZING
945,GLUTAMINE,METABOLIC,NCOA2,SRC,SREBP,TCA
374,388,SHP
455,671,722,BACKGROUND,COLLEGE,CONCLUSION,FUNDING,INSTITUTES,LABEL,LIMITATION,METHODS,OBJECTIVE,PRIMARY,RADIOLOGY,RESULTS,SCREENING,SECONDARY,SETTING,TRIAL
956
998,LOD,LOQ,MSM,NSM,PSM,SEM,TYR
HOWEVER,SMALL,THESE
169,HOWEVER,PRESS,PUBLISHED,UNIVERSITY
000,001,100,440,740,900,910,AMONG,BACKGROUND,END,HIV,HODGKIN,LABEL,METHODS,NHL,POISSON,PRESS,PUBLISHED,RESULTS,UNIVERSITY
342,FINALLY,MICRORNAS,NSCLC,RAP2B,UTR
000,100,128,160,169,194,482,510,767,860,923,AMONG,BACKGROUND,COPYRIGHT,FACTORS,FOUNDATION,HISPANICS,HOWEVER,INC,LABEL,METHODS,PUBLISHED,RATES,RESULTS,SETTING,SIR,THESE
169,AUHNS,COPYRIGHT,DOX,LTD,NIR,PEGYLATED,TAKEN
169,AKT,COMBINING,COPYRIGHT,GEFITINIB,H1975,HOWEVER,HSP90,INC,NSCLC,THESE,TKI,XRCC1
163,169,COPYRIGHT,CXCR4,HSC,INC,R334X
169,COPYRIGHT,EMT,INC
110,130,140,169,AUC,BIS,CONCLUSION,COPYRIGHT,DBONE,DWA,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,OBJECTIVES,REGIONS,RESULTS,VMS
104,120,160,169,413,AFTER,BACKGROUND,COPYRIGHT,CSS,FORTY,INC,LABEL,METHODS,NSCLC,PROPENSITY,PUBLISHED,RESULTS,RFS,SOCIETY
116,169,16S,COPYRIGHT,EIGHT,FIFTY,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PPI,PRINCIPAL,RESULTS,THERE
169,303,532,682,915,COPYRIGHT,INDICATING,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SMR,STATISTICS
169,CHANGES,COPYRIGHT,CROWN,MMP,MYPT1,PREVIOUSLY,PUBLISHED,RHO,SAS,SPCA1,TAKEN,THROUGH
169,954,APOPTOSIS,COPYRIGHT,HOWEVER,HSP90,NSCLC,ROMIDEPSIN,ROS,SAS,THESE
145,169,BIOMARKERS,COPYRIGHT,DFS,ISH,NON,NSCLC,PCR,SAS,THESE
169,COPYRIGHT,DDP,HOECHST,ICAM1,MTT,NSCLC,PCR,SAS,TIMP4,WISP2
169,COPYRIGHT,MEANWHILE,MICRORNAS,MIR,SAS,TAKEN
160,169,177,460,683,760,780,961,976,CCL20,CD4,COPYRIGHT,FOXP3,HOWEVER,IHC,III,MFI,NSCLC,PCR,SAS,TIL
169,BANCR,COPYRIGHT,ERK,JNK,LNCRNAS,SAS,THESE
169,ATP,CD3,CIK,COPYRIGHT,CRT,DOCETAXEL,HMGB1,HOWEVER,SAS,SPC
140,160,169,177,210,6NM,945,956,9NM,ANOVA,CIS,CISPLATIN,CONCLUSION,COPYRIGHT,DSC,GNS,HOWEVER,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SAS,THEREFORE
169,ARRAY,COPYRIGHT,GENOTYPING,HPV,INC,INK4A,PATHOLOGIC,ROCHE,SMALL
BMJ,DUE,EXCELLENCE,GROUP,INSTITUTE,LIBRARY,LIMITED,MEDLINE,NSCLC,PFS,PUBLISHED,PUBLISHING,THERE
147,169,264,8MRNA,954,CD147,COPYRIGHT,INC,RAW,TAKEN
169,NSCLC,PRESS,UNTIL
CURRENT,DESPITE,IDIOPATHIC,IPF
047,115,169,992,BACKGROUND,COPYRIGHT,HOWEVER,INC,LABEL,LOCAL,METHODS,NSCLC,RESULTS,SRS
148,169,CONCLUSION,COPYRIGHT,DDLPS,DISTANT,IQR,LABEL,LOG,LTD,MATERIALS,METASTATIC,METHODS,OBJECTIVE,RECORDS,RESULTS
ALK,AREAS,BACKGROUND,COVERED,CRIZOTINIB,FDA,HOWEVER,LABEL,MET,METHODS,NSCLC,OPINION
AAH,ACTIVATION,AID,AT2,BASED,HOWEVER,INCREASED,MALLS,SIMILAR
001,003,023,111,386,AGGREGATE,GAMMA,KNIFE,LABEL,METHODS,NON,NSCLC,OBJECTIVE,RESULTS,SEVEN,SRS,THEREFORE
001,007,169,261,649,AMONG,BACKGROUND,COMPARISON,CONCLUSION,EGFRM,HRS,III,LABEL,LUX,METHODS,NSCLC,OPTIMAL,PFS,PRESS,RESULTS,TKI,UNIVARIATE,WJTOG3405
169,AKT,BP1,COPYRIGHT,FAK,GBC,IHC,IRELAND,LTD,MMP,NOZ,THESE
169,DISCOVERY,FLYNN
169,231,233,ALK,COPYRIGHT,PUBLISHED,SAS,SEVERAL
100,107,113,138,169,500,AIM,COLLEGE,CONCLUSION,COPYRIGHT,INCIDENTAL,LABEL,LTD,MALIGNANT,MATERIALS,METHODS,MRI,OBJECTIVE,PUBLISHED,RESULTS,ROYAL,SEPTEMBER,THEREFORE
ABI,H12,H14,H17,RESULTS,THEIR,WESTERN
036,042,043,228,301,501,CHINESE,HAN,HOWEVER,RS8042059,SEVENTEEN
ACUTE,PATIENT,PRIMARY
CFM,GSH,ID8,L1210,L1210FR,NOVEL,OET,PET,RME
000,400,SHS
100,875,879,886,CHINA,EPIDERMAL,FURTHER,JANUARY,LDA,NSCLC,PRIMARY,SOUTHWEST,SVM,USING
001,036,037,121,HOWEVER,NSCLC,PCR,THEREFORE,WNT,WNT7A
169,CSC,NPS,PRESS,PUBLISHED,RES,THESE,UNIVERSITY
160,AFTER,BACKGROUND,CD11C,CD123,CHI,CHINESE,CHUAN,CONCLUSION,DC11C,LABEL,METHODS,NKT,NSCLC,PBMCS,PERIPHERAL,REGULAR,RESULTS,TAI,TCC,TRC,TRIAL
956,ANNEXIN,CCK,CONCLUSION,DDP,LABEL,LRP,MEANWHILE,METHODS,OBJECTIVE,PCR,RESULTS,WESTERN
002,005,012,014,015,017,026,177,BMJ,BRITISH,GD1,GROUP,HOWEVER,LABEL,LIMITED,MACROPHAGE,METHODS,OBJECTIVE,OBJECTIVES,OUTCOME,PRIMARY,PUBLISHED,PUBLISHING,RESULTS,SECONDARY,SETTING,THERE,TOTAL,VANCOUVER
169,ENGINEERS,MALIGNANT,OCT,OPTICAL,PHOTO,RAMAN,SOCIETY
284,469,ADDITIONAL,LABEL,METHODS,MHD,MLD,OBJECTIVE,OVH,PRINCIPAL,PTV,PURPOSE,RESULTS
CARLO,DOSIMETRY,FURTHER,LABEL,LINAC,LORENTZ,METHODS,MONTE,MRI,OBJECTIVE,ORIENTING,PTV,PURPOSE,RESULTS
DRX,LABEL,METHODS,NU2,OBJECTIVE,PARTIAL,PET,PSF,PURPOSE,PVE,RESULTS,RICHARDSON,SNR
HEALTHCARE,INITIAL,LABEL,MEDICAL,METHODS,NUCLEAR,OBJECTIVE,OPTIMIZED,PHILIPS,PURPOSE,RESULTS,SUN,SYSTEMS,UIMAT
174,CARLO,CHANGES,DVH,LABEL,METHODS,MONTE,OBJECTIVE,PURPOSE,RESULTS,SEVERAL,TREATMENT
177,CARLO,DOSIMETRIC,LABEL,METHODS,MONTE,OBJECTIVE,PHASE,PURPOSE,RESULTS
AGENT,BAX,BCL,BESIDES,METADHERIN,MTT,NSCLC,TAKEN,WESTERN
AST,BACKGROUND,ELISA,GRECO,HILIT,KAN,LABEL,METHODS,RESULTS,SAFRA,SAVDA,SPP24
169,BACKGROUND,CURRENT,FRAMINGHAM,HIGHEST,LABEL,METHODS,OFFSPRING,RESULTS,SOCIETY,THESE
169,BASED,OTHER,SOCIETY
954,JNK,KEY,LABEL,METHODS,OBJECTIVE,OVERALL,RESULTS,TNF,TNFIS,USING,WHEREAS
COEXISTENT,OPHN1,OTHER,PECOMAS,PSF,RRAGB,ST3GAL1,TSC
169,BPE,CHRONIC,COLLEGE,CRT,NSCLC,PHYSICIANS,ROYAL,THESE
001,169,202,350,552,BACKGROUND,CD3,CD8,DIAMIDINO,HOWEVER,INCREASED,LABEL,METHODS,NSCLC,OBJECTIVE,PRESS,PUBLISHED,QIF,RESULTS,STUDIES,TIL,UNIVERSITY,USING,YTMA140
169,198,351,522,708,906,COPYRIGHT,CPG,DESPITE,EPIGENETIC,INC,THERE,THESE,USING
000,169,900,BACKGROUND,BETWEEN,END,LABEL,METHODS,OVERALL,PREDICTING,RESULTS,SINCE,SOCIETY
169,BRAIN,COPYRIGHT,PUBLISHED,SAS
169,956,BACKGROUND,ECS,HEART,HOWEVER,INC,JAK,JANUS,LABEL,METHODS,OBJECTIVE,RATIONALE,RESULTS,SMALL,SOCS3,STAT3
169,AFTER,AMONG,HOWEVER,THESE
024,107,176,ASN118ASN,C8092,ERCC1,THESE,XPD,XRCC1
JANUARY,NSCLC,TOXICITIES
001,011,012,021,169,BACKGROUND,BSP,COPYRIGHT,CPG,EPIGENETIC,INC,LABEL,METHODS,MSP,NPTX1,PCR,RESULTS,THESE,TNM
500,AMONG,CD8,ELISPOT,HLA,HOWEVER,IAV,M13,PB1,PB2,POISSON,PR8,X31
003,169,215,232,259,328,378,591,945,COMPARING,HOWEVER,LABEL,METHODS,OBJECTIVE,PRESS,PUBLISHED,RESULTS,S100B,THEREFORE,UNIVERSITY
ECM
100,169,COPYRIGHT,PUBLISHED,ULTRASOUND
ACUTE,AFTER,AMONG,CONCLUSION,KNOWLEDGE,LABEL,LOCAL,METHODS,NSCLC,OBJECTIVE,RESULTS
169,946,AKT,COPYRIGHT,EMT,INC,TGF
169,945,BIO,BRITISH,CCL,IMMUNOLOGY,MDSCS,MYELOID,NSCLC,PERIPHERAL,RFA,SOCIETY,THERE,THESE,TNF,TREGS
169,946,ADC,DOCK4,LABORATORY,PRESS,PUBLISHED,TGF,THESE
169,351,428,557,747,AMONG,CONSISTENT,COX,JANUARY,USING
111,169,215,476,510,730,953,DISCOVERY,FDR,FFAR4,INC,WILEY
IRELAND,LTD,PUBLISHED,SEVERAL,THEREFORE
BACKGROUND,BETWEEN,CALLS,CONCLUSION,DESPITE,FUNDING,HRS,INDIVIDUAL,INSTITUTE,LABEL,LIMITATION,METHODS,NURSING,OBJECTIVE,PRIMARY,PROXY,RESULTS,RETIREMENT,SETTING
169,750,BACKGROUND,CETUXIMAB,DECREASED,DLT,ERBB2,FIFTY,FURTHER,JAK,LABEL,METHODS,RESULTS,SOCIETY
169,FORCE,PREVENTIVE,SCREENING,SINCE,SOCIETY,TRIAL
169,231,233,COPYRIGHT,PEMETREXED,PUBLISHED,SAS
160,169,510,900,CHINA,COPYRIGHT,ELISA,GENOMIC,HOWEVER,IGG,IRELAND,LTD,PCR,PREVALENCE,THREE,TOXOPLASMA
100,169,4N0,7TH,AFTER,BACKGROUND,GYE,IIA,LABEL,LCR,METHODS,NSCLC,RESULTS,SHORT,SOCIETY
169,COLORECTAL,COPYRIGHT,CPG,CUR,CURCUMA,DELETED,DLEC1,HDAC4,INC,KNOCKDOWN,MSP,TAKEN
169,AUTHORS,FURTHER,G3H,GFP,HGF,HOWEVER,LTD,MET,PTY,PUBLISHING,SCIENCE,SMALL,THEREFORE,THESE,WILEY
169,ARG275TRP,COPYRIGHT,INC,PARK2,PARKINSON,PUBLISHED,SOCIETY,THESE
169,VCH,WILEY
963,BIS,FINALLY,HAMMETT,INHIBITOR,PEG,WHILE
001,054,10540,169,178,HCC,HIV,INC,INSURANCE,PWH,THERE,WILEY
169,COPYRIGHT,HCC,INC,PUBLISHED,SOCIETY,TAE
169,COPYRIGHT,INC,PUBLISHED,SOCIETY
001,169,BACKGROUND,BASED,END,HODGKIN,HOWEVER,LABEL,LARGE,METHODS,PRESS,PUBLISHED,RESULTS,SEPARATELY,SMALLER,UNIVERSITY,YOUNGER
460,CAT,FINALLY,GPX,HAG,HOP,LCC,OXIDATIVE,SOD,TXNIP,USING
004,146,169,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,OLDER,RESULTS,ROBOTIC,UNIVARIATE
169,946,947,BAX,CELLS,COPYRIGHT,INC,SER
169,177,COPYRIGHT,GENERAL,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PBS,PHANTOM,PURPOSE,RESULTS,SURFACE
001,169,ARM,BCS,COPYRIGHT,DUE,GROUP,HOWEVER,IMN,INC,LABEL,MATERIALS,METHODS,MRM,OBJECTIVE,PURPOSE,RADIATION,RESULTS
169,CBCTS,CONCLUSION,COPYRIGHT,DAVIS,INC,KRESS,LABEL,MATERIALS,METHODS,OBJECTIVE,PICCS,PURPOSE,RESULTS,SMEIR,USING
003,100,169,945,COPYRIGHT,EVALUATION,FDG,FIFTEEN,GTV,INC,LABEL,MAASTRICHT,MATERIALS,METHODS,NSCLC,OBJECTIVE,PET,RESULTS
001,106,150,166,169,215,498,945,946,AMONG,BED,COPYRIGHT,COX,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS
100,169,BECAUSE,COPYRIGHT,GRADE,INC,LABEL,LARGE,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THREE
169,231,233,ASSESSMENT,COPYRIGHT,PROGNOSTIC,PUBLISHED,SAS,THESE
169,231,233,COPYRIGHT,PUBLISHED,SAS,SEVERAL,THESE
MALIGNANT,MPE,PLEURAL
CETUXIMAB,GROUP,III,INSPIRE,LABEL,NSCLC,OBJECTIVE,PURPOSE,RESULTS,SOUTHWEST,SUMMARY
END,FIFTY,FORTY,FRANKEL,LABEL,MEDICAL,METHODS,OBJECTIVE,RESULTS,SELECTING,SRS,TRILOGY
549,BACKGROUND,BF1,EXPRESSION,LABEL,METHODS,MIGRATION,MMP,NSCLC,PCR,RESULTS,RIZ,TIMP1,TIMP2,TIMPS
18F,BACKGROUND,BESIDES,FDG,LABEL,METHODS,PET,RESULTS,SPM,UNIVERSITY,ZHENGZHOU
169,BIOLOGY,HOWEVER,IAP,INC,MKN45,MOLECULAR,SOCIETY,TREATMENT,YM155
100,EMA,GLUT1,HOWEVER,IHC,VARIOUS
160,969,AMONG,BACKGROUND,CONCLUSION,DENMARK,GENERAL,HOWEVER,III,INITIATING,LABEL,METHODS,NON,OBJECTIVE,PATIENT,PHD,RESULTS,SERVICE,SPIROMETRY,STUDIES,UNIVERSITY,UNLABELLED,WOMEN
ACUTE,GRADE,HOWEVER,III
001,012,016,018,029,033,036,045,083,160,169,172,187,371,433,546,558,568,681,976,991,BACKGROUND,COPYRIGHT,INC,LABEL,METHODS,PROGNOSTIC,PUBLISHED,RESULTS,SOCIETY,SOLID
001,048,187,AFTER,BACKGROUND,CONCLUSION,CRP,ESTIMATING,LABEL,METHODS,MPM,NLR,RESULTS
001,005,124,150,AMONG,BACKGROUND,CONTEXT,ETE,LABEL,LARGE,METHODS,OBJECTIVE,PREDICTORS,PTC,RECURRENCE,RESULTS,RFS,SECULAR
169,231,ATTACHMENT,COPYRIGHT,FAK,FINALLY,FOCAL,LVC,MDA,PAX,SOCIETY,THESE
946,ERK,FBS,FPP,HOWEVER,MTT,RII,STATINS,TGF,THEREFORE,WESTERN
946,ERK,FAK,MMP,ROS,SRC,SUPPRESSED
544,891,AIM,CENTRAL,CNS,LIVER,PFS,PPS,PROGNOSIS,RESULTS,THERE
CONVERSELY,NON,THESE
001,106,169,AFTER,AMONG,FORCEPS,INDIVIDUAL,JANUARY,LABEL,MAY,METHODS,OBJECTIVE,PRESS,PUBLISHED,RESULTS,UNIVERSITY
169,18F,216,609,AMONG,LABEL,LY0V0PL0N0,METHODS,OBJECTIVE,PRESS,PUBLISHED,RESULTS,SMALL,SOLID,STAGE,UNIVERSITY
130,169,ENDOSCOPIC,GRADE,III,MAY,PHASE,PRESS,PUBLISHED,SECONDARY,UNIVERSITY
BMJ,DESPITE,GROUP,LIMITED,PUBLISHED,PUBLISHING
BRAIN,HISTOLOGY,NSCLC
KIF5B,LADCS,NSCLC,REARRANGED,RET,SEVERAL
001,006,007,019,041,264,BACKGROUND,CONCLUSION,LABEL,METHODS,MTSS1,NSCLC,RESULTS,SCC
169,ACTIVATION,CISPLATIN,COPYRIGHT,CROSS,CYCLINB,HOWEVER,INC,KEY,LABEL,METHODS,OBJECTIVE,RESULTS,SEVERAL,TYR15
090,169,482,ADVERSE,AGREEMENT,CONCLUSION,EXAMINING,GIVEN,INSTITUTE,LABEL,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS,SOCIETY,SUBJECTIVE,TREATMENT
111,148,169,261,CHINA,COMMITTEE,CONCLUSION,IASLC,JOINT,LABEL,METHODS,NSCLC,OBJECTIVE,PURPOSE,RESULTS,SIX,SOCIETY,TNM
001,109,166,169,253,275,888,ALK,AMONG,CONCLUSION,CRIZOTINIB,DCR,HOWEVER,LABEL,METHODS,NSCLC,OBJECTIVE,PROFILE,PURPOSE,RESULTS,SOCIETY,TTP
001,160,169,APRIL,BACKGROUND,COPYRIGHT,FURTHER,III,INC,LABEL,MARCH,METHODS,PUBLISHED,RESULTS,SOCIETY
002,011,014,034,052,054,169,945,AKT,COPYRIGHT,EDUCATION,FAK,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,WESTERN
169,COLLEGE,COMBINING,COPYRIGHT,EARLY,LTD,PUBLISHED,PULMONARY,ROYAL
003,009,208,DFS,LCR,LNR,NCR,NSCLC,THEREFORE
169,ATM,BIOLOGY,EPHA5,FINALLY,INC,MOLECULAR,SOCIETY
100,160,169,AGE,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PULMONARY,PURPOSE,RESULTS,TEN,THESE
169,CONCLUSION,COPYRIGHT,CROWN,IMAGE,LABEL,LAT,LTD,MATHWORKS,MEDICAL,METHODS,OBJECTIVE,ORGAN,PUBLISHED,PURPOSE,RESULTS,SYSTEMS,USA
100,169,177,956,AUC,BROMO,COPYRIGHT,HENCE,HOWEVER,INC,NOS,THEREFORE
122,THESE
001,028,143,160,169,316,AMONG,BACKGROUND,BASED,BETWEEN,COPYRIGHT,INC,LABEL,MEIER,METHODS,PUBLISHED,RESULTS,SOCIETY
001,045,118,160,167,169,347,AMONG,BACKGROUND,COPYRIGHT,INC,LABEL,METHODS,PUBLISHED,RECURRENCE,RESULTS,SOCIETY
945,HOWEVER,L755P
95D,AKT,CXCR4,LOW,MILLICELL,MTT,THEREFORE,TRANSWELL,WESTERN
946,BAD,BAX,EMT,JUN,KNOCKDOWN,NSCLC,SHORT,THESE,USING,WESTERN
169,786,945,AUC,BACKGROUND,BECAUSE,HOWEVER,LABEL,METHODS,MOTIVATION,PRESS,PUBLISHED,RESULTS,THEREFORE,UNIVERSITY
GIANT,OPG,RANKL
169,COPYRIGHT,IRELAND,LTD,NSCLC,PTP1B,THESE
002,006,HDACI,LABEL,LARGAZOLE,METHODS,OBJECTIVE,PURPOSE,RESULTS,TGI,THESE,USING
150,FIFTY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PFS,RESULTS,TEN,THESE
BACKGROUND,BRIGHAM,DEPARTMENT,HOWEVER,LABEL,MALIGNANT,MATERIALS,MEDICAL,METHODS,MPM,RADIATION,RESULTS,STAGE,UNIVERSITY,WASHINGTON
BACKGROUND,CONCLUSION,GROUP,III,LABEL,MALIGNANCY,METHODS,RESULTS,STAGE,THERE,WORLD
BACKGROUND,CONCLUSION,LABEL,METHODS,RESULTS
143,169,BASED,COPYRIGHT,FEDERATION,LUCIFERASE,MYB,NCP,NPC,PUBLISHED,SOCIETIES
001,045,169,172,242,CMV,CSA,INC,MMF,MTX,PSM,THERE,WILEY
ALK,HODGKIN
177,197,ASSESSMENT,BRM,CNS,GPA,INTRABEAM,KARNOFSKY,LABEL,LOCAL,METHODS,OBJECTIVE,PROGNOSTIC,RESULTS,SCALE,SIX,SURGERY
177,4T1,AKT,IGF,IGFBP,INSULIN,WHILE
136,149,155,169,171,285,AMONG,CENTERS,CONCLUSION,FDG,IMAGING,INC,LABEL,METHODS,MOLECULAR,NUCLEAR,PET,RESULTS,SOCIETY,UNLABELLED
169,215,CONCLUSION,FDG,HENCE,IMAGING,INC,LABEL,METHODS,MOLECULAR,NUCLEAR,PET,RESULTS,SNR,SOCIETY,SUPPORTED,SUVMEAN,UNLABELLED
003,BSP,HOWEVER,NSCLC,PCR,TMA
001,002,007,008,170,196,343,665,HOWEVER,III
001,004,104,529,ANNEXIN,ARNT2,MTT,NSCLC,OVERALL,TAKEN
100,120,169,GRADE,IRINOTECAN,LABEL,METHODS,NON,OBJECTIVE,PHASE,PRESS,PUBLISHED,RESULTS,UNIVERSITY
163,AMONG,BACKGROUND,CONCLUSION,EGFRS,ERLOTINIB,LABEL,METHODS,OBJECTIVE,RESULTS,THEREFORE
ADDITIONAL,AKT,BACKGROUND,CONCLUSION,EVEROLIMUS,LABEL,METHODS,MPM,OVERALL,PFS,RESULTS,THERE
001,939,ASSESSMENT,BACKGROUND,CHEMONAIVE,EASTERN,FUNCTIONAL,GENERAL,GROUP,III,LABEL,METHODS,NSCLC,NTX,POINTBREAK,QOL,RANDOMIZED,RESULTS,THERAPY,TREATMENT
005,100,127,138,BACKGROUND,BECAUSE,CORRECT,KOREA,LABEL,METHODS,NPV,NSCLC,RESULTS
DRESDEN,EVALUATION,HOWEVER,IASLC,SOLID,WORLD
PROGNOSIS,PULMONARY,RADIOLOGY
001,005,006,553,BACKGROUND,CONTEXT,LABEL,LBP,METHODS,OBJECTIVE,PULMONARY,RESULTS
BACKGROUND,CONTEXT,DISEASE,IDR,LABEL,METHODS,OBJECTIVE,RESULTS
ADVERSE,DFS,EPIDERMAL,III,LABEL,NSCLC,OBJECTIVE,PHASE,PURPOSE,RESULTS,SUMMARY,THERE,TKI
AZD9291,HM61713,L858R,LABEL,NSCLC,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,THIRD,TKI
169,ACIDS,AKT,CLINICALLY,HDAC1,HOWEVER,NOTABLY,NUCLEIC,OC4,PRESS,PUBLISHED,SP1,THROUGH,TNC,UNIVERSITY
169,231,233,254,APRIL,BACKGROUND,CEA,COPYRIGHT,FASAY,JANUARY,LABEL,LOUIS,METHODS,PFS,PUBLISHED,RESULTS,ROUTINE,SAINT,SAS,THERE
169,MMP,RIBAVIRIN
18F,FDG,HISTOLOGIC,PET,SUBSEQUENT
001,246,311,618,EPIDERMAL,LABEL,LOW,METHODS,OBJECTIVE,PET,PURPOSE,RESULTS,SEVENTY,SUV,WHITNEY
001,100,18F,APRIL,DEFINITIVE,FDG,HISTOLOGY,JANUARY,LABEL,METHODS,OBJECTIVE,OVERALL,PET,PURPOSE,RESULTS,SUV,TCS
13C,DUE,FRESHLY,GLS,KREBS,NSCLC,THESE
JCI,SELLERS,TCA,THERE
HOWEVER,NSCLC
169,4T1,600,802,946,AMONG,BIOLOGY,EMT,EPITHELIAL,HIT,HOWEVER,INC,KNOCKDOWN,MOLECULAR,NMUMG,SOCIETY,TGF
174,ACCURAY,CONCLUSION,FIF,HELICAL,INC,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,RESULTS,SIB,SIMILARLY,SIX,SUNNYVALE,TOMODIRECT
ASSESSING,BLAND,CONCLUSION,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,RESULTS
169,215,21H,23H,945,CDS,CEA,COPYRIGHT,LTD,NSE,WILEY
19A,CONVERSELY,HOWEVER,NSCLC,PCR,SOCS1,STAT3,TAKEN,UTR
AREAS,BACKGROUND,CAR,COVERED,EWING,GD2,IGG,LABEL,METHODS,OPINION
169,4T1,BV8,CSF,CXCR2,IFN,LLC,METASTASES,OVERALL
COMPETING,THERE
001,029,037,049,067,160,263,479,547,768,779,CIORR,CIPFS,ERLOTINIB,HRPFS,LIBRARY,MEDLINE,NSCLC,ORR,PFS,RRORR,SCIENCE,STATA,TKI,WEB
001,002,014,025,028,107,120,157,158,160,164,187,279,321,338,374,399,416,470,499,541,686,732,746,757,818,821,823,82G,840,882,908,936,976,981,ASIAN,CAUCASIAN,LIBRARY,MEDLINE,OVERALL,SCHOLAR
169,801,803,BACKGROUND,BTMED,CAUSE,CONTINUED,DEPARTMENT,DOE,INC,LABEL,MEDICAL,METHODS,MORTALITY,PROGRAM,RESULTS,RISKS,SCREENING,WILEY,WORKERS
169,242,ABCG2,CISPLATIN,COPYRIGHT,DCR,HOWEVER,INC,INOPERABLE,MTT,PFS,QCR,USING
169,ABCB1,ABCC1,ATP,CONVERSELY,COPYRIGHT,HDL,HOWEVER,INC,LDL,LRP,MDR,MULTIDRUG
246,327,345,513,AMONG,AUDIT,BACKGROUND,DIAGNOSIS,ENGLISH,EXCELLENCE,GENERAL,INSTITUTE,IQR,KINGDOM,LABEL,METHODS,PRESENTING,PRIMARY,RESULTS
FINALLY,III,LABEL,NSCLC,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,TARGETING
LABEL,NSCLC,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,THESE
004,110,121,147,160,166,169,185,200,205,207,217,228,237,250,400,AUC,BACKGROUND,BETWEEN,BRISTOL,COPYRIGHT,FUNDING,III,INSTITUTE,IQR,LABEL,LTD,METHODS,MYERS,NOV,PET,RADIATION,RESULTS,THERE,USA
169,COPYRIGHT,INC,KISS1,NON,NSCLC,SINCE,SMALL,SRC
169,CONVERSELY,FUNCTIONAL,NSCLC,THERE
169,946,CIGARETTE,EMT,NSCLC,SRC,TAKEN
263,360,485,824,993,AFRICAN,ASIAN,DANES,EASTERNERS,EUROPEANS,HRS,IRANIAN,LOW,NORTH,ORDINAL,PANCREATIC,SOUTHEAST,SWEDISH,TURKISH,TURKS
169,AFTER,BACKGROUND,CATHETERS,CONCLUSION,COPYRIGHT,CSF,LABEL,METHODS,MRI,OBJECTIVE,RESULTS,TEXAS,THESE,UNIVERSITY
169,945,946,AKT,AUTHORS,CONVERSELY,DNMT1,ERK,FOUNDATION,HOWEVER,JOURNAL,LTD,METFORMIN,MOLECULAR,NSCLC,PD98059,RHIZOMA,SP1,TAKEN,WILEY
169,COPYRIGHT,ECD,ESI,INITIAL,NARCISSUS,NMR
169,BECAUSE,COPYRIGHT,HOWEVER,III,NSCLC,PUBLISHED,SUSTAINED,VEGFS
169,248,ACCORDING,ADF,COFILIN,COPYRIGHT,KNOCKDOWN,LIN28,LNA,NSCLC,PREVIOUSLY,TAKEN,TWIST
169,COPYRIGHT,FGF,HOWEVER,IRELAND,LTD,THESE
001,CONCLUSION,ELEVATION,FIRST,III,LABEL,METHODS,NSCLC,OBJECTIVE,PFS,PHASE,QOL,RESULTS
142,169,251,651,BIOMARKERS,FDR,IL12A,IL8,INC,NSCLC,SNP,THESE,WILEY
025,169,BACKGROUND,COPYRIGHT,FIFTY,INC,LABEL,LARGE,LCNEC,MARCH,METHODS,OVERALL,PUBLISHED,RECURRENCE,RESULTS,SOCIETY
001,005,018,127,130,ARG399GLN,ASN118ASN,COX,ERCC1,ERCC2,LYS751GLN,MEIER,NSCLC,RFS,XPD,XRCC1
002,183,ERK,HOWEVER,MEANWHILE,NSCLC,THERE,THEREFORE,TNM
169,48H,500,769,BENZO,COPYRIGHT,FINALLY,INC,TEN,THESE,THREE,WESTERN
169,AKT,ERBB2,ERBB3,ERK,FINALLY,GAB,L858R,MET,SIMILAR
007,015,120,169,ALK,CNB,COPYRIGHT,FNA,LABEL,METHODS,MOLECULAR,OBJECTIVE,OBJECTIVES,OBTAINING,PATHOLOGY,RESULTS,SOCIETY,UNIVARIATE
008,010,1377G,196,379,844,844CC,AGE,APOPTOSIS,CHINA,FAS,HOWEVER,OCTOBER,PCR,SNP,SOUTH
169,COPYRIGHT,DIAGNOSES,INC,MALIGNANT,PNSTS,SIX
153,364,6TH,ANY,GDP,HEALTHCARE,HOWEVER,LMI,LOW,MEDICAL,MEDLINE,NCD,SCHOLAR,STUDIES
001,018,027,ACCORDING,AMONG,BMJ,CBC,CNS,DMS,EXPRESSION,GEMININ,GROUP,LABEL,LIMITED,MBC,METHODS,OBJECTIVE,PUBLISHED,PUBLISHING,RESULTS,THERE
AMONG,DESPITE,INITIAL,LABEL,MATERIALS,METHODS,OBJECTIVE,PREVENTION,RESULTS,SCC,SIX
001,004,005,018,042,046,051,100,111,FEDERATION,GYNECOLOGY,III,LABEL,LRP,METHODS,MRP,OBJECTIVE,OBSTETRICS,PGP,RELAPSE,RESULTS
169,217,839,CONCLUSION,FIFTY,IMAGING,INC,LABEL,METHODS,MOLECULAR,NAF,NUCLEAR,OVERALL,PET,RESULTS,SOCIETY,UNLABELLED
100,169,945,946,CONSISTENT,COPYRIGHT,EMT,ESTRADIOL,INC,MALAT,PTBP2
169,AMONG,ASPIRATION,BACKGROUND,CHEST,COPYRIGHT,INC,LABEL,METHODS,RESULTS,ROCHESTER,THESE
CXCR4,FINALLY,FURTHER,HOWEVER,LPS,ML171,NADPH,NSCLC,ROS
169,177,183,COPYRIGHT,LEVENBERG,LTD,MARQUARDT,PDI,USING
169,ALK,BACKGROUND,CLONOGENIC,COPYRIGHT,CRIZOTINIB,H3122,IRELAND,LABEL,LLC,LTD,METHODS,MVD,NON,NSCLC,OBJECTIVE,PURPOSE,RESULTS
169,COPYRIGHT,LTD,MICRORNAS,THEREFORE,WHILE
100,138,143,INVADER,L858R,MUTATIONS,NSCLC,PCR
181,183,GEORG,NMR,STUTTGART
954,BCL,FURTHER,NOTCH
023,111,113,169,209,213,229,237,239,246,345,364,BACKGROUND,BOEHRINGER,COPYRIGHT,FUNDING,HOWEVER,INGELHEIM,IQR,LABEL,LEU858ARG,LTD,LUX,METHODS,PREVIOUSLY,RESULTS,THESE
019,041,045,071,076,088,105,107,109,111,115,125,149,159,160,190,195,202,248,254,273,308,313,410,730,974,CYS,OVERALL,SER,SER326CYS,WEIPU
001,160,182,290,384,470,652,920,946,961,COX,MYC,NPC,RBMS3,THEREFORE,TSG,WESTERN,WNT
011,396,ALK,AP26113,ASP3026,BASED,CHALLENGES,CRIZOTINIB,FDA,III,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,TSR
144,701,BACKGROUND,BMI,CONCLUSION,COX,CUTOFFS,INITIATIVE,LABEL,METHODS,OBESITY,RESULTS,ROC,USING,WHR,WOMEN
036,169,AMONG,BACKGROUND,COPYRIGHT,COX,IRELAND,LABEL,LTD,MEIER,METHODS,OVERALL,RESULTS
100,177,1EP,206,215,300,AFP,CONCLUSION,HCG,INCLUSION,LABEL,LDH,METHODS,OBJECTIVE,PURPOSE,RESULTS,ULN
001,006,037,141,169,174,259,279,456,950,ABCC4,ATP,BACKGROUND,COPYRIGHT,GST,LABEL,METHODS,OTHER,RESULTS,THESE
011,ACS,ASSESSMENT,COMPARING,CONCLUSION,FAACT,FUNCTIONAL,LABEL,METHODS,OBJECTIVE,PURPOSE,QOL,RESULTS,THERAPY
947,APOPTOTIC,BCL,FIFTY,H1299,INHIBITION,MTT,NCI,NSCLC,ROS,TREATMENT,TUNEL
181,ANNEXIN,BAX,BCL,BID,CONSISTENT,H28,HOWEVER,LCA,MALIGNANT,MCL,MPM,SP1
BACKGROUND,EUS,FNA,JANUARY,LABEL,MCC,METHODS,OBJECTIVE,PET,RESULTS,THREE,TTF
042,102,107,113,215,DFS,FUKUSHIMA,HOWEVER,IHC,IMMUNOBLOT,JAPAN,MEDICAL,NSCLC,SCC,SPECIMENS,UNIVERSITY
107,169,ACCORDING,AGE,BACKGROUND,CR2,EWING,EWS,FIFTY,HDT,IFO,III,INC,ISG,LABEL,METHODS,PROCEDURE,PRS,RESULTS,RFI,SSG,WILEY,WITHOUT
100,675,BACKGROUND,BNP,LABEL,METHODS,RESULTS,SINCE
737,ABT,APOPTOSIS,BCL,MCL,MR29072,PYRIDOCLAX,SURFACE,WHEREAS,WITHOUT
169,248,277,490,501,946,COPYRIGHT,GSH,INC,NADPH,SRC,TAKEN,TGF
032,956,H2122,SNC
001,004,010,023,805,CONCLUSION,COX,FDG,LABEL,MATERIALS,MEIER,METHODS,MTBWB,MTVWB,NSCLC,OBJECTIVE,PET,PURPOSE,RESULTS,TLGWB,TNM
001,119,136,140,954,ACCURACIES,AGREEMENTS,CONCLUSION,FDG,LABEL,MATERIALS,MCNEMAR,METHODS,NSCLC,OBJECTIVE,PET,PURPOSE,REGARDING,RESULTS,TNM
135,228,676,ADVERSE,CONCLUSION,ELEVATION,FDG,LABEL,MATERIALS,METHODS,OBJECTIVE,PET,PURPOSE,RESULTS,ROC,SUV,SUV95
COMPOUNDS,IAP
169,239,276,996,CONCLUSION,III,LABEL,METHODS,NSCLC,OBJECTIVE,PURPOSE,RESULTS,SOCIETY
001,049,10877,10878,13YEARS,169,201,321,587,BACKGROUND,CONCLUSION,COPYRIGHT,CRC,HOWEVER,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,OVERALL,PROGNOSTIC,PURPOSE,RESULTS,RFA
169,363,AES,BACKGROUND,CONCLUSION,COPYRIGHT,IRELAND,LABEL,LTD,MATERIALS,MEDLINE,METHODS,NSCLC,OBJECTIVE,ORR,PFS,PURPOSE,RESULTS,THERE,TKI,UPFRONT
038,169,234,264,424,494,984,ADDITIONAL,CONCLUSION,FORTY,HOWEVER,JAPAN,LABEL,METHODS,OBJECTIVE,PREFECTURE,PRESS,PUBLISHED,RESULTS,SEVENTEEN,THREE,UNIVERSITY
160,A427V,DEPENDING,ECH,G333C,G350S,G364C,G379D,G430C,G476R,ITC,KEAP1,KELCH,NMR,R413L,R415G
169,365,AUSTRALIA,CONCLUSION,COPYRIGHT,EXCLUDING,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SETTING,SOUTH,WALES
127,169,622,947,956,BASED,COPYRIGHT,FIFTEEN,HOWEVER,LTD,MDR,TAXOL,THF,THOSE,VERAPAMIL
001,003,006,142,169,ACADEMY,BACKGROUND,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,PUBLISHED,RESULTS,SCL,SSC,UNDER
169,5H1,AUTHORS,BESIDES,COPYRIGHT,E1L3N,LTD,PUBLISHED,SMALL,USING
169,A20,A925L,ALK,AUTHORS,LTD,PTY,PUBLISHING,SCIENCE,WILEY
FFAR2,FFAR3
169,200,916,936,956,APOPTOSIS,CELLS,CONCLUSION,DIOC6,LABEL,LTD,MATERIALS,MELATONIN,METHODS,MTT,NSCLC,OBJECTIVE,OBJECTIVES,RESULTS,THESE,WILEY
169,ABL,AES,BCR,FAERS,FDA,GAMMA,INC,MULTI,POISSON,REPORTING,SIGNALS,THESE,WILEY
169,7WT,960,COPYRIGHT,DOX,PEO,SEM
160,170,363,CBM,CHINA,JANUARY,NSCLC,PFS,SCIENCE,WAN,WEB
AKT,CISPLATIN,DDP,ERK,EXPRESSION,MTT,SGC7901,SORAFENIB,WESTERN
ALK,COLLEGE,GIVEN,MOLECULAR,PATHOLOGY,THEREFORE
160,169,BECAUSE,COPYRIGHT,INC,METASTATIC,PUBLISHED,RENAL
169,AKT,COPYRIGHT,ERK,FINALLY,HOWEVER,IRELAND,LTD,SEVERAL,THESE,UBIQUITIN,UCH,UCHL1
264,486,956,95D,DAVID,EGR,NSCLC,PATHWAY,TOTAL,VALIDATION,WNT
100,DETECTION,MONITORING,NON,USING

016,026,039,500,CHINESE,COX,HAN,MCT,MEIER,NON,NSCLC,RFS,SNP
001,002,003,132,166,177,346,ALK,CHEST,KEY,LABEL,LOWER,METHODS,OBJECTIVE,RESULTS,SOLID,TDR,TKI
CONCLUSION,EIGHT,LABEL,METHODS,MOTIVATION,OBJECTIVE,PURPOSE,RESULTS,RICOEUR
153,859,AFTER,HOWEVER,LABEL,METHODS,NSCLC,OBJECTIVE,ORR,PFS,PURPOSE,REGARDING,RESULTS
169,ALK,BIOVIEW,COPYRIGHT,CRIZOTINIB,III,IKONISCOPE,INC,PHASE
169,25A,BASED,BTG,COPYRIGHT,INC,NSCLC,THEREFORE
001,002,005,049,130,170,198,238,445,485,789,815,855,950,954,961,ALK,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
APRIL,BASED,HOWEVER,LABEL,METHODS,OBJECTIVE,OCTOBER,OVERALL,RESULTS,UNIVERSITY
169,ATLAS,BACKGROUND,FURTHER,LABEL,MODEL,MOTIVATION,PRESS,PUBLISHED,RESULTS,SIMULATION,UNIVERSITY
BIP,CHINESE,E2F,ERP72,NCI,NSCLC,UPR,WESTERN
110,113,117,130,163,ALDH1,FGFR1,HOWEVER,LABEL,LOW,METHODS,OBJECTIVE,PURPOSE,RESULTS
169,AKT,CBL,COPYRIGHT,IRELAND,LTD,NSCLC,SH2,SPC,TARGETING,UPS
DIF,FBS,NSCLC,PC9,SIMILARLY,VNR
181,946,A549CIS,CALU1,H460CIS,WNT
AKT,BAX,BCL,ERK,FINALLY,MAPKS,PD98059,REGULATION,TAKEN,WHILE
001,140,160,320,916,AES,FORTY,MWA,NSCLC,OBJECTIVE,PFS
104,130,160,191,205,224,230,269,271,CED,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RADIATION,RESULTS
GPS,ITALIAN,THEREFORE
181,AIF,ALONG,ARSENIC,ATO,BCL,BHA,DMS79,GSH,H69,NAC,ROS,WESTERN
169,954,ERK,OVERALL,TNBCS
169,AREAS,CONCLUSION,FDG,III,IMAGING,INC,LABEL,METHODS,MOLECULAR,NSCLC,NUCLEAR,PET,RESULTS,SEVENTEEN,SOCIETY,UNLABELLED,VARIOUS
060,100,160,169,198,200,206,300,324,662,BACKGROUND,CONCLUSION,COPYRIGHT,III,INC,LABEL,METHODS,NSCLC,OVERALL,RENAL,RESULTS,UNTREATED
005,169,1ST,BACKGROUND,CONCLUSION,COPYRIGHT,INC,JANUARY,LABEL,MARCH,METHODS,RESULTS,SIGNS
ZNO
149,187,202,657,737,763,777,958,980,994,996,998,AOR,BACKGROUND,ESTIMATED,LABEL,MALIGNANT,METHODS,NPV,OVERALL,PET,RESULTS,SPECIMENS,TTNBS
001,002,004,011,160,168,GSE3268,III,MEANWHILE,NSCLC,PCR,UNIVARIATE,USING
10Q25,349,457,609,731,AMONG,CLASS,CONSORTIUM,FLCCA,HAP,HLA,HOUSEHOLD,SOUTHEAST
129,948,AZA,CPG,HOWEVER,LUCIFERASE,PCR,THESE,VCP,WESTERN
032,174,424,CYTOKINES,NSCLC,PCR,REGARDING,SNP
ERK,FGFR1,INHIBITION,JNK,MMP26,NSCLC
169,459,AMONG,APRIL,BACKGROUND,ILD,LABEL,MARCH,METHODS,OBJECTIVE,RESULTS,TKI
001,169,BACKGROUND,CONSORTIUM,CORRELATES,COX,EUROQOL,EXAMINING,HRQOL,LABEL,MEIER,METHODS,RESULTS,SOCIETY,YOUNGER
169,AAS,AFRICAN,AMERICANS,BACKGROUND,CANCORS,CONSORTIUM,CRC,CURRENT,HISPANICS,LABEL,METHODS,RESULTS,SOCIETY
284,369,COX,JANUARY,LABEL,METHODS,OBJECTIVE,OPIOIDS,OSAKA,PURPOSE,RESULTS,THERE,UNIVARIATE
134,169,388,838,DENMARK,FINLAND,HOPEFULLY,ICELAND,LABEL,METHODS,OBJECTIVE,RESULTS,SIR,SOCIETIES
169,2YL,COPYRIGHT,FURTHER,HENCE,LTD,MCF
BIOCOAT,CHAMBER,DECREASED,DPI,FINALLY,FURTHER,INCREASED,INHIBITION,ISOLATION,KIT,NADPH,NOX,PRIMARY
160,AUC,CONCLUSION,FORTY,LABEL,METHODS,NSCLC,OBJECTIVE,ORR,PFS,PURPOSE,RESULTS,SIXTY
104,160,314,517,842,ILD,LABEL,METHODS,NSCLC,OBJECTIVE,PURPOSE,RESULTS
1564A,3073A,320,346,ARG194TRP,ARG399GLN,CHINESE,XRCC1
169,BORCK,III,LABORATORY,POL,PRESS,PUBLISHED,TAKEN,TBP,WHOLE
032,101,184,2N0M0,AFTER,BACKGROUND,GENERALLY,HOWEVER,LABEL,METHODS,NSCLC,RESULTS
001,002,006,148,169,BAL,CENTRAL,CONCLUSION,CONTROLLED,ENGLISH,GUIDELINES,HOWEVER,LABEL,MEDLINE,METHODS,OBJECTIVE,PURPOSE,RESULTS,SOCIETY,STUDIES
022,118,169,200,650,779,CONCLUSION,HRS,LABEL,LINIFANIB,METHODS,NSCLC,OBJECTIVE,PFS,PURPOSE,RESULTS,SOCIETY
1970S,ANOTHER,DROSOPHILA,FDA,HOWEVER,PTCH1,SINCE,VISMODEGIB
000,100,169,201,BACKGROUND,EARLIER,END,HNSCC,HOWEVER,LABEL,MEDICAL,METHODS,PITTSBURGH,PLUSS,RANDOMIZED,RESULTS,SCREENING,SOCIETY
169,946,ACTIVIN,AUTHORS,COPYRIGHT,ERK,INC,MALIGNANT,MIGRATION,MIGRATORY,PUBLISHED,SMAD2,SMAD3,TGF,THESE
169,181,350,900,AFTER,AUC,BACKGROUND,INC,LABEL,METHODS,MOL,PROCEDURE,RESULTS,SCA,WILEY
AREAS,BACKGROUND,COVERED,HOWEVER,LABEL,METHODS,NSCLC,OPINION,SQCLC
169,233,403,CAD,COPYRIGHT,LTD,SVM
169,ADDITIONAL,ALK,BACKGROUND,HOWEVER,KRISTEN,LABEL,METHODS,RESULTS,SALIENT,SOCIETY
131,169,201,APMIS,L858R,LMD,LTD,PCR,PUBLISHED,SAMPLES,SEVERAL,WILEY
169,PHASE,VARIOUS
169,215,5FU,7DAYS,HOWEVER,LEWIS,LLC,SINCE,VEGFA
ALECTINIB,ALK,CRIZOTINIB,CSF,FURTHER,MET
163,DFS,LABEL,METHODS,NSCLC,OBJECTIVE,OPN,RESULTS,THESE
100,169,17P13,420,BACKGROUND,BETWEEN,BLOOD,CLL,COPYRIGHT,DEC,FOUNDATION,FUNDING,GRADE,HEART,INC,INSTITUTE,INSTITUTES,INTRAMURAL,IQR,JAN,LABEL,LTD,MEDICAL,METHODS,NORDISK,PROGRAM,RESULTS,SOCIETY,USA
169,215,2YL,BAX,BCL,COPYRIGHT,H2O,HOWEVER,INC,MTT,SGC7901,WESTERN
169,199,363,COPYRIGHT,ELISA,HOWEVER,INC,NON,NSCLC
169,453,464,722,AUTHORS,CIR,CONCLUSION,COPYRIGHT,LABEL,LIVER,LTD,MEIER,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,QALYS,RESULTS,WHILE
10A,123,169,231,AMONG,COPYRIGHT,COUMARINS,CYTOTOXIC,DOCETAXEL,ESTER,INC,MCF,MDA,MMP,MRC,PC3,RHODAMINE,THESE
160,200,250,300,400,FIFTY,HOWEVER,LABEL,METHODS,MTD,NSCLC,OBJECTIVE,PFS,PLANNED,PURPOSE,RESULTS,THERE,THREE,TREATMENT,VORINOSTAT
CD66C,CEA,CYFRA,FORTY,MPE,VARIOUS
169,AUTHORS,BACKGROUND,CELLS,CHRONIC,HEART,INC,LABEL,METHODS,PUBLISHED,RESULTS,SMC,TELOMERASE,WOLTERS
BECAUSE,BIOMARKERS,BMJ,GROUP,LIMITED,PUBLISHED,PUBLISHING,THESE
HOWEVER,HOX,HOXA5,NSCLC,TNM
001,100,BACKGROUND,CONCLUSION,COX,DBF,FORTY,LABEL,MEIER,METHODS,OBJECTIVE,PRIMARY,RESULTS
NANOG,THROUGH
BENEFICIAL,THERE
DIFFERENT
169,ANOTHER,COPYRIGHT,HEPOXILIN,INC,USING
ADI,ASS,CELLS,LABEL,LCNEC,METHODS,OBJECTIVE,PEG,PURPOSE,RESULTS,SIXTY,THESE,TREATMENT
113,127,169,198,242,555,561,871,AMONG,CONCLUSION,COPYRIGHT,COX,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,SWEDISH
397,BCR,THERE
001,169,362,573,844,CONCLUSION,LABEL,MEIER,METHODS,OBJECTIVE,PREDICTORS,PURPOSE,RESULTS,SOCIETY
160,CONCLUSION,LABEL,LOW,METHODS,OBJECTIVE,PS1,PS2,PS3,PURPOSE,RESULTS,TNM,URINE
CRYSTAL,DISCOVERY,SCIENCE,TKI
169,CD11C,DCS,EMT,INC,MALAT,SNAIL,TADCS,WILEY
007,010,020,023,035,043,168,18F,324,439,506,537,695,897,916,953,973,BACKGROUND,EARLY,FDG,LABEL,METHODS,OBJECTIVE,PET,PURPOSE,RESULTS,SUV,TLG,UNIVARIATE
FDG,HYNIC,PET,SPECT,SPN,TOC,WHOLE
BACKGROUND,CONCLUSION,ECTOPIC,LABEL,METHODS,MTC,MYH13,OBJECTIVE,ONCOGENIC,RESULTS,RET,THREE
100,169,946,99M,CCA,LTD,PET,PTY,PUBLISHING,RESULTS,SOUTH,WILEY
044,128,134,ADC,CHEST,FEMALES,HPV,NSCLC,PCR,SAMPLES,SQC,THERE,TNM
001,010,013,016,025,105,272,766,CONCLUSION,DFS,HOWEVER,LABEL,MACC1,METASTASIS,METHODS,NSCLC,OBJECTIVE,PURPOSE,RESULTS
100,169,241,572,859,967,996,ALT,COPYRIGHT,INC,LABEL,MARCH,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY
BUN,NOTABLY,NSCLC,THESE
NNK,THOUSANDS
169,COPYRIGHT,HRT,INC,INHALATION,PAH,PM1,PM2,RESULTS,TEQ,THESE,THREE
100,169,ACTIVATING,AE1,AE3,BREAKPOINT,COPYRIGHT,EWING,EWSR1,INC,SARCOMA
169,231,946,HOWEVER,HOXB7,INCREASED,MDA,PCR,PROVIDING,SMAD3,TAKEN,TAM,TGF
169,3T3,COPYRIGHT,GCMSN,LTD,NMSNS,SERVING
169,5GY,CARLO,CLINICALLY,COPYRIGHT,DVH,GTV,INC,MEDICAL,MONTE,PTV,PUBLISHED,STAGE,TCP
169,761,946,947,AFTER,ATP,COPYRIGHT,HOWEVER,LABEL,LAP,NAD,NSCLC,PARP1,PEG,PLA,PRE,UNASSIGNED,UNLABELLED
169,992,AMONG,COPYRIGHT,FURTHER,INC,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
169,COPYRIGHT,DISCUSSION,FORTY,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS,SECONDARY
002,004,III,MMP,NEUTROPHIL,PROGNOSIS,SUR,TUMORAL,UNIVARIATE
CISPLATIN,DDP,FANCONI,HOWEVER
100,200,300,400,500,956,AGS,AKT,ANNEXIN,BAX,ECM,FLUOS,P53,PCR
169,571,661,676,800,801,970,BACKGROUND,COPYRIGHT,III,JAPAN,LABEL,LTD,METHODS,RESULTS
169,BCL,BIRC5,COPYRIGHT,DR4,DR5,FAS,HOWEVER,LTD,MICROARRAY,TNF,TRAIL
169,AMONG,AZD6244,BCL,BIM,CISPLATIN,COPYRIGHT,IRELAND,LTD,NSCLC,THESE,USING
169,AMONG,BACKGROUND,CONCLUSION,DIFFUSION,DOCETAXEL,EFFORTS,END,FDA,III,LABEL,MAY,METHODS,PRESS,PROGRAM,PUBLISHED,RESULTS,UNIVERSITY
100,111,306,876,929,AMONG,BACKGROUND,DSS,END,HOWEVER,LABEL,MEIER,METHODS,OVERALL,PROGRAM,RESULTS
169,16Q23,BIOLOGY,DESPITE,SOCIETY
169,COPYRIGHT,FEW,FURTHER,INC
916,936,GSH,HOWEVER,MMP,NAC,ROS,TRX,WHILE
934,945,BACKGROUND,DOWNSTREAM,FAS,LABEL,LEWIS,METHODS,OBJECTIVE,OBJECTIVES,RATIONALE,RESULTS,THESE
BACKGROUND,ENZYMATIC,FUNCTIONAL,FURTHER,LABEL,METHODS,PCR,PREDICTED,RESULTS
002,007,202,494,BACKGROUND,LABEL,METHODS,OVERALL,RESULTS
003,029,045,123,124,136,169,177,250,788,BACKGROUND,COPYRIGHT,FIFTY,IHM,INC,LABEL,METHODS,RESULTS,WOMEN
169,200,ACT,AFFORDABLE,CONCLUSION,IIB,III,INSTITUTE,LABEL,METHODS,NETWORK,OBJECTIVE,PURPOSE,RESULTS,SOCIETY,STUDIES,USING
169,181,842,CONCLUSION,LABEL,LIBRARY,MEDLINE,METHODS,OBJECTIVE,PURPOSE,RESULTS,SES,SOCIETY
169,AUTHORS,BACKGROUND,C30,CONCLUSION,COPYRIGHT,EUROQOL,LABEL,LTD,METHODS,NSCLC,PATIENT,PRO,PUBLISHED,QOL,QUALITY,RATES,RESULTS,THERE,TREATMENT,VAS
001,0CM,169,3CM,8GY,9CM,COPYRIGHT,INC,MEDICAL,OAR,OVERALL,PUBLISHED,REGRESSION,V20
HOWEVER,PFS
PET
000,169,254,BACKGROUND,CIS,COLORECTAL,COX,HOWEVER,INCIDENCE,INSTITUTE,LABEL,METHODS,NBP,OVARIAN,RESULTS,SCREENING,SOCIETY,SQX,TRIAL,WOMEN
169,AUTHORS,COPYRIGHT,DESPITE,LTD,PUBLISHED,WHILE
176,HSA,INC,PET,PUBLISHED,RSA,TFP,THESE
169,945,COPYRIGHT,CROHN,EMPLOYING,HOWEVER,IEC,INC,PARKINSON,TAKEN,TNF,VPS4B
001,169,967,BECAUSE,CARCINOIDS,CASES,COPYRIGHT,DIFFUSE,DIPNECH,INC,NEP,THREE
789,790,797,947,BIMAS,CTL,ELISPOT,EPIDERMAL,H1975,HLA,HOWEVER,IFN,IMQLMPFGC,ITQLMPFGC,NCSLC,NSCLC,PBMCS,T790M,TKI,USING
124,DFS,FURTHER,NCL,NSCLC,STAT3,TNM,UTR
06H,169,5MG,AES,AZD1480,BID,COPYRIGHT,IWG,JANUS,LTD,MRT
120,ARG753GLN,ASP299GLY,ELISA,IGE,IRANIAN,PCR
BAL,CSF,IEP
160,169,AUDIT,BACKGROUND,COPYRIGHT,INC,JANUARY,LABEL,LYMPH,METHODS,PUBLISHED,RESULTS,SOCIETY
169,AMD3100,CD8,CONCLUSION,CXCR4,HCC,HOWEVER,INHIBITION,LABEL,LIVER,SORAFENIB,UNLABELLED,USING
100,169,AUTHORS,EPR,LTD,PREVIOUSLY,PTY,PUBLISHING,SCIENCE,SMA,THESE,THP,WILEY
169,COPYRIGHT,EBC,FIRST,FURTHER,LTD,MET,SAR
140,169,AUTHORS,BACKGROUND,BECAUSE,CNB,FNA,HOWEVER,INC,KIRSTEN,LABEL,METHODS,MOLECULAR,NON,NSCLC,RESULTS,SOCIETY,WILEY
100,169,ALK,BACKGROUND,CURRENTLY,FIFTY,IHC,LABEL,METHODS,MPE,NSCLC,PCR,RESULTS,SOCIETY,VENTANA

169,183,967,BACKGROUND,BJS,CONCLUSION,CRC,FAILURE,FIFTY,LABEL,LTD,METHODS,PUBLISHED,RESULTS,SOCIETY,THOSE,WILEY
AUTOPHAGY,HOWEVER,SIMILARLY,TAKEN,WHILE
102,169,512,688,BACKGROUND,COPYRIGHT,FURTHER,III,INC,INCOMPLETE,LABEL,METHODS,NSCLC,PUBLISHED,RESULTS,SOCIETY
169,183,231,CLL,COPYRIGHT,INC,MDA,MTT,NMR,PDCL2
158,241,6TH,AFRICAN,CKD,EASTERN,FINANCIAL,GIVEN,LATIN,MEDLINE,OOP,PACIFIC,RANDOMIZED,SCHOLAR,STUDIES,WESTERN
HOWEVER,INDIVIDUAL,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SEVERAL,WHEREAS
001,005,215,260,464,724,HOWEVER,LDH,PNI,UNIVARIATE
600,ADDITIONAL,ALECTINIB,ALK,BACKGROUND,CURRENTLY,FDA,LABEL,METHODS,NSCLC,OVERALL,RESULTS,THREE
BACKGROUND,CONCLUSION,LABEL,METHODS,PATIENT,RESULTS,SARCOID
AKT,CELECOXIB,CXB,MTT,NSCLC,THEREFORE,THESE,TUNEL
AKT,CURRENTLY,SINCE
181,BCL,MICRORNAS,NSCLC,TAKEN
946,CHINA,DECORIN,DEPARTMENT,HOWEVER,JINLING,MARCH,NANJING,NSCLC,P21,P53,PCR,SEPTEMBER,SURGERY,TGF,THROUGH,UNIVERSITY,VIA,WESTERN
169,COPYRIGHT,FINALLY,IRELAND,LTD,NSCLC,OVERALL,SAC
169,BACKGROUND,BASED,CONTEXT,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,OUTCOME,PATIENT,PURPOSE,PVP,RADIOLOGIC,RESULTS,THERE,UNDER,VAS
BACKGROUND,EPCAM,LABEL,RESULTS,SINCE,TROP1,TROP2
169,BECAUSE,ERLOTINIB,HGF,HOWEVER,MET,NSCLC,TKI
206,AKT,EBC,EXPRESSION,MET,SCC,THEREFORE
001,750,BACKGROUND,END,FURTHER,LABEL,METFORMIN,METHODS,NSCLC,OBJECTIVE,OBJECTIVES,OVERALL,PRIOR,PROPENSITY,RATIONALE,RESULTS,USING
BACKGROUND,DETECTION,EARLY,LABEL,LUCSS,METHODS,OBJECTIVE,OBJECTIVES,PITTSBURGH,PLUSS,PROGRAM,RATIONALE,RESULTS,SCREENING,VALIDATION
003,956,AVERAGE,BACKGROUND,CNB,CONTEXT,DIAGNOSTIC,LABEL,METHODS,OBJECTIVE,OVERALL,RESULTS,TOUCH,TPS
CONVERSELY,MCC,MCC13,MCC26,MKL,USING,YET
169,FIRST,NSCLC,SOCIETY,T790M,TKI
JAPAN,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PATHWAY,PUBLISHED,UNASSIGNED
110,AFTER,BAD,CLINICALLY,FINALLY,HBE,NSCLC
169,HISEQ,HOWEVER,LABORATORY,PRESS,PUBLISHED,RPM,SMALL,SOCIETY,THESE
169,92A,945,CYP24A1,NOTABLY,NSCLC
10Q,215,640,AMONG,AWT,BACKGROUND,LABEL,MAGI2,METHODS,OBJECTIVE,OBJECTIVES,RATIONALE,RESULTS,SNP,THREE
INCREASING,LABEL,NOVEL,OBJECTIVE,PURPOSE,RESULTS,SEVERAL,SONIC,SUMMARY
530,650,PARKINSON,SPR,UBIQUITIN,UCH
215,457,493,536,AMERICA,ASIAN,GOVERNMENT,GRS,PUBLISHED,SNP,STRATIFIED,USING,WBC,WOMEN
169,BAL,COLLEGE,COPYRIGHT,HOWEVER,IDIOPATHIC,IPH,ROYAL
945,CDK,FURTHER,HOWEVER,MTT
177,ANNEXIN,BLM,MSC,MTT,PARACRINE
BESIDES,CURVE,FORESTS,HOWEVER,IFS,LOOCV,MAXIMUM,MINIMUM,NSCLC,OPERATING,RECEIVING,REDUNDANCY,RELEVANCY,RFS,ROC,SQCLC,TAKEN,THERE
169,295,945,ACC,AMP,ATP,COPYRIGHT,INC,INDONESIA,SER79,U87
169,945,COLLAGENS,COPYRIGHT,IRELAND,LTD
169,COPYRIGHT,IRELAND,LTD,MWCNT,THERE,USING
EPIDERMAL,HOWEVER,KIT,TAKEN,THESE
APOPTOSIS,BAX,CHANGES,HEPG2,MCF,MTT,PT2
168,169,180,200,COPYRIGHT,PBS,PF127,PVA
169,ASP,BIOLOGY,FINALLY,HOWEVER,INC,MOLECULAR,SOCIETY
169,IMT,INC,VDA,WILEY,WILMS,XRT
079,169,231,AKT,CXCR4,ERK,GTP,HODGKIN,LY2510924,MDA,SDF
150,169,800,AFTER,DL1,DL2,DLT,MTR,PAZOPANIB
039,042,083,1B1,4326C,4390A,967,COX,CYTOCHROME,FORTY,HISTOLOGY,LABEL,MEIER,METHODS,NSCLC,OBJECTIVE,PEARSON,PFS,PURPOSE,RESULTS,SEVERAL
001,023,024,139,AIM,APRIL,ARSENIC,BETWEEN,CHINA,DCR,GUANGZHOU,LABEL,METHODS,OBJECTIVE,ORR,RESULTS,TTP
169,UTILIZING,VCH,WILEY
001,002,009,012,017,020,045,113,224,234,648,945,HGF,MET,NSCLC
CXCR4,METASTASIS,SBC,SDF,STROMAL
100,BACKGROUND,FORCE,HOWEVER,LABEL,MAJOR,METHODS,RESULTS,SCREENING,THESE,TRIAL
ALK,CRIZOTINIB,H2228,H3122,HGF,HOWEVER,MET,NON,NSCLC,THESE
AFTER,APOPTOSIS,DEPLETING,FIRST,HOWEVER
169,811,AKT,AMYLOID,APP,CELLS,INC,NSCLC,PI3,PRECURSOR,PROTEIN,SINCE,THESE,WILEY
BACKGROUND,III,LABEL,METHODS,NON,NSCLC,RESULTS,THERE
046,778,ADDITIONAL,AML,CPG,FURTHER,HTB56,NSCLC,TALALAY,THESE,WHILE
HOWEVER,KRUPPEL,NSCLC,TNM
148,152,300,452,AFTER,AUC,BLOOD,CURRENT,FURTHER,HENCE,HOWEVER,LOW,MICRORNAS,NSCLC,PCR,SERUM,STRATIFIED
34A,946,H1299,LUCIFERASE,MICRORNAS,NSCLC,PCR,TGF,UTR,WESTERN
169,945,946,AKT,CSC,HOWEVER,MALIGNANT,MET,MYC,NK4,THESE,WNT
CEACAMS,FURTHER,HNO,HOWEVER,THESE
169,BRITAIN,COPYRIGHT,GREAT,INHERITED,IRELAND,LTD,PPB,PUBLISHED,SOCIETY,THESE,WILEY
001,014,018,024,028,044,100,177,691,753,ACCORDING,ACS,CTP,LABEL,LCC,MATERIALS,METHODS,MTT,NSCLC,OBJECTIVE,OBJECTIVES,PIMAX,PULMONARY,RESULTS,THERE,UNION,USING
200,632,DUE,HOWEVER,INFECTIOUS,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SEOUL,TREATMENT,UNIVERSITY
169,BROADLY,COLLEGE,COPYRIGHT,ENGLAND,LTD,MALTHUS,PUBLISHED,ROYAL
020,100,169,AES,BACKGROUND,CALIFORNIA,COLLEGE,COPYRIGHT,DIEGO,FURTHER,GROUP,HOWEVER,INC,LABEL,MCS,METHODS,PCS,PRIOR,PUBLISHED,QOL,RESULTS,SAN,SHORT,SHORTNESS,SURGERY,T1A,T1B,THERE,UNIVERSITY,Z4032
003,169,177,BACKGROUND,COPYRIGHT,DESPITE,EUROQOL,FIFTY,INC,IQR,LABEL,METHODS,RESULTS,RHO,THERE,VAS
169,175,31001,BACKGROUND,CALGB,COMPARISON,COPYRIGHT,INC,LABEL,MCNEMAR,METHODS,PROPENSITY,PUBLISHED,RESULTS,SOCIETY,THERE
042,096,169,612,629,AFTER,BACKGROUND,COPYRIGHT,FINALLY,INC,LABEL,MEIER,METHODS,OVERALL,PUBLISHED,RESULTS,SOCIETY,THERE,THESE,TREATMENT
030,038,169,APRIL,BACKGROUND,CEA,COPYRIGHT,HOWEVER,INC,LABEL,METHODS,OWING,PUBLISHED,RECURRENCE,RESULTS,SOCIETY,THERE
100,169,183,409,432,841,BACKGROUND,BETWEEN,BLOOD,COPYRIGHT,FEB,FOCUS,FUNDING,HEART,INSTITUTE,IQR,LABEL,LIBERAL,LTD,METHODS,RESULTS,THESE,TREATMENT,USA
169,CONVERSELY,COPYRIGHT,FINALLY,HOWEVER,IRELAND,LTD,LYS,OTU,OTUD5,PDCD5,PROGRAMMED
169,945,954,COPYRIGHT,H1299,IRELAND,LTD,SILENCING,V12
169,176,210,2CM,359,8CM,COPYRIGHT,D99,ECLIPSE,INC,MEDICAL,MUS,PTV,PUBLISHED,V10
169,BLOOD,BOS,COPYRIGHT,FIFTY,INC,INSTITUTES,PUBLISHED,SOCIETY
160,169,549,BACKGROUND,COPYRIGHT,H322M,HENCE,INC,LABEL,METHODS,MTT,NEWER,NSCLC,PAC,PROCASPASE,RESULTS,SIMILARLY,WESTERN
003,006,169,AMBULATORY,ASPIRATION,CHANGES,COPYRIGHT,DYSPHAGIA,FIFTEEN,HNC,IMPAIRMENT,INC,INVENTORY,LABEL,METHODS,OBJECTIVE,OUTCOME,PAS,PROFILE,PUBLISHED,RESULTS,SCALE,SETTING,SWALLOW,USING
169,COPYRIGHT,HOWEVER,INC,LOW,PATHOLOGY,PUBLISHED,SOCIETY,TEC,THESE,VERAPAMIL
131,169,177,215,330,669,BBS,BECAUSE,COPYRIGHT,INC,LABEL,LYS,METHODS,RESULTS,TREATMENT,UNLABELLED
169,AWARENESS,COPYRIGHT,IRELAND,LTD,NORTH,PRIORITIES,RADIATION
169,BLY,COMPARING,COPYRIGHT,GVP,HMOX1,HOWEVER,HSP70,NCI,REFERENCE,TPM
0MONTHS,169,5MG,7DAYS,9MONTHS,COPYRIGHT,FIFTY,III,IRELAND,LABEL,LTD,METHODS,NSCLC,OBJECTIVE,OVERALL,PFS,PRIMARY,PURPOSE,RESULTS
169,COPYRIGHT,HOWEVER,MMP1A,MMP1B,THESE,USING
169,COPYRIGHT,FURTHER,HOWEVER,INC,LOBECTOMY,NSCLC,PUBLISHED,SOCIETY
104,169,18F,BACKGROUND,COPYRIGHT,FDG,IIA,IIB,INC,LABEL,METHODS,NSCLC,PET,PUBLISHED,RESULTS,SOCIETY,T1A,T1B,T2A,T2B,THERE
169,2DAYS,945,97L,BERBERINE,CONSISTENT,COPYRIGHT,HCC,HIF,STRIKINGLY,USING
169,CONCLUSION,COPYRIGHT,DIPNECH,ELECTRONIC,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OTHER,RESULTS

240,CONTEXT,HOWEVER,IHC,LABEL,METHODS,NEN,OBJECTIVE,OBJECTIVES,PCR,RESULTS,SIMILAR,SSTR1,SSTR5,SSTRS
120,160,800,956,HCC,HIF,KEEPING,MMP,MVD,PRESENTLY,SP1,STAT3,TAKEN,TUNEL
160,CHEMOKINE,OVERALL
169,394,441,477,786,918,AMONG,BACKGROUND,CASES,CRC,LABEL,METHODS,RAS,RESULTS,SOCIETY
00006,004,006,009,116,ANXIETY,BACKGROUND,DEPRESSION,INVENTORY,LABEL,METHODS,RESULTS,SCALE,SYMPTOM,TAIWANESE
313,CHANGES,CONCLUSION,GODDARD,JAPAN,KNOWLEDGE,LABEL,MEDICAL,METHODS,OBJECTIVE,RESULTS,STAGE,THERE,TOKYO,UNIVERSITY
CIGARETTE,CONSISTENT,FOS,FRA,HEIGHTENED
169,215,956,COPYRIGHT,INC,LABEL,MET,METHODS,OBJECTIVE,OBJECTIVES,PCR,PUBLISHED,RESULTS,SERUM,SOCIETY,TNM
169,382,953,AUSTRALIAN,HODGKIN,LABEL,METHODS,OBJECTIVE,READERS,RESULTS
088,091,092,160,169,954,AUR,BECAUSE,CLOUD,COPYRIGHT,EVALUATION,IMAGE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RATIONALE,REFERENCE,RESULTS,RIDER,SOLID,THESE,VBR
169,929,BACKGROUND,COLLEGE,COMMISSION,COPYRIGHT,COX,DIMINISHED,INC,LABEL,METHODS,PUBLISHED,RESULTS,SEVERAL,SOCIETY
169,777,BRITAIN,CONTINUED,COPYRIGHT,GREAT,INC,LABEL,METHODS,OBJECTIVE,PAF,PURPOSE,RESULTS
24H,AKT,ERK,GLC,H1184,K252A,MEK,MYC,PROCESS,THESE,UCN
160,190,217,793,AMONG,APOA5,III,LDL,MYOCARDIAL,PREVIOUSLY
FEV,LABEL,MEANS,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
169,199,263,ABT,BAK,BCL,BH3,COPYRIGHT,GDC,INC,MCL,SMALL
009,EMT,H1975,HOWEVER,KIRSTEN,L858R,NCI,NON,NSCLC,RAF,T790M,THESE,TKI
145,946,EMT,WNT,WNT3A
HSC,THEREFORE
004,011,040,045,114,131,142,466,ANGPTL2,ANGPTL5,ANGPTLS,NSCLC,THEREFORE
950,HAIYPRH,PEG,PTX,TAT
587,731,936,LNCRNAS,NSCLC,SEVERAL,SIX
712,954,CDK,CKD,G2M,MMP,TAKEN,THI
169,231,397,944,COLLEGE,COPYRIGHT,LTD,ONTARIO,OVERALL,PALLIATIVE,PRT,PUBLISHED,ROYAL
169,ACUTE,CONCLUSION,COPYRIGHT,EASTERN,FIFTY,GROUP,HYPOTRT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
001,004,018,126,160,FINALLY,HOWEVER,PCR,USING
169,BACKGROUND,CONCLUSION,CONSORTIUM,CONTACT,FEDERATION,FINDING,HOWEVER,IMMUNOLOGY,LABEL,METHODS,MOTIVATION,PRESS,PROJECT,PUBLISHED,RESULTS,SOCIETIES,UNIVERSITY
136,169,HOWEVER,JANUARY,LABEL,METHODS,OBJECTIVE,PRESS,PROVISION,PUBLISHED,RECEIPT,RESULTS,SOCIETY,STAGE,UNIVERSITY
018,029,033,046,067,069,079,169,375,436,461,973,CONCLUSION,COX,LABEL,METHODS,OBJECTIVE,PRESS,PUBLISHED,RESULTS,THERE,UNIVERSITY
008,049,169,CXCR2,HOWEVER,IL8,SNP,USING,UTR
EXPRESSION,HOWEVER,PCR,SMALL
001,106,160,177,ELISA,MEIER,NSCLC,TNM,UNIVARIATE,USING
169,CONCLUSION,COPYRIGHT,DISCS,HOWEVER,INC,KNOCKDOWN,LABEL,MEIER,THESE,UNLABELLED
954,BELGIAN,CAD,COHEN,DUTCH,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
169,AZD9291,METASTATIC,T790M,USING
008,010,042,169,AGGRESSIVE,BACKGROUND,COPYRIGHT,DFS,HOWEVER,LABEL,LTD,METHODS,OCTOBER,PREVENTING,RECURRENCE,RESULTS,SACRECTOMY,STUDIED,THREE
C30,EASTERN,ELD14,EORTC,GROUP,HRQOL,LABEL,METHODS,OBJECTIVE,OVERALL,PURPOSE,QLQ,RESULTS,SIX,UNION
169,COPYRIGHT,INC,UNREPORTED
1970S,1980S,1990S,AUSTRALIA,CHINA,GDP,INDUSTRIAL,ITALIAN,ITALY,JOURNAL,SIX
169,COPYRIGHT,INC,INCREASING,IRS
ALA119SER,ASN453SER,CAUCASIANS,LEU432VAL
169,178,AIM,BACKGROUND,CNS,CONCLUSION,COPYRIGHT,DESPITE,IMPROVING,LABEL,LTD,METHODS,OBJECTIVE,OVERALL,PATIENT,RESULTS,THERE,THESE
001,002,006,169,947,BACKGROUND,COPYRIGHT,INC,LABEL,METHODS,RESULTS
FLT,III,IPF,NINTEDANIB,NSCLC,PDGFR,SRC,VEGFR
001,085,169,327,389,AMONG,CUMULATIVE,END,LABEL,METHODS,OBJECTIVE,RESULTS,THESE,USING,VALIDATED
122,CCNG1,HOWEVER,MEF2D,OLEANOLIC,RESTORING
CAUCASIANS,HENCE,OVERALL
169,919,ABSTRACTS,AES,CENTRAL,CONTROLLED,HOWEVER,INCREASED,MEDLINE,NSCLC,TREATMENT
169,945,946,BASED,CSF,HUVEC,PRE,TNF
CONCLUSION,GREATER,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,RESULTS
039,160,169,AUTHORS,DFS,FGFR1,HOWEVER,LTD,MET,NSCLC,PATIENT,PDX,WILEY
169,945,946,BRITAIN,COPYRIGHT,GREAT,IRELAND,LTD,OVERALL,PCR,PLACING,PUBLISHED,SOCIETY,TGF,WILEY
001,005,016,024,160,169,17A,330,382,73G,APMIS,FURTHER,HOWEVER,LTD,NSCLC,PUBLISHED,WILEY
169,ALK,COPYRIGHT,CTC,INC,PREDICTIVE,PROGNOSTIC,THESE
001,169,CAIRO,COMBINING,CONCLUSION,COPYRIGHT,DOPPLER,EGYPT,FEDERATION,FLV,GYNECOLOGY,IRELAND,JANUARY,LABEL,LTD,METHODS,OBJECTIVE,OBSTETRICS,PUBLISHED,RDS,RESULTS,RIS
160,169,ALK,AUTHORS,BACKGROUND,CONCLUSION,COPYRIGHT,ERBB2,IHC,INC,LABEL,MATERIALS,METHODS,PCR,PUBLISHED,RESULTS,RET
160,169,BACKGROUND,CONCLUSION,COPYRIGHT,HOWEVER,III,INC,INTENSITY,JANUARY,LABEL,METHODS,NSCLC,RESULTS,SIB
131,169,177,231,233,BACKGROUND,CAV,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,PFS,RESULTS
000,169,183,279,AGAINST,AMERICA,ATLANTA,AUSTRALIA,BACKGROUND,BELFAST,CENTERS,CONTINUOUS,CONTROL,COPYRIGHT,DEC,DISEASE,ECUADOR,ESTIMATES,FOCUS,FUNDING,INDIVIDUAL,INSTITUTE,IRELAND,JAPAN,KOREA,LABEL,LEXINGTON,LIVER,LTD,METHODS,NORTH,PREVENTION,PUBLISHED,RESULTS,SOUTH,SWISS,TORONTO,UNIVERSITY,USA,WALES,WORLDWIDE
100,169,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS,UPRIGHT
169,COLLEGE,COPYRIGHT,FURTHER,HENCE,HOWEVER,LTD,MODELLING,PATIENT,POPULATION,PUBLISHED,ROYAL,WHITE
127,169,AFTER,COPYRIGHT,COX,EXPRESSION,GLC,HOWEVER,INC,LAK,MEIER,PBK,PDZ,THEREFORE,TNM,WESTERN
169,AUTHORS,BELGIAN,BELGIUM,COPYRIGHT,HOWEVER,INCIDENCE,LTD,POISSON,PUBLISHED,THESE,WORLD
BECAUSE,COLLEGE,ROYAL,TREATMENT
169,954,BECAUSE,COPYRIGHT,EXTRACTED,INC,SGP40,SGP65,THESE,TREATMENT
169,24H,AKR,AKR1B10,COPYRIGHT,ERK,HOWEVER,IRELAND,JUN,LTD,MAP,THESE,TPA,U0126
169,COPYRIGHT,FURTHER,HOWEVER,ISSUE,KNOCKDOWN,MEDICAL,PCR,PROTEOMIC,PROTEOMICS,PUBLISHED,ROS,SPECIAL,THESE,WESTERN
116,169,460,549,COMPOUNDS,COPYRIGHT,HCT,INC,MOLECULAR,SAR
160,169,239,446,ACADEMY,ASSESSMENT,BACKGROUND,CHRONIC,CONCLUSION,CONTEXT,COPYRIGHT,EASTERN,FATIGUE,FUNCTIONAL,GENERAL,GROUP,HOSPICE,ILLNESS,INC,KARNOFSKY,LABEL,METHODS,NSCLC,OBJECTIVE,OBJECTIVES,PALLIATIVE,PUBLISHED,QOL,RESULTS,THERAPY,VISIT
130,169,AGA,BACKGROUND,COPYRIGHT,EMAST,EXPRESSION,IL6,INC,INCUBATION,INSTITUTE,LABEL,METHODS,OBJECTIVE,PUBLISHED,RESULTS,STAT3
169,COPYRIGHT,INC,LABEL,THESE,UNASSIGNED,UNLABELLED
169,1PM,AUNPS,COPYRIGHT,NEANA
175,18F,459,960,CENTERS,CHINA,CHINESE,CNY,CONCLUSION,GDP,GUIDELINES,LABEL,METHODS,MODEL,NON,NSCLC,OBJECTIVE,PET,RESULTS,ROBUSTNESS,SMALL
169,552,COPYRIGHT,GAB,INC,MAP,PI3,PLC,PREVIOUSLY,RHO
169,COPYRIGHT,FEW,HOWEVER,IRELAND,LTD,PUBLISHED,RDI,STUDIES
169,COPYRIGHT,CROWN,CTC,FURTHER,IRELAND,LTD,ONGOING,PUBLISHED,THERE
001,015,029,160,169,ACT,AMENDMENTS,ARIZONA,ASSESSMENT,BACKGROUND,BECAUSE,CENTERS,CONCLUSION,CONTROL,COPYRIGHT,DISEASE,EDUCATION,INC,LABEL,LOW,MATERIALS,METHODS,PREVENTION,PROGRAM,RADIATION,RESEP,RESULTS,SCREENING,SOCIETY,THESE,TOBACCO,TOTAL,VARIATIONS,YET
169,ALK,COPYRIGHT,III,INC
160,169,500,BACKGROUND,CONCLUSION,COPYRIGHT,FIFTEEN,INC,LABEL,METHODS,NSCLC,PFS,RESULTS
169,AUTHORS,AUTOPHAGY,BECLIN1,BEV,C26,HSA,LTD,PTY,PUBLISHING,SCIENCE,SIMILAR,SNO,THEREFORE,WILEY
169,COPYRIGHT,FOURIER,LTD
001,005,110,134,160,169,177,340,450,COPYRIGHT,LABEL,LTD,METHODS,NON,NSCLC,OBJECTIVE,OBJECTIVES,RESULTS
169,946,COPYRIGHT,FEDERATION,FINALLY,IKB,IKK,LARGE,MCF,MLL,PC3,PKC,PUBLISHED,RAPID,SOCIETIES,SW620,TARGETING
001,160,169,433,740,AUTHORS,BACKGROUND,CONCLUSION,COPYRIGHT,ELECTRONIC,HOWEVER,INC,LABEL,METHODS,NSCLC,PFS,PUBLISHED,RESULTS,SMOKING,TKI
169,239,BAGGING,BAYES,CISLS,COPYRIGHT,LTD,SVM,THESE
169,COPYRIGHT,DIFFUSING,INC,LABEL,METHODS,OBJECTIVE,PUBLISHED,RESULTS,SURGERY,THERE,TREATMENT
169,945,COPYRIGHT,H23,NSCLC,THESE
169,CHT,COPYRIGHT,III,INC,NSCLC,SIMILARLY
169,685,COPYRIGHT,FIFTEEN,III,IMPROVING,INC,JANUARY,LABEL,MATERIALS,METHODS,NSCLC,OBJECTIVE,PEARSON,PURPOSE,RESULTS,THERE
169,COPYRIGHT,FORTY,GRADE,INC,LABEL,METHODS,NSCLC,OBJECTIVE,PURPOSE,RESULTS,SECONDARY,TKI,TREATMENT
169,673,946,ACEIS,ASPIRIN,BACKGROUND,CONCLUSION,COPYRIGHT,COX,DFS,III,INC,INCIDENTAL,LABEL,LRPFS,METHODS,NSCLC,RESULTS
018,160,169,710,816,983,BACKGROUND,COPYRIGHT,INC,INSURANCE,LABEL,MEDICATION,METHODS,OLDER,OVERALL,RESULTS,SCC
169,ACCOUNTING,ADC,AKT,COPYRIGHT,ERK,INC,LOH,MEK,NAC,NSCLC,RAF,RAS,SCC,THESE
169,COPYRIGHT,FINALLY,INC,TAKEN
169,946,COPYRIGHT,INC
10000,169,BACKGROUND,CONCLUSION,ENGLAND,GPS,LABEL,METHODS,OBJECTIVE,ONGOING,PRESS,PUBLISHED,RESULTS,THESE,UNIVERSITY
125,150,169,BACKGROUND,COPYRIGHT,DISEASE,LABEL,METHODS,NSCLC,PRIOR,RESULTS,THREE
028,087,ALDH1,AMONG,CD204,LABEL,METHODS,OBJECTIVE,PFS,PURPOSE,RESULTS,THESE
169,176,177,267,CONTINUOUS,COPYRIGHT,DOF,INC,KIM,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE,VARIOUS
169,327,ACCORDING,BASED,BESTKEEPER,BRCA1,COPYRIGHT,ERCC1,GAPDH,INC,NORMFINDER,PCR,RPLPO,STMN1,TOP2A,TUBB3,USING
169,563,BLOOD,COPYRIGHT,SOCIETY,TRANSPLANT
164,169,174,582,ASA,COPYRIGHT,COX,DEFINITIVE,EDUCATION,GLEASON,HOWEVER,INC,LABEL,MATERIALS,MAY,METHODS,OBJECTIVE,PATIENT,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,302,ANIMALS,COPYRIGHT,CROWN,HOWEVER,IPM,IRELAND,LTD,PUBLISHED
169,945,AMD3100,COPYRIGHT,CXCR4,HIF,IRELAND,KC7F2,LTD,THESE
169,192,215,CONVERSELY,COPYRIGHT,FINALLY,FUNCTIONAL,H1299,IRELAND,LTD,R273H,TAKEN
169,202,293,315,ALK,ATM,COPYRIGHT,EP300,HGF,IRELAND,KDR,LTD,MOLECULAR,OTHER,PDX,RUNX1,SETD2,STK11
169,945,954,CD163,COPYRIGHT,IRELAND,LTD,MIP,STAT3
169,180,210,916,BECAUSE,COPYRIGHT,FURTHER,HOWEVER,IRELAND,LTD,PDCD5
169,COPYRIGHT,PUBLISHED,SEPAR
169,450,945,947,954,ACADEMY,ALLERGY,BACKGROUND,CD3,CD4,CONCLUSION,COPYRIGHT,GATA3,IFN,IGE,IMMUNOLOGY,INC,LABEL,METHODS,OBJECTIVE,OVA,PUBLISHED,REMARKABLY,RESULTS,TH1,TH2,THESE,TNF
169,376,425,BACKGROUND,COPYRIGHT,DECREASES,DEPARTMENT,INC,JOURNAL,LABEL,METHODS,MULTILEVEL,OBJECTIVE,PREVENTIVE,PUBLISHED,PURPOSE,RESULTS
169,BCL,COPYRIGHT,DESPITE,HOWEVER,INC,NON,PACLITAXEL,PREVIOUSLY
100,115,120,121,CACTTTG,ECTOPIC,OVERALL,SOX,SOX30,SRY
132,212,CELLS,CONVERSELY,H1299
110,116,130,150,169,176,180,210,230,250,3DCRT,4GY,COPYRIGHT,INC,MEDICAL,OAR,PHYSICS,PROGRAMME,PUBLISHED,RADIATION
COLORECTAL,CRC,HCT16,HOWEVER,THESE,USING
ERCC1,EXPRESSION,FCM,FIRSTLY,H1299,MRP,MTT,NSCLC,THEREFORE
BPS,LEWIS,LLC
946,APOPTOSIS,EXPRESSION,GAL,INJURED,LCC,PLEURAL,PMC,TGF,WESTERN
960,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE,THESE,USAGE
001,002,004,012,1686C,169,391,398,COPYRIGHT,CRS,GROWING,PCR,THESE,XRCC1
001,160,AMONG,CONCLUSION,DSS,FDG,III,INITIAL,LABEL,METHODS,MORTALITY,NAC,OBJECTIVE,PET,PURPOSE,RESULTS
CDC42,NSCLC,PCR
161,ACT,CERTAIN,CONCLUSION,IMAGING,INSURANCE,KNOWLEDGE,LABEL,METHODS,MRI,OBJECTIVE,PLEURAL,PRIMARY,RECURRENT,RESULTS,SMALLER,SSS
ARSENIC,AS2O3,FAS,HOWEVER
945,AKT,HOWEVER,KNOCKDOWN,LENTIVIRUS,METASTASIS,MMP,PI3KP85,TAKEN,THESE
002,107,408,998,AMERICA,CIS,COLORECTAL,COX,GOVERNMENT,HRS,OVARIAN,PUBLISHED,RCC,SCREENING,TRIAL
169,309GG,331,501,532,717,749,830,AUTHORS,CONSISTENT,INC,PUBLISHED,SNP285C,SNP285G,SNP309T,WILEY
169,945,946,BRITAIN,COPYRIGHT,GREAT,IIB,IRELAND,LTD,PUBLISHED,SOCIETY,WILEY
104,235,380,BMJ,GROUP,LABEL,LIMITED,METHODS,OBJECTIVE,PCR,PUBLISHED,PUBLISHING,QUBIT,RESULTS
BMJ,GENOMIC,GROUP,LABEL,LIMITED,METHODS,MILLISECT,OBJECTIVE,PROTEOMIC,PUBLISHED,PUBLISHING,RESULTS,SLIDE
134,CONCLUSION,COX,HOWEVER,LABEL,LSMIS,METHODS,NSCLC,OBJECTIVE,PURPOSE,RESULTS
132,339,365,386,672,753,788,EASTERN,GROUP,INDWELLING,JANUARY,LABEL,MALIGNANT,METHODS,MPE,OBJECTIVE,RESULTS,SIXTY,THERE
BMJ,GROUP,IMPORTANCE,LABEL,LIMITED,METHODS,MORTALITY,OBJECTIVE,ONTARIO,POPULATION,PUBLISHED,PUBLISHING,RELEVANCE,RESULTS,SETTING
100,157,282,439,CEACAM6,CEACMA6,SMALL
145,945,ADP,ATF,BIP,BORON,DIETARY,GRP78,LOW
AKT,ERK,HOWEVER,NSCLC,THESE,USING
109,119,121,133,141,145,AVERAGE,BACKGROUND,CONCLUSION,DESPITE,HOWEVER,LABEL,METHODS,OBJECTIVE,QUESTIONS,RESULTS
ANAPLASTIC,ATC,BACKGROUND,CONTEXT,DESPITE,JNK,LABEL,METHODS,OBJECTIVE,RESULTS,THESE,USING
HPV,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,TREATMENT
486,538,572,ALCOHOL,BACKGROUND,HEAVY,HODGKIN,LABEL,METHODS,NON,RESULTS,RRS,THERE
001,169,499,842,AFTER,CONCLUSION,COX,III,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SOCIETY,TREATMENT
AUTOPHAGY,CONCLUSION,DESPITE,III,LABEL,METHODS,OBJECTIVE,PURPOSE,REGULATION,RESULTS,THESE
956,ANOTHER,HOWEVER,NPS
945,TUNEL
001,160,169,598,658,APMIS,CAUCASIAN,KIT,LTD,MUTATIONS,NSCLC,PCR,PUBLISHED,RGQ,WILEY
169,CD11B,IL6,LABEL,METASTASIS,ST6GALNAC4,THOMSEN,UNLABELLED
169,175,ANY,EASTERN,GROUP,KETTERING,LABEL,LIVER,METHODS,OBJECTIVE,PHASE,PRESS,PUBLISHED,RESULTS,SLOAN,UNIVARIATE,UNIVERSITY
946,EMT,EPITHELIAL,MORTALITY
8TH,GEFITINIB,NSCLC,TEN,TKI,TOXIC,TREATMENT
500,B12,BETWEEN,BEV,CHINESE,DISEASE,NSCLC,OCTOBER,OVERALL,PFS,TOXICITIES
001,CONCLUSION,DLP,KEY,LABEL,MATERIALS,METHODS,OBJECTIVE,PRECISION,PROCEDURE,RESULTS,ROBOT
001,007,010,050,102,116,372,BACKGROUND,COX,EASTERN,GROUP,HOWEVER,ICU,INTENSIVE,JANUARY,LABEL,METHODS,RESULTS,SEVERANCE,SIXTY,UNIVERSITY
001,005,011,015,028,ANXIETY,AUC,CHANGES,CHRONIC,CONCLUSION,DEPRESSION,DISEASE,FORTY,FVC,IMT,LABEL,MATERIALS,METHODS,NRS,NSCLC,OBJECTIVE,OBJECTIVES,OUTCOME,RESULTS,SCALE,SEVENTY,THESE
100,169,1RA,242,IGFBP,NSCLC,THESE,URINE
120,132,AFTER,GRADE,III,METHODS,RESULTS,SINCE,THEREFORE
169,BACKGROUND,LABEL,METHODS,MOTIVATION,PRESS,PUBLISHED,SAMNETWEB,SUMMARY,THESE,THROUGH,UNIVERSITY
177,957,968,978,AGREEMENT,BACKGROUND,BLAND,CONCLUSION,ICC,INTERSCAN,IQR,KEY,LABEL,METHODS,RATIONALE,RESULTS,SSN,VOLUMETRIC,WHITNEY
001,084,112,152,169,177,184,194,359,403,665,BECAUSE,BETWEEN,LABEL,LNR,METHODS,MULTIMODAL,OBJECTIVE,OBJECTIVES,PRESS,PUBLISHED,RATIO,RESULTS,SURGERY,UNIVERSITY
ALK,CRIZOTINIB,MET,OPTIMIZING,PROFILE,WHILE,XALKORI
001,002,006,017,157,COX,HOWEVER,MEIER,NSCLC,PCR,PPM1D
945,CHRONIC,FLICE,GOVERNMENT,KNOCKDOWN,PASSAGE,PRESS,PUBLISHED,SOCIETY,SWCNT,TNF,TOXICOLOGY,UNIVERSITY,WHOLE
177,CD4,NCI,PBMCS,PNS
945,BACKGROUND,BASED,HMB,LABEL,LAM,METHODS,RESULTS,TSC,WESTERN,WHEREAS
000,169,COPYRIGHT,CTM,GEOMETRIC,HOWEVER,SEVERAL,SINGLET,SOCIETY,THESE,THROMBOTIC,VTE
169,BACKGROUND,CONTACT,DEG,LABEL,METHODS,MOTIVATION,NMF,PRESS,PUBLISHED,RESULTS,TREMENDOUS,UNIVERSITY
169,181,344,ADVERSE,BACKGROUND,EXPOSURES,INSTITUTE,LABEL,METHODS,MTD,RESULTS,SOCIETY,THERE
001,119,127,281,AMONG,BACKGROUND,CONCLUSION,FURTHER,KOREA,LABEL,METHODS,NSCLC,RESULTS
160,CHINA,HEAVY,HOWEVER,POISSON,RESULTS
225,ANTIBIOTIC,APRIL,CDI,CONVERSELY,CURIOUSLY,HOWEVER,INPATIENT,JANUARY,LABEL,LATER,METHODS,OBJECTIVE,OCTUBRE,PURPOSE,RESULTS,UNIVERSITY
001,012,072,086,BACKGROUND,CRT,JANUARY,LABEL,METHODS,NEITHER,OTHERWISE,PRECISE,RECURRENCE,RESULTS
001,004,024,927,AFTER,BACKGROUND,BLACK,FINALLY,LABEL,METHODS,RESULTS,THESE,WHITE
946,EMT,PCC,SMAD3,TAKEN,TGF
946,AMS,ATP,CONVERSELY,FURTHER,LIPID
945,946,BROAD,THERE
001,005,169,343,446,897,D140E,E139D,INC,SNV,THERE,WILEY
169,AUTOPSY,FORTY,LABEL,LTD,MAY,METHODS,OBJECTIVE,RESULTS,UNUSUAL,WILEY
005,100,169,225,AMONG,BACKGROUND,CONCLUSION,FDG,FOUNDATION,FOV,LABEL,METHODS,OBJECTIVE,PET,PURPOSE,RESULTS,SMM,TORSO
ABCC1,ABCC4,ERCC2,FOLH1,LC6,LU130,PRSS3,SHMT1,TGI,TK1,TST,TXN
106,169,387,946,BRITAIN,COPYRIGHT,GREAT,IRELAND,LTD,NSCLC,P53,PUBLISHED,SOCIETY,WILEY,WNT
169,462,501,539,963,AFTER,AUTHORS,COX,DIETARY,FURTHER,HORDALAND,INC,PAR,PLP,PUBLISHED,PYRIDOXAL,WILEY
AFTER,BETWEEN,CHRONIC,CONSENSUS,ELDERLY,FURTHER,GROUP,JANUARY,LABEL,METHODS,NSCLC,OBJECTIVE,OBJECTIVES,RESULTS
169,181,AMONG,RRS
102,141,169,DUE,PRESS,PUBLISHED,STUDIES,SURGERY,UNIVERSITY
000,100,169,4T1,8430506,956,COMBINING,FASEB,HEPG2,KI16425,KNOCKDOWN,LPA,ONO
HOWEVER,PARTNER,PCR,WESTERN
169,947,GROUP,HEP3B,NPS,OVERALL,PRESS,PUBLISHED,ROS,SOCIETY,TOXICOLOGY,UNIVERSITY
102ND,169,ALECTINIB,ALK,LABORATORY,PHASE,PRESS,PUBLISHED,STAGE,THERE,UNIVERSITY
BMJ,FORMULA,FURTHER,GROUP,LIMITED,MEDLINE,OUTCOME,PAH,POLYCYCLIC,POPULATION,PUBLISHED,PUBLISHING,WHILE
001,078,161,594,CTX,FURTHER,GCT,IPFSG,LABEL,METHODS,OBJECTIVE,OVERALL,PFS,PURPOSE,RESULTS,SALVAGE
DESPITE,HDAC4,NOTABLY,STAT1,THESE,TSA
470,AFTER,ASSAY,CFI,CHINESE,COMPLEMENT,GENOTYPING,HAPLOVIEW,MASSARRAY,NSCLC,ORS,THERE,TOTALLY
102,109,242,385J1,586,AMONG,HOWEVER,NSCLC,SEVERAL,USING
AUSTRALIA,CHEST,INTERVIEWS,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,ROYAL,SOUTH,SUPPORT
003,032,033,044,046,DFS,III,INCREASING,LABEL,MATERIALS,METHODS,NSCLC,OBJECTIVE,OVERALL,OVERSIZED,PURPOSE,RESULTS,RFA,SEX,TREATMENT
123,954,960,ABCA2,ABCA5,AKT,ATP,CHINA,DDP,ERK,HOWEVER,MDR,MULTIDRUG,STAT5
035,103,AMONG,BACKGROUND,LABEL,METHODS,RESULTS
AKT,BAX,BCL,CAV,DENDROBIUM,ERK,GTP,MCL,RAC,RESISTANCE,RHO,TAKEN,WESTERN
183,956,GSH,HOWEVER,NAC,ROS,TRX
954,HOWEVER,LARGE,LATS2,NSCLC,TAKEN
640,915,ASIAN,CIS,CRUDE,GROWING,ORS,SEPTEMBER,STATA
169,737,ABT,AUTHORS,FOUNDATION,H1299,JOURNAL,LTD,MOLECULAR,REGULAR,WILEY
200,247,CONCLUSION,GSTM1,GSTP1,GSTT1,ILE462VAL,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PCR,PORTUGUESE,RESULTS,TOBACCO
106,169,CAF,EPIDERMAL,ERK,LABEL,METHODS,NSCLC,OBJECTIVE,PODOPLANIN,PURPOSE,RESULTS,TKI
ABL,BCR,CML,HLA,LINEAGE,PRS,SCT,TKI
169,BENEFIT,GEP,IDEAL,INTRA,NET,SOCIETY,TAE,THESE
16S,181,946,ATCC204508,ENDOPHYTIC,FDC83,INDOLES,KOCURIA,LGMB259,PC3,R5A,VINYL
H2052,H2452,H28,MPM,PDT,PEMETREXED,WST
100,H23,MMP,NCI,NKG2DLS,PREVIOUSLY
007,ASIAN,CHINA,CHINESE,COX,FGFR1,III,JAPAN
26S,947,FURTHER,MG132,R175H,THESE
126,128,15A,210,34A,EXPRESSION,HOWEVER,NSCLC,PCR,SAMPLES,SCC,TNM
BACKGROUND,CCDC6,CONCLUSION,HCC78,LABEL,METHODS,NSCLC,RESULTS,RET,SLC34A2
111,BACKGROUND,FURTHER,GRADE,HOWEVER,IPN,LABEL,METHODS,RESULTS,T1A,T1B,T2A
169,CASPASE,FINALLY,H1975,HISTONE,HOWEVER,T790M,TKI,WHILE
INTRAVITAL,KIF22,KIF2C,NOTCH,SRF,SUBSEQUENT
ANGIOMOTIN,CL1,CYR61,FURTHER,HOWEVER,KNOCKDOWN,LEWIS,PDZ,RESULTS,TAZ,THESE,YAP,YES
637,BACKGROUND,DESPITE,IPF,LABEL,METHODS,RESULTS
947,948,CYTOTOXIC,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
956,AGS,DUE,GASTRIC,HOWEVER,LC3,THESE,WESTERN
BMJ,GROUP,INCREASING,LIMITED,PUBLISHED,PUBLISHING
036,169,245,271,298,307,407,453,507,672,699,870,897,BACKGROUND,COLORECTAL,DESPITE,INCIDENCE,INPATIENT,LABEL,METHODS,NATIONWIDE,RESULTS,SOCIETY
032,132,140,169,180,BACKGROUND,LABEL,METHODS,NSCLC,OCTOBER,PFS,RESULTS,SOCIETY,TREATMENT
024,036,094,691,709,726,775,892,910,945,988,COX,FURTHER,MEIER,NSCLC,ROC
CD105,CD106,HBMMSCS,LIPID,MYOD1,P10,P25,P57
096,149,157,169,217,254,IQR,LABEL,LEPIDIC,LOCAL,METHODS,OBJECTIVE,OBJECTIVES,PRESS,PUBLISHED,RESULTS,SURGERY,THESE,UNIVERSITY
222,338,577,597,615,696,944,FURTHER,HISEQ,MICRORNAS,NSCLC,SEQ,SINCE,TARGETS,THERE
014,048,099,137,214,299,335,914,BACKGROUND,EPIDERMAL,GENOMIC,LABEL,METHODS,NSCLC,RESULTS
BACKGROUND,LABEL,METHODS,MULTILEVEL,RESULTS,SWEDISH,THERE
000,072,100,242,286,363,480,554,612,654,725,787,BACKGROUND,DEPARTMENT,DESPITE,EMERGENCY,INPATIENT,LABEL,METHODS,NATIONWIDE,NIS,NUMBERS,RESULTS
156,BACKGROUND,CARCINOID,CTS,LABEL,METHODS,NATIONWIDE,OBJECTIVE,PURPOSE,RESULTS,SPM,THREE
338,ECTOPIC,HOWEVER,NSCLC,RAB14,RAS,THEREFORE,THESE
ADP,BCL,CHINESE,FORSYTHIA,FSEER,FSFEE,FSLEE,FSREE,JANUS,THESE
001,004,396,AES,CONCLUSION,DCR,ELECTRONIC,FURTHER,LABEL,METHODS,NSCLC,OBJECTIVE,ORR,PFS,PURPOSE,RESULTS
ARSENIC,AS4S4,CELLS,CHINESE,HEPG2,L02,LEWIS,MKN45,THESE
169,946,HOWEVER,INC,TGF,THEREFORE,WILEY
822,BACKGROUND,CONCLUSION,HISPANICS,LABEL,METHODS,NSCLC,RESULTS,THERE,THESE,TREATMENT
552,APART,BACKGROUND,CENTRAL,CONCLUSION,COX,DENMARK,DUE,INITIAL,LABEL,METHODS,PATIENT,POPULATION,RESULTS,TREATMENT,WOMEN
945,ERK,FOLLOWING,HOWEVER,NSCLC
001,177,CASES,CONCLUSION,CURRENT,CVD,LABEL,METHODS,OBJECTIVE,RESULTS,SCREENING,TRIAL
100,169,195,720,COLLEGE,ICU,METABOLISM
001,177,380,455,677,718,768,813,927,985,998,AIF,BLAND,CONCLUSION,ICC,ICCMANUAL,KCC,KENDALL,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,ROI,THREE
SOLID,THESE
095,169,224,549,BACKGROUND,COMPONENT,EMOTIONAL,END,HODGKIN,HRQOL,LABEL,MCS,METHODS,PCS,RESULTS,SCALE,SHORT,SOCIETY,SUMMARY,SURVIVORS
001,003,008,011,018,019,LINKS,NUTRITION,SURVEYS,THERE,THEREFORE,URINARY
191,ELISA,HOWEVER,LABEL,METHODS,NOVEL,NSCLC,OBJECTIVE,PURPOSE,RESULTS,USING
119,195,318,796,ADJUSTMENT,CONCLUSION,HISTOLOGY,LABEL,METHODS,OBJECTIVE,RESULTS
215,CY5,DISCOVERY,M13,NOVEL
145,15A,169,19B,203,294,295,483,615,ADENO,ADV,AFTER,AMONG,CRE,INC,LEWIS,LOX,LSL,MIR,MIRNA,PCR,SCA,UTR,WILEY
169,ALTOGETHER,CELASTROL,JNK,NSCLC,THESE
001,169,177,946,AKT,CRC,CXCR4,FASEB,FOLLOWING,KIRSTEN,SERPINE,VEGFA
100,BAX,BCL,FURTHER,THEREFORE
100,122,BMJ,CIS,ENGLAND,GROUP,HODGKIN,LABEL,LIMITED,METHODS,MORTALITY,NOR,OBJECTIVE,OBJECTIVES,PUBLISHED,PUBLISHING,RESULTS,SMR,WALES
701,ASSESSMENT,C30,CCD,CHINA,EORTC,FUNCTIONAL,GENERAL,LABEL,METHODS,OBJECTIVE,PURPOSE,QLQ,QOL,RESULTS,THERAPY,TREATMENT
004,005,051,082,106,162,169,180,256,296,337,395,565,687,841,CEA,CRC,LABEL,LNI,LNR,METHODS,OBJECTIVE,OBJECTIVES,OTHERWISE,PRESS,PUBLISHED,RESULTS,SURGERY,THERE,UNIVERSITY
115,183,187,947,ASA,BACKGROUND,CLINICALLY,FIFTEEN,GREATER,HRQOL,LABEL,METHODS,RESULTS,SECONDARY,SOCIETY,TECHNICAL,THERE
AVERAGE,BACKGROUND,LABEL,METHODS,PULMONARY,RESULTS
ATS,CHEST,COLLEGE,NETWORK,PHYSICIANS,PREVENTIVE,SOCIETY,STATEMENTS,SURGERY
008,075,086,169,177,AMONG,ANOTHER,BASED,CEA,HOWEVER,PRESS,PUBLISHED,SURGERY,UNIVERSITY
954,CONCERNING,GROUP,LABEL,METHODS,MPM,OBJECTIVE,PET,PURPOSE,RESULTS,SIXTY,TNM
015,020,022,028,169,CDR,DTC,HERC5,NSCLC,PCR,QRT,SEVEN,STAGE
022,215,439,559,709,907,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS,UIP
99A,DU145,FOLLOWING
020,022,023,026,035,037,313GG,351,NSCLC,PFS,SIPA1
2MAPK,AKT,CD151,FAK,FINALLY,LAC,MEK,MTT,REDUCED,TAKEN
160,203,477,ADDITIONAL,ASSESSMENT,CHRONIC,EVALUATION,FAACT,FACIT,FATIGUE,FUNCTIONAL,HCL,III,ILLNESS,LABEL,METHODS,NSCLC,OBJECTIVE,PURPOSE,QOL,RESULTS,SEA,SEF,SIMPLIFIED,THERAPY,THESE
169,BRITAIN,COPYRIGHT,FOLKMAN,GREAT,HOWEVER,IRELAND,LTD,PUBLISHED,SOCIETY,THESE,WILEY
MEDICAL,PATHOLOGY,SOCIETY,SPANISH
177,BACKGROUND,HOWEVER,LABEL,METHODS,RESULTS,TCP,TREATMENT
100,895,AFTER,CONCLUSION,EARLY,MATERIALS,METHODS,OBJECTIVE,PROGRAM,RESULTS
169,DISEASE,EMD,FORTY,FURTHER,IGM,INC,WILEY
169,707,834,844,905,919,945,ADC,AUC,ELISA,FURTHER,GLYCANS,NSCLC,PRESS,PUBLISHED,UNIVERSITY
129,FINALLY,SINCE,SRC
001,011,036,120,169,ADC,AGAIN,BRITAIN,COPYRIGHT,GREAT,HOWEVER,IRELAND,LTD,PUBLISHED,RAS,SCC,SOCIETY,TAKEN,WILEY
115,215,BAP,LOD,PAH,SOUTHWEST,SPAIN
169,209,215,381,AGILENT,AMENDMENTS,BACKGROUND,COLLEGE,EXCISIONAL,HISEQ,LABEL,LABORATORY,METHODS,MISEQ,NGS,NSCLC,RESULTS,SEQUENCING,SOCIETY,SURESELECT,TAT
000,300,450,BACKGROUND,CONCLUSION,DUE,INITIAL,LABEL,METHODS,NON,NSCLC,RESULTS,SMALL
108,221,AFTER,ASIAN,CAUCASIANS,HOWEVER,OVERALL
149,152,160,796,ANXA1,IGG,PEARSON,ROC,STUDENT
001,002,003,010,EXPRESSION,GEO,HMGA1,III,MEANWHILE,NSCLC,OMNIBUS,PCR,USING
049,177,DUSP6,MKP,NSCLC,OCTUBRE,PCR,UNIVERSITY,USING
169,99M,DIFFUSE,IMAGING,INC,MOLECULAR,NUCLEAR,SOCIETY
945,AKT,BAD,BECAUSE,CONCLUSION,ERK,HOWEVER,LABEL,MEK,METHODS,NSCLC,OBJECTIVE,PURPOSE,RESULTS,TAKEN,THEREFORE
111,857,BACKGROUND,CD3,CONCLUSION,HODGKIN,INDUCTION,LABEL,MATCH,METHODS,MUROMONAB,NHL,POISSON,POLYCLONAL,RECIPIENTS,REGISTRIES,RESULTS,SCIENTIFIC,STUDIES,TRANSPLANT
000,BACKGROUND,EGGER,JANUARY,LABEL,MEDLINE,METHODS,RESULTS,SIXTEEN,THERE
100,123,160,200,956,FURTHER,MTT,NPS,PCR,TAKEN,TYPICAL
AIM,CBA,FDA,HENCE,LABEL,MCA,MCF,OBJECTIVE,RESULTS
169,AGAINST,FINALLY,JOURNAL
160,177,231,956,BLUME,DUNAL,HEPG2,LNCAP,MCF,MDA,NMR,SW480,THEIR,VIETNAM
000,169,1970S,DESPITE,NSCLC,SMALL,SOCIETY
074,093,508,828,HENCE,HOWEVER,OVERALL,THERE
BACKGROUND,DISCUSSION,ELECTRONIC,GOVERNMENT,INSTITUTES,LABEL,OBJECTIVE,PRESS,PUBLISHED,PURPOSE,RESULTS,SOCIETY,THEIR,THESE,TOBACCO,UNIVERSITY
140,169,AUSTRALIAN,BACKGROUND,COLLEGE,FDG,LABEL,METHODS,MICROWAVE,MWA,NSCLC,PET,RESULTS,ROYAL,SEVEN,THERE,THREE,ZEALAND
032,043,131,BACKGROUND,CONCLUSION,COX,DTC,JANUARY,LABEL,MEIER,METHODS,PTC,RESULTS,SERUM
169,372,BRAIN,BRESLOW,CLARK,COX,HOWEVER,LEVEL,RECURRENCE,SEVENTY,STAGE,THESE
001,253,467,BACKGROUND,CONCLUSION,COX,HARRELL,HOWEVER,LABEL,METHODS,OTHER,RESULTS,SEVERAL,THOSE
121,122,142,ANN,CONCLUSION,INDEX,LABEL,METHODS,OBJECTIVE,PATIENT,RESULTS
BACKGROUND,COMBINING,CPG,DA3,LABEL,METHODS,RESULTS
157,ATTRITION,FUNCTIONAL,LABEL,METHODS,MISSING,OBJECTIVE,PURPOSE,RESULTS,SEM,T12,T13,T24
BACKGROUND,CONCLUSION,DISCUSSION,EPA,GST,HODGKIN,INTEGRATED,LABEL,METHODS,OBJECTIVE,OBJECTIVES
AKT,H1975,HGF,LABEL,MAP,MEK,MET,METHODS,OBJECTIVE,PD0325901,PURPOSE,RESULTS,T790M,THESE
001,002,006,007,012,015,177,1RM,BACKGROUND,BMJ,GROUP,LABEL,LIMITED,METHODS,OTHER,PUBLISHED,PUBLISHING,QOL,RESULTS,TRIAL
LCSCR
001,003,004,047,070,149,169,174,227,231,263,402,417,502,530,542,556,671,780,808,856,926,BACKGROUND,CSS,INC,LABEL,METHODS,NSCLC,RESULTS,RFS,WILEY
042,100,588,HOWEVER,JANUARY,MAY,SUN,THERE,THESE,TREATMENT,UNIVERSITY,YAT
100,122,CLINICALLY,EBV,EPSTEIN,GRADING,INSTITUTE,LYG
008,124,131,216,268,333,344,357,AFTER,AIM,CONCLUSION,DEPARTMENT,HOWEVER,LABEL,LYMPH,MATERIALS,MEDICAL,METASTASIS,METHODS,NUCLEAR,OBJECTIVE,PET,RAI,RESULTS,UNIVERSITY
100,111,BACKGROUND,CONCLUSION,HOWEVER,LABEL,MAY,METHODS,NEWLY,NOTABLY,OCTREOSCAN,RESULTS,SMALL,SSTRS
169,B16,BRITAIN,C26,C38,COPYRIGHT,FINALLY,GREAT,III,INSTEAD,IRELAND,LTD,MAT,PUBLISHED,SOCIETY,THESE,WILEY
621,BACKGROUND,COX,CURRENT,III,LABEL,LOBECTOMY,MEIER,METHODS,RESULTS,THESE
PULMONARY,THESE
EMT,NSCLC,STAT3,TWIST
169,AUC,COPYRIGHT,DIAGNOSTIC,LTD,PARAMETRIC,ROC,WILEY
522,725,ARG,ASIAN,CHINESE,HIS139ARG,STRATIFIED,THESE,TYR,TYR113HIS
001,002,011,100,123,169,224,945,946,COPYRIGHT,IGF,IGFBP,INC,LABEL,METHODS,OBJECTIVE,PUBLISHED,REFINEMENT,RESULTS,SURGERY,THESE,UNIVERSITY,WHITNEY
169,549,929,CD2,COMPLEX,COPYRIGHT,DIC,DICLOFENAC,FRIDOVICH,H2O,MCF,T24
142,BACKGROUND,BMJ,CXR,GROUP,INDIVIDUAL,LABEL,LIMITED,METHODS,NETWORK,PUBLISHED,PUBLISHING,RESULTS
140,160,169,COPYRIGHT,FORCE,INC,JANUARY,LABEL,METHODS,OBJECTIVE,OLDER,OUTPATIENT,PUBLISHED,RESULTS,SETTING,THESE,UNIVERSITY
169,237,AMONG,BACKGROUND,BPD,COPYRIGHT,CYFRA,ECL,HOWEVER,LABEL,METHODS,NSCLC,RESULTS,ROC,SERUM,THEREFORE,WHITNEY
119,EZRIN,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
HOWEVER,INCREASING,MVD,NSCLC,PCR
PDGFS
169,CCDC6,FINALLY,NON,NSC,NSCLC,PARP1,RAD51,REMARKABLY,TMA
160,663,956,BCL,H3255,HOWEVER
004,039,655,715,HOWEVER,ORR,PFS,SIXTY
946,ECTOPIC,EMT,EPITHELIAL,FOS,FRA,INHIBITING,MOLECULAR,TGF
945,947,AMPAR,BACKGROUND,BARCELONA,BMJ,DISCUSSION,EEG,GROUP,LABEL,LIMITED,METHODS,MRI,PUBLISHED,PUBLISHING,RESULTS,SERUM,THREE
018,025,036,042,044,046,151,473,BACKGROUND,CIS,COX,HRS,LABEL,METHODS,NSCLC,RESULTS,RTL,WOMEN
001,146,149,250,BACKGROUND,BASED,CONCLUSION,LABEL,MEIER,METHODS,NLR,PLR,RESULTS,ROC,THERE
100,150,200,AMONG,BACKGROUND,BSA,CONCLUSION,CONTINUOUS,FORTY,LABEL,METHODS,RESULTS
001,736,828,909,ACCORDING,ACTN4,BACKGROUND,CL1,LABEL,METHODS,NSCLC,RESULTS,THESE
945,947,BASED,LABEL,METHODS,OBJECTIVE,PLS,PURPOSE,RESULTS,SAMPLES,SERUM
137,478,ALTOGETHER,BACKGROUND,CONCLUSION,HOWEVER,LABEL,METHODS,NSCLC,RESULTS
BACKGROUND,BASED,BETWEEN,CONCLUSION,JANUARY,LABEL,MAY,METHODS,NSCLC,PBT,PFS,RBE,RESULTS,SEX,THERE
169,3MA,AKR,AKR1B10,BHQ,COPYRIGHT,IRELAND,LC3,LTD,NEITHER,TBE,TBQ
115,130,300,CONCLUSION,DIAGNOSIS,FLEISCHNER,HOUNSFIELD,KEY,LABEL,METHODS,OBJECTIVE,RESULTS,SOCIETY
FINALLY,FOXO3,MICRORNAS,MIR,NSCLC,PCR,SPC,THEREFORE,TRANS,UTR,WESTERN
495,MICRORNAS,NSCLC,THESE
100,215,EPIDERMAL,IHC,L858R,PCR
946,EMT,HOWEVER,METASTATIC,TGF,THESE
CLINICALLY,DUB,FURTHER,HOWEVER,MYC,UBIQUITIN,USP37,WARBURG
031,069,169,BACKGROUND,CURRENT,INCREASING,LABEL,METHODS,NSCLC,OVERALL,RATES,RESULTS,SOCIETY,SPLCS,THERE,TOBACCO
169,947,ADDITIONAL,AFTER,AMYLOID,APP,BP1,COMPLEX,GSI,HYPOXIC,INC,KEY,NOTCH,NSCLC,PRECURSOR,PROTEIN,RAPAMYCIN,TARGETING,TORIN,WILEY
001,008,014,168,169,BACKGROUND,COPYRIGHT,EXHALED,INC,LABEL,METHODS,PNEUMONIA,RESULTS
004,317,394,711,BACKGROUND,HOWEVER,JANUARY,LABEL,METHODS,MLS,NSCLC,RCT,RESULTS,SML,THERE,THESE
ANXIETY,FEW,LABEL,METHODS,NSCLC,OBJECTIVE,PURPOSE,RESULTS,USING
ADDITIONAL,AMONG,BACKGROUND,CURRENT,DIPNECH,FORTY,LABEL,METHODS,RESULTS
001,004,014,033,034,049,054,131,133,151,171,177,230,311,336,435,456,628,813,974,984,995,AGING,BACKGROUND,CURRENT,DISEASE,FVC,GROUP,HOWEVER,IPF,LABEL,METHODS,RESULTS,THESE
18F,ERLOTINIB,FDG,PET
004,086,170,295,391,531,877,950,ATS,BACKGROUND,DFS,DRESLER,IASLC,LABEL,LNS,MEIER,METHODS,NSCLC,RESULTS,SOCIETY
004,009,016,060,160,197,304,501,CONCLUSION,DFS,DISEASE,GGN,KEY,LABEL,MAXIMAL,METHODS,OBJECTIVE,RESULTS
169,AFTER,DUE,EPHB4,MFH,NVP,SEVERAL,SILENCING,STS,THEREFORE
001,003,045,169,733,945,951,ALK,AMONG,BACKGROUND,CONSORTIUM,KIRSTEN,LABEL,MET,METHODS,RAS,RESULTS,SOCIETY,THESE,V600E
037,045,047,051,FURTHER,MENDELIAN,OVERALL,THERE,TOTAL,USING,WMD
169,519,AFP,BACKGROUND,CONCLUSION,EIGHT,FOUNDATION,HCC,ITPAS,LABEL,METHODS,MULTI,OBJECTIVE,PURPOSE,RESULTS,SEVENTEEN,THEIR,THESE
AMPLIFIED,ATOH1,BESIDES,CRC,HES,HOWEVER,MASTERMIND,NCOA3,NOTCH
DROSOPHILA,EPIDERMAL,EPS15,PDZ,PTPN3,RAS,TAKEN,USING
210,945,A549L,ACTIVATION,AKT,DOWNSTREAM,HIF,P85,RAD52,THESE,VMP
169,946,DVL,HBE,HEK293T,HOWEVER,INC,INCREASED,P120CTN,THESE,TNM,WESTERN,WILEY,WNT,ZBED3
091,138,234,326,462,967,DFS,GLASGOW,GPS,HOWEVER,LABEL,METHODS,NSCLC,OBJECTIVE,OBJECTIVES,RESULTS,SIMILAR
169,240,384,946,ACR,AKT,BRITAIN,CCL19,CCL21,CCRL1,CLINICALLY,COPYRIGHT,GREAT,HCC,IRELAND,LTD,PUBLISHED,SOCIETY,WILEY
AFTER,GRADE,IHC,LABEL,LND,LNS,LNU,MEIER,METHODS,OBJECTIVE,PURPOSE,RECURRENCE,RESULTS,RFS,THEREFORE
ACA,ALK,BACKGROUND,CONTEXT,ERBB2,LABEL,METHODS,OBJECTIVE,RET,SOURCES
169,191,946,BASP1,CSC,EMT,HBE,INC,THERE,WILEY,WNT,WT1
169,332,ALK,ANAPLASTIC,BAR,CLB,ERK,HOWEVER,INC,SAMPLES,STAT3,TAKEN,THESE,WHEREAS,WILEY
167,ANXIETY,FCS,HOWEVER,IL1,IL1R2,LABEL,METHODS,NFKB2,OBJECTIVE,PURPOSE,RESULTS,THEREFORE,THESE,USING,VARIATIONS
169,BRITISH,CONTACT,COPYRIGHT,LTD,PUBLISHED
003,011,013,040,044,114,COX,LABEL,LYMPHATIC,METHODS,OBJECTIVE,RESULTS,THERE
AGE,AIM,APRIL,BCA,FIFTY,FURTHER,JANUARY,LABEL,METHODS,OBJECTIVE,PET,RESULTS,TNM
18F,FDG,PET,PULMONARY,STOMACH
BMJ,GROUP,LIMITED,PUBLISHED,PUBLISHING,SEVERAL,SINCE,WHILE
BACKGROUND,CONCLUSION,GENITAL,HPV,LABEL,METHODS,THESE
100,108,ACUTE,APRIL,BACKGROUND,BETWEEN,CHART,CONCLUSION,KARNOFSKY,LABEL,METHODS,NSCLC,RESULTS,THERE,TOTAL,WHILE
CONCLUSION,FUNCTIONAL,FURTHER,LABEL,LUCIFERASE,METHODS,MTT,NSCLC,OBJECTIVE,PCR,PURPOSE,RESULTS,THESE,WESTERN
100,169,BECAUSE,BONFERRONI,CONCLUSION,LABEL,MATERIALS,MCNEMAR,METHODS,MPD,MPM,OBJECTIVE,PLEURAL,PURPOSE,RESULTS
945,AFTER,BILATERAL,HEPATIC
001,104,169,312,315,375,997,CENTRAL,CRC,JANUARY,RECORDS,SEPTEMBER,SIR,SMR,SOUTH,USA,VITAL
138,169,852,AGE,CASES,CHINA,ESTIMATES,FOLLOWING,LIMITED,WHILE
101,176,GROUP,INC,PHYSICISTS,PUBLISHED,RADIATION,THERAPY,TREATMENT,USING
031,102,169,382,748,COPYRIGHT,COX,EDUCATION,HARRELL,HOWEVER,INC,IQR,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RENAL,RESULTS,UROLOGICAL
169,COPYRIGHT,DESPITE,ISSUE,OXYGENATED,SPECIAL,THERE,THESE
3DMCO,4DMCO,4DMCRECAL,4DMCRENORM,ACCURAY,CARLO,COMPARISON,CONCLUSION,CYBERKNIFE,GTV,INC,LABEL,MATERIALS,METHODS,MONTE,OAR,OBJECTIVE,PURPOSE,RESULTS,SUNNYVALE,THREE
169,BACKGROUND,BETWEEN,COPYRIGHT,END,HOWEVER,INC,LABEL,MATERIALS,METHODS,PRIOR,PROCEDURES,RESULTS,THESE,USING
169,344SQ,BACKGROUND,COPYRIGHT,CURRENTLY,H1299,INC,ITGB4,LABEL,MATERIALS,METHODS,RESULTS
BMJ,FOLLOWING,GROUP,LABEL,LIMITED,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,PUBLISHED,PUBLISHING,RESULTS
BMJ,GROUP,LABEL,LIMITED,METHODS,OBJECTIVE,OTHER,PUBLISHED,PUBLISHING,RESULTS,THESE,VILLAGE
169,AMERICA,HPYV7,HPYVS,INFECTIOUS,PRESS,PUBLISHED,ROLLING,SOCIETY,UNIVERSITY
REGUCALCIN
070,138,169,571,ADJUSTMENT,CIS,COLORECTAL,CONCLUSION,COX,GLEASON,HOWEVER,HRS,III,LABEL,METHODS,OBJECTIVE,OTHER,OVARIAN,PURPOSE,RESULTS,SCREENING,SOCIETY,THEREFORE,TRIAL
002,003,007,023,040,071,073,BACKGROUND,CONCLUSION,HOWEVER,LABEL,METHODS,NSCLC,RESULTS,SARCOPENIA,SIXTEEN,STAGE,THERE
114,160,169,1990S,BACKGROUND,CCS,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,RESULTS,T1AN0,THERE
B72,CAM,CD117,CEA,DIFFUSE,EMA,PAS
005,025,101,149,169,ACCORDING,COX,GASC1,MYC,NANOG,PPARG,ROC,THEREFORE
000,169,723,745,ESTIMATES,OVERALL
169,COPYRIGHT,CTC,EFFICIENT,INTRA,MCA,UNDER
169,17Q,AUTHORS,INC,NPY,PDX,PUBLISHED,SYP,WHOLE,WILEY
007,169,2003_VS,2005_VS,2006_VS,2012_VS,428,64_VS,BESIDES,COX,EINDHOVEN,HRMALE_VS,HROTHER_VS,NSCLC,_2001,_2010,_FEMALE
HOWEVER,MEDICINAL,SYSTEMATIC
AUC,FORTY,KEY,LABEL,METHODS,OBJECTIVE,RESULTS,ROC,TEXTURE,USING,WHITNEY
169,BAMHI,BART3,BART7,EBV,EPSTEIN,III,NPC,SYSTEMATIC,THESE
160,BACKGROUND,E1A,HSPA5,LABEL,METHODS,RESULTS,THERE
157,181,268,BACKGROUND,FURTHER,FVC,GAP,HOWEVER,IPF,LABEL,METHODS,RESULTS,SEOUL,UNIVERSITY,WESTERN
103,108,177,300,396,956,ALT,BACKGROUND,DESPITE,GOVERNMENT,HEPATIC,HOWEVER,INITIAL,LABEL,LABORATORY,METHODS,OVERALL,PHLEBOTOMY,PRIOR,PROVIDING,PUBLISHED,RBC,RESULTS,TIO,USA
169,AFTER,DESPITE,EMT,INC,MALIGNANT,THEREFORE,WILEY
121,169,500,817,827,AMIGO,IMAGE,OPERATING,SOCIETY
133,169,198,218,CONCLUSION,DYNAMIC,FDG,FINALLY,LABEL,MATERIALS,MCNEMAR,METHODS,NODULES,OBJECTIVE,PET,PURPOSE,RESULTS,TOTAL,TUKEY
177,AFTER,CONCLUSION,CY5,EPO,HOWEVER,KEY,LABEL,METHODS,NSCLC,OBJECTIVE,PET,PROBE,RESULTS,THEREFORE
169,215,289,748,COX,FIRST,ITALY,NCI,PTPRG,SNP,THESE
169,946,DAPK1,EARLY,EBV,EPSTEIN,HOWEVER,HRM,NPC,RAR,RASSF1A,SINCE,VIRUS
00001,581,CONCLUSION,EVENT,FDG,III,INCLUSION,LABEL,MANAGER,MEDLINE,METHODS,MTV,NSCLC,OBJECTIVE,PET,PURPOSE,RESULTS,TLG,TNM,VOLUMETRIC
160,172,181,197,238,252,255,492,516,BACKGROUND,DISEASE,LABEL,METHODS,RESULTS,STUDIES,THERE,THESE
008,160,2N1M0,781,784,BACKGROUND,COX,END,FACTORS,LABEL,MEIER,METHODS,NSCLC,OVERALL,RESULTS,THESE
012,160,437,841,967,BACKGROUND,COLORECTAL,CONCLUSION,CRC,GROUP,INTER,IPN,KAPPA,LABEL,METHODS,PATHOLOGY,PATIENT,PRIMARY,RESULTS,WHITNEY
026,232,407,838,ASSESSMENT,BACKGROUND,DIAGNOSTIC,FDG,LABEL,LIBRARY,METHODS,PET,QUALITY,RESULTANT,RESULTS,STUDIES
169,99A,FURTHER,INC,MICRORNAS,NSCLC,WILEY
104,124,169,228,394,445,479,AMONG,BACKGROUND,FNA,LABEL,LNS,METHODS,NPV,RESULTS,SOCIETY,STUDIES
31MARCH,759,818,AUDIT,BMJ,CROSS,ENGLAND,ENGLISH,EPISODE,GROUP,LABEL,LIMITED,MEASURE,METHODS,NSCLC,OBJECTIVE,OBJECTIVES,OUTCOME,PUBLISHED,PUBLISHING,RESULTS,SETTING,STATISTICS
169,BAX,BCL,CHINESE,INC,JNK,KEAP1,PRO,PYDDT,ROS,SW620,TAKEN,THERE,WILEY
160,169,296,432,464,760,COLLEGE,CONCLUSION,COPYRIGHT,GUIDELINES,INC,JANUARY,LABEL,METHODS,NETWORK,OBJECTIVE,PUBLISHED,PURPOSE,RADIOLOGY,RESULTS,SCREENING,SIMILAR,TRIAL
169,AFTER,BACKGROUND,BOARD,CONCLUSION,COPYRIGHT,ELBOW,INC,JOURNAL,LABEL,METHODS,PUBLISHED,RESULTS,SOCIETY,SURGERY
004,169,769,939,INC,MTS,THESE,WILEY

CDC42,EGF,ERK,H1299,MMP,NSCLC
027,043,100,169,AUC,BACKGROUND,CONCLUSION,FOUNDATION,GENERAL,LABEL,LCD,MEDICAL,METHODS,OBJECTIVE,PURPOSE,RESULTS,ROC,T1A,T1AN0M0,THERE
030,100,150,177,JANUARY,LABEL,MAY,METHODS,OBJECTIVE,POD,RESULTS,THERE,THREE,VAS
001,169,502,710,BACKGROUND,BETWEEN,COPYRIGHT,INC,INCREASING,INDEX,INPATIENT,LABEL,MCS,METHODS,NATIONWIDE,RESULTS
169,AKT,BENZO,HOWEVER,IGF,INC,INSULIN,PPP,TREATMENT,WILEY
160,177,FALSE,FINAL,FORTY,LABEL,METHODS,OBJECTIVE,PET,PRIMARY,PURPOSE,RESULTS,STUDENT,SUV
126,169,458,NSCLC,PCR,SIX,STAGE
001,004,613,AVERAGE,BED10,CONCLUSION,DOSES,III,LABEL,LOCAL,MATERIALS,MEIER,METHODS,MORTALITY,NSCLC,OBJECTIVE,PET,PURPOSE,RESULTS,STAGING
100,956,EPIDERMAL,EXONS,FIFTY,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THEREFORE
169,945,954,BAY,DVL,INC,NSCLC,SP1,THESE,TREATMENT,WILEY
008,169,922,APEX1,ASP148GLU,CHINESE,INC,PAH,POLYCYCLIC,SNP,WILEY
169,476,ADJUSTING,CIS,COLORECTAL,DBP,NEITHER,ORS,OVARIAN,SCREENING,TRIAL
169,METASTASIS,NIR,THEREFORE,WHILE
004,008,131,160,BACKGROUND,COMPARISON,CONCLUSION,HOWEVER,LABEL,LOW,MEIER,METHODS,MVD,NOVEL,RESULTS
100,120,159,160,177,99M,EIGHT,GALLIUM,LABEL,METHODS,MSA,OBJECTIVE,PET,PURPOSE,RESULTS
001,005,010,016,022,043,089,112,114,130,136,184,185,215,228,270,273,335,366,514,571,574,688,726,738,820,833,879,890,936,957,968,999,ALT,AMONG,CERTAIN,CHINESE,JANUARY,LABEL,METHODS,NSCLC,OBJECTIVE,PURPOSE,RESULTS,THERE,VTE
0CM,169,177,215,5CM,8CM,COPYRIGHT,FIELD,GROUP,INC,ITV,MEDICAL,PTV,PUBLISHED,RADIATION,THERAPY
160,315,391,542,891,CAUCASIANS,HENCE,OVERALL,STK15
009,019,025,029,165,189,262,393,447,464,514,579,586,645,651,704,743,801,873,898,948,953,965,ADDITIONAL,AFTER,BACKGROUND,CCCCC,CONCLUSION,HAPLOTYPES,HAPLOVIEW,HOWEVER,LABEL,METHODS,OCCURRENCE,RESULTS,SEVEN,UNIVARIATE,UTR
945,946,EMT,FINALLY,MYC,SILENCING,SRC,STRIKINGLY
221,222,340,CDK,FINALLY,HOWEVER,MET,MICRORNAS,NSCLC,PUMILIO,ROCK1,SCF,THEREFORE,THESE,UTR
CSC,MYC,NOTABLY,STAT3,VEGFR
AAA,BACKGROUND,CAS,DISCUSSION,ENGLISH,FORCE,LABEL,METHODS,OVERALL,PREVENTIVE,RESULTS,SIXTY,SYSTEMATIC
160,215,327,365,703,906,BACKGROUND,CHINA,CHINESE,COX,LABEL,METHODS,NANJING,NSCLC,RESULTS,STUDIES,THESE
169,286,946,E2F,GSK,NSCLC,PSAT1,THESE
029,044,047,130,135,CONCLUSION,JANUARY,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SEPTEMBER,SEVERAL
148,389,730,810,BACKGROUND,CONCLUSION,EXCLUSION,FOLLOWING,GRADE,ITEMS,LABEL,LOCAL,MARCH,MEDLINE,METHODS,OVERALL,PREFERRED,RCC,REPORTING,RESULTS,REVIEWS,SYSTEMATIC,THERE,TREATMENT
18F,BASED,FDG,PET
FDG,LIVER,MRI,PET
00001,169,409,AFTER,BACKGROUND,CENTRAL,CETUXIMAB,COPYRIGHT,III,IRELAND,LABEL,LTD,MEDLINE,METHODS,ORR,PFS,RESULTS
045,100,100TH,169,ABOUT,AMERICA,AMONG,BACKGROUND,DISEASE,LABEL,METHODS,PRESS,PUBLISHED,RESULTS,RETIREMENT,SOCIETY,UNIVERSITY,WHILE
001,111,169,652,749,846,AUC,COLLEGE,LABEL,METHODS,OBJECTIVE,OUTCOME,POPULATION,RESULTS,ROYAL,SETTING,THERE,THESE,WOMEN
144,169,267,416,ACADEMY,ANXIETY,BACKGROUND,CONCLUSION,CONTEXT,COPYRIGHT,DEPRESSION,ENGLAND,FLOOR,GDS,GERIATRIC,GERMANY,HOSPICE,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OUTCOME,PALLIATIVE,POS,PREVALENCE,PUBLISHED,RESULTS,ROC,SCALE
169,CAUCASIAN,COPYRIGHT,CTA,DESPITE,DIAGNOSIS,INC,LABEL,METHODS,NSG,OBJECTIVE,OBJECTIVES,PATHOLOGIC,PATHOLOGY,RESULTS
160,169,946,ASP,BASED,BIOLOGY,FLK,GLU,KDR,KDRSCFV,LEU,LYS,NSCLC,SOCIETY,THESE,VEGFR
169,CONCLUSION,GRADUAL,INDEX,LABEL,METHODS,OBJECTIVE,RESULTS,VOICE
207,217,247,BMJ,GROUP,JANUARY,LIMITED,PET,PUBLISHED,PUBLISHING,RESULTS
284,CONCLUSION,CRT,HNC,LABEL,METHODS,NSCLC,OBJECTIVE,PURPOSE,RESULTS,RID,WHEREAS,WHILE
945,946,954,THESE,TNF
AUC,CONSORTIUM,GABOR,IMAGE,INITIATIVE,SVM,TEXTURE,THESE,WHILE
001,006,169,215,AIM,CONCLUSION,COX,LABEL,METASTATIC,METHODS,OBJECTIVE,OCTOBER,RESULTS,SEPTEMBER,THERE,UNIVARIATE
118,169,231,E362A,ECM,HOWEVER,INT,KNOCKDOWN,MCF,MDA,SEVERAL,THESE,VIA
169,220,348,AUSTRALIA,AUSTRALIAN,BACKGROUND,BURNOUT,COLLEGE,CORRECTION,CPD,FURTHER,HSS,INVENTORY,LABEL,MASLACH,MBI,METHODS,RESULTS,ROYAL,SPECIALIST,THERE,THOSE,ZEALAND
946,BACKGROUND,EPIGENETIC,HCC,LABEL,METHODS,RESULTS,WNT
170,246,254,670,716,BASED,BETWEEN,LABEL,MARCH,MAY,METHODS,OBJECTIVE,RESULTS,SMOKERS,THERE,UNIVARIATE
169,INCUBATION,NSCLC,SURGERY,THESE,TLR,USING
169,ATO,INHIBITION,KNOCKDOWN
169,320,DYNAMIC,EIGHT,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PRESS,PUBLISHED,RESULTS,SURGERY,SVC,UNIVERSITY
169,945,AMP,CONSISTENT,NSCLC,THESE
001,106,AFTER,BASED,FDG,HOWEVER,LABEL,METHODS,OBJECTIVE,PARTIAL,PET,PROCEDURES,PURPOSE,PVE,REGRESSION,RESULTS,SUVMEAN,TLG,VOLUMETRIC
169,650,BACKGROUND,COPYRIGHT,DISEASE,HOWEVER,LABEL,LTD,METHODS,OBJECTIVE,PURPOSE,RESULTS,THEREFORE,WILEY
124,144,159,211,370,BMJ,GROUP,JANUARY,LIMITED,PRESTON,PUBLISHED,PUBLISHING
871,BACKGROUND,BMJ,COX,GREATER,GROUP,HOWEVER,LABEL,LIMITED,METHODS,NSCLC,OBJECTIVE,PUBLISHED,PUBLISHING,RESULTS,THESE
001,120,134,135,BACKGROUND,INDUCTION,LABEL,MEDLINE,METHODS,NSCLC,OBJECTIVE,OVERALL,RESULTS,SIX,SPINE,UNIVARIATE
169,219,241,288,306,312,628,798,850,CENTRAL,CNS,COSTS,EASTERN,EVERY,HODGKIN,PREMATURE,STOMACH,THESE,WESTERN,YEARS
153,169,AKT,AMO,KNOCKDOWN,LUCIFERASE,UTR
CYR61,PECAM,SPARC,TAKEN,THESE,USING
120,169,495,617,BRCA1,CCND1,CHUNG,CURRENTLY,DDX3X,EPHA2,FGFR1,FGFR2,FGFR3,HNSCC,HPV,KRIGSFELD,LABEL,METHODS,MUTATIONS,NOTCH,OBJECTIVE,PURPOSE,RESULTS,S249C
001,008,169,172,ALK,BACKGROUND,LABEL,METHODS,NEURO,NSCLC,OVERALL,PRESS,PUBLISHED,RECEIPT,RESULTS,SOCIETY,SUBSEQUENT,UNIVERSITY
169,916,946,ALTERED,BMP,FURTHER,HTY,NOTABLY,PC3,RUNX2,SMADS,TGF
169,BRAIN,CLDN1,TAKEN
100,169,177,956,BIOLOGY,COMBINING,FEDERATION
001,011,028,169,853,967,BACKGROUND,BETWEEN,CONCLUSION,COPYRIGHT,COX,ENHANCING,INC,LABEL,MEIER,METHODS,PMGCT,PMNSGCT,PRIMARY,RESULTS
001,107,160,169,195,203,673,AMONG,BACKGROUND,CNS,COPYRIGHT,IBC,III,INC,LABEL,METHODS,NETWORK,OVERALL,RESULTS
FIFTEEN,LABEL,METHODS,OBJECTIVE,RESULTS,SURGERY,THERE
BECAUSE,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SEVEN,WHOLE
945,946,AGAINST,IDIOPATHIC,IPF,MOTHERS,SMAD4,TGF
006,946,DACT2,III,MEIER,RESTORING,THESE,WHEREAS,WNT
HOMOLOG,NSCLC,ONCOGENIC,RAS,ROS
BECAUSE,CO2,NET,USING
001,143,251,ALZHEIMER,CIS,CONCLUSION,EGGER,HOWEVER,LABEL,MAY,METHODS,OBJECTIVE,PURPOSE,RESULTS,RRS,SCIENCE,STUDIES,THESE,WEB
183,404,BACKGROUND,BPH,COLORECTAL,LABEL,MEN,METHODS,OVARIAN,POISSON,RESULTS,SCREENING
FDG,PET,THERE
FDG,PET
954,AKT,AMONG,FRAGILE,HOWEVER,NSCLC,THEREFORE
BMP,PYVMT,THESE,TREATMENT
916,AMP,FINALLY,NCI,SILENCING
BRONCHIAL,PREVIOUSLY
011,018,024,028,048,06895,169,456,807,946,AFTER,ANOTHER,FDR,HAPLOTYPE,HSD11B1,INC,NNK,SCC,SNP,THESE,WILEY
169,CHINESE,CLINICALLY,EMT,HUANG,INC,INCREASING,QIN,SNAIL,STAT3,TAKEN,THP,TWIST,WILEY,WOGONIN
169,945,BACKGROUND,CONCLUSION,HOWEVER,INC,LABEL,METHODS,NUCLEAR,PRO,PROEX,RESULTS,TMA,WILEY
160,ABL,CABLES1,CDK,MACROPAIN,PROSOME,PSMA3
100,160,169,198,BACKGROUND,CONCLUSION,CONTEXT,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PER,PUBLISHED,RESULTS,SIMILARLY,THERE,THESE
001,002,169,234,CETUXIMAB,CIS,KNOWLEDGE,NSCLC,RRS,SOCIETY,WEB
169,FINALLY,INC,MET,NSCLC,RESULTS,THESE,WILEY
001,009,853,AFTER,BACKGROUND,CONCLUSION,CONSORTIUM,CONTEXT,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RELATIVELY,RESULTS
100,135,169,AMONG,BETWEEN,HOWEVER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PRESS,PUBLISHED,RESULTS,SOLID,SURGERY,THERE,UNIVERSITY
JAVASCRIPT,QUERY,SCREENING,SEVERAL,SQL,STRUCTURED,TRIAL,USING
005,169,177,492,BACKGROUND,CONCLUSION,DESPITE,FOUNDATION,LABEL,METHODS,MYLAB,OBJECTIVE,PURPOSE,RESULTS,SCC,SINCE,SUBPLEURAL,TUS,TWICE,UNDER
ABOUT,BACKGROUND,CRC,DFS,DISEASE,HOWEVER,LABEL,MEIER,METHODS,OBJECTIVE,PFS,RELAPSE,RESULTS,VII
005,201,329,463,BACKGROUND,LABEL,METHODS,NEITHER,OBJECTIVE,PRE,RESULTS,SCPNS,SIX,THERE,THESE
159,169,985,CONSORTIUM,HOWEVER,ORS,RESULTS,ZEALAND
169,CSC,DNMT1,KNOCKDOWN,PCR,STAT3,THESE,WESTERN
DU145,H1299,HOWEVER,MUTATIONS,NUCLEAR,SPP,THESE,TMS
008,036,160,169,COPYRIGHT,DATES,EASTERN,LABEL,METHODS,NSCLC,OBJECTIVE,RESULTS,THERE
001,967,BACKGROUND,BMJ,ENGLAND,EPISODE,FURTHER,GROUP,LABEL,LIMITED,METHODS,PUBLISHED,PUBLISHING,RESULTS,STATISTICS
000,140,169,CANCERS,FIRST,INDIANS,NATIONS,ONTARIANS,ONTARIO
169,654,BACKGROUND,CONCLUSION,DOR,DTP,EBSCO,FDG,FOUNDATION,HOWEVER,KNOWLEDGE,LABEL,LYMPH,METHODS,NLR,NSCLC,OBJECTIVE,PET,PLR,PURPOSE,RESULTS,STP,SUMMARY,WEB
169,320,429,CHINA,COOKING,COX,HOWEVER,IAP,THESE
169,481,829,AFTER,CHINESE,CIS,COX,DIETARY,HRS,TOTAL,VITAMIN,WOMEN
169,318,ARID2,PBRM1,SETD2,SMARCA4,SMARCC1,SNF,SWI,THESE
BACKGROUND,DYSPNEA,GRADE,LABEL,MEDLINE,METHODS,RESULTS,SCHOLAR,UNTIL
BARD1,BRCA1,PHOSPHO,RAF,RAS,THESE
29B,AMONG,COX,MEIER,MYC,NSCLC,RFS,THEREFORE
115,120,BACKGROUND,FIFTY,III,LABEL,METHODS,NSCLC,PCR,PHYSICIANS,RESULTS
120,169,H2B,H3K79,PTM,RNF20,RNF40,SOCIETY,USP22,USP44
945,946,B16,CYTOKINES,KNOCKDOWN,LAL,LEWIS,LYSOSOMAL,MDSCS,MYELOID,THEREFORE
001,100,169,FDG,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PET,POSITIVITY,PRESS,PUBLISHED,RESULTS,SURGERY,SUV,UNIVERSITY
BASED,DESPITE,FAK,FAS,GEF,RHO,SINCE
169,18F,COPYRIGHT,FDG,LTD,PET,WILEY
DESPITE,GGN,LABEL,LIMITED,METHODS,OBJECTIVE,PURPOSE,REGARDING,RESULTS,SOLID
017,029,032,183,233,BACKGROUND,JANUARY,LABEL,METHODS,OBJECTIVE,OVERALL,PROPENSITY,REPORTS,RESULTS
169,DIAGNOSTIC,FOUNDATION,MRI,WESTERN
133,177,208,ASSESSMENT,ERLOTINIB,EVENTUALLY,HOWEVER,LITERATURE,TDM,THESE
169,342,496,609,625,DENMARK,JOURNAL,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OUTCOME,POPULATION,RESULTS,SETTING,SIR
ANOTHER,WHILE
001,004,012,025,414,436,AMONG,LABEL,METHODS,NSCLC,OBJECTIVE,PLC,PURPOSE,RECURRENCE,RESULTS,TNM
169,191,271,298,AZA,CONVERSELY,H23,HOWEVER,HOXA9,INC,NSCLC,PCR,TRANSIENT,WILEY
INSTITUTE,LABEL,METHODS,MWA,NSCLC,OBJECTIVE,PRIMARY,PURPOSE,RESULTS
169
APRIL,BACKGROUND,BETWEEN,GRADE,LABEL,METHODS,RECURRENCE,RESULTS,THERE
169,CIGARETTE,CSC,H1299,INC,NADPH,NOX,NSCLC,TREATMENT,USING,WILEY
10058,160,ASIAN,JQ1,LIVER,MYC
549,CONCLUSION,DEVELOPED,LABEL,METHODS,NAKED,OBJECTIVE,PRE,PURPOSE,RESULTS,THESE
169
169,482,CHINESE,FUNCTIONAL,INC,MEIER,NON,NSCLC,SNP,WILEY
169,PRESS,PUBLISHED,PULMONARY,SURGERY,UNIVERSITY
01910,169,AUTHORS,LTD,MDS,PROGNOSTIC,REVISED,RIGOSERTIB,SCORING,TRIAL,WILEY
945,954,BBS,GLI,GTPASES,PAR,RHO,SHH,SMALL,SONIC
ALZHEIMER,EMT,FURTHER,HUNTINGTON,SNAIL,TAKEN,THESE,UBIQUILIN1,UBQLN
AMERICANS,BACKGROUND,LABEL,LOW,METHODS,OBJECTIVE,RESULTS,STRATEGIES,THOUSANDS,USING
100,113,135,169,177,BASED,ICU,LABEL,MEIER,METHODS,OBJECTIVE,OBJECTIVES,PRESS,PUBLISHED,RESULTS,SURGERY,TEN,THERE,UNIVERSITY
AKT,AMONG,ERK,HOWEVER,NNK,NOTABLY,STAT3,TRP53
001,CIS,ILD,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,TREATMENT
138,COX,GLASGOW,GPS,HRS,LABEL,METHODS,NSCLC,OBJECTIVE,OBJECTIVES,PFS,RESULTS,UNIVARIATE
169,CONSISTENT,FURTHER,INC,MET,MTT,THESE,TUNEL,WILEY
169,945,FOXC2,HUVEC,INC,INCREASED,OPN,THESE,WILEY
009,187,BACKGROUND,CONTEXT,INCREASED,KIRSTEN,LABEL,METHODS,OBJECTIVE,RAS,RESULTS,SOCIETY
FINALLY,HOWEVER,LFCIN,MEANWHILE,NCI,PCR,THESE,WESTERN
000,117,136,138,427,549,672,767,AFTER,BACKGROUND,BIOLOGICS,BMJ,BRITISH,GROUP,LABEL,LIMITED,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,PUBLISHING,RATES,RESULTS,SOCIETY,THERE,TNF,TREATMENT
BMS,MPDL3280A,NSCLC
009,487,588,838,CHEST,ESOPHAGEAL,HNSCC,HOWEVER,SYSTEMATIC
010,014,127,169,HOWEVER,INC,NSCLC,PCR,SIX,THEREFORE,WILEY
169,ERK,H1299,HBE,HOWEVER,INC,MMP,PCR,PD98059,THERE,THESE,TREATMENT,WESTERN,WILEY
946,AKT,BCL,FGFR3,HCC1954,HOWEVER,INHIBITION,MET,MKN45,PATHWAY,SAIT301,TREATMENT
945,ANG,CSF,E47,EMT,EPITHELIAL,LOXL2,TFS,TNF
H1299,H23,PEP,PEPCK,STILL,UNDER
ALK,HIF1A,HOWEVER,MMP,NCL,NUCLEOLIN,TFG
169,177,BACKGROUND,BETWEEN,CONCLUSION,FOUNDATION,JANUARY,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THEIR,TRANSIENT
169,ATPASES,CARDIAC,CGS,HOWEVER,INC,KNOCKDOWN,NKA,NSCLC,PP2,ROS,SRC,THESE,WILEY
ACCORDING,BACKGROUND,GRADE,ILD,LABEL,METHODS,REGARDING,RESULTS,SIXTY
125,CHO,EGF,III,SURFACTANT,THESE
00128,945,946,CHINA,NPC,THESE
169,LABEL,METHODS,OBJECTIVE,PLACE,REDUCED,RESULTS,ROYAL,SINCE,SMOKING,SOCIETY,TOTAL
100,181,239,468,MDA,NCI,RESULTS,USA
130,169,COPYRIGHT,ECO,EUCAN,EUREG,EUROCIM,EUROCOURSE,EXCELLENCE,INCIDENCE,LTD,MORTALITY,POPULATION,REGISTRIES,SCIENTIFIC
ADVERSE,GRADE,INSTITUTE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,VERSION
169,ERK,FURTHER,HISTONE,INC,KAZAL,MMP,REVERSION,SP1,TAKEN,WILEY
002,027,148,364,CBCT1,CBCT2,CBCT3,CBCT4,CBCT5,GTV,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UNIVARIATE
169,PHASE,UNTIL
945,946,AZD8931,EPCAM,FIBROBLAST,NSCLC,SERPINE,SPHK1,TGF
169,FURTHER,HOWEVER,INC,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,SUBJECTIVE,WILEY
HOX,LABEL,MALAT,METHODS,NFPAS,OBJECTIVE,PURPOSE,RESULTS,THERE
156,506,954,ECTOPIC,ROS
185,NMR,PACLITAXEL,PTX,THESE
001,003,005,015,039,061,846,967,HCC,LABEL,LITERATURE,METHODS,OBJECTIVE,PITUITARY,PURPOSE,RESULTS
740,ADJUSTING,BMJ,GROUP,LABEL,LIMITED,METHODS,OBJECTIVE,PACKS,PICTORIAL,PUBLISHED,PUBLISHING,RESULTS,SMOKERS
169,947,ACCESSORY,CD11B,CLP,IFN,NKT
169,INC,MEANWHILE,NSCLC,PCR,TAKEN,TNM,WILEY
169,AVM,BRAGG,JAMES,LINDA,MEDICAL,TREATMENT,UNIVERSITY,WHILE
HOWEVER,PULMONARY,SEVERAL,THESE,V10,V15,V20,VS5
001,002,004,169,177,DOSIMETRIC,EFFICIENCY,GTV,KUTCHER,LYMAN,OAR,PTV,USING,WHILE
169,PET,RESULTS,TESTS
152,169,215,300,ABS,AVERAGE,BRAGG,BRCA1,BRCA2,CCNB2,DNMT1,GADD45A,GOLGI,GTSE1,HLE,IFNB1,JUN,PCR,PERCENTAGE,PTTG1,RAD51,SIAH1,STUDIES,TDR,TNF,WT1,XRCC2,XRCC3
CHEST,FDG,PET,PRIMARY,VIDEO
169,BACKGROUND,COPYRIGHT,DENMARK,DESPITE,GENERALLY,GIVEN,ICELAND,LABEL,LTD,METHODS,MIXED,PREVENTION,RESULTS,SMOKING,THERE,TRUNCATED,WORLD
169,945,954,CHINESE,INC,THESE,TREATMENT,WILEY
169,18B,CPG,INC,NOTABLY,PCR,THESE,WILEY
215,EIGHT
000,139,180,956,LEUKEMOID
169,FOS,INC,JUN,TAKEN,WESTERN,WILEY
001,110,346,665,AVERAGE,DOSIMETRIC,GTV,HOWEVER,LABEL,METHODS,MLD,OBJECTIVE,OBJECTIVES,PTV,RESULTS,SIXTY,THERE,V10,V20,V30
169,HOWEVER,INC,NSCLC,THESE,WILEY

100,BACKGROUND,CAV,HOWEVER,INDIANA,LABEL,METASTATIC,METHODS,NED,RESULTS,RPLND,SIX,TREATMENT,UNIVERSITY
113,171,228,FNA,FORTY,LABEL,METASTASES,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,ROCHESTER
014,018,028,041,129,967,ABC,ABCG2,ATP,COX,LABEL,MDR,MEIER,METHODS,NSCLC,OBJECTIVE,OBJECTIVES,RESULTS,THEREFORE
001,006,032,037,042,336,359,655,HOWEVER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
III,PRESENT,STUDIES,THESE
001,249,287,CONCLUSION,DESPITE,JANUARY,LABEL,LRC,MATERIALS,MEIER,METHODS,OBJECTIVE,PURPOSE,RESULTS
001,353,LABEL,METHODS,NSCLC,PFS,RESULTS,TESTS,UNASSIGNED
480,ALGORITHMS,BACKGROUND,CRC,GENERIC,ICD,INCLUSION,JANUARY,LABEL,MARCH,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THESE
180,COMPARING,LABEL,METHODS,MST,OBJECTIVE,OBJECTIVES,RESULTS,SENSITIVE,SIXTY,TFI,THERE
